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Hypothyroidism is the most common endocrine disorder in dogs, but it is also 
the most over diagnosed.  Indeed, evaluation of thyroid function in dogs is not always 
straightforward.  The vague and non-specific clinical signs of hypothyroidism and the 
fact that numerous factors can influence thyroid function test results are major 
contributors to the difficulty in diagnosing this disease. Thyroid physiology, canine 
hypothyroidism, specific diagnostic tests and factors influencing thyroid homeostasis 
will be described in chapter 1. 
 
 Changes in thyroid hormone concentrations induced by drugs or disease can be 
confusing and lead to an erroneous diagnosis of hypothyroidism resulting in 
inappropriate life long treatment.  Many drugs have been shown to alter thyroid 
function in humans and rats.  These medications alter the synthesis, secretion, transport, 
or metabolism of thyroid hormones.  Some drugs also directly inhibit the hypothalamic-
pituitary-thyroid axis.  Many of these drugs affect more than one aspect of thyroid 
hormone physiology.  Species differences exist in all areas of the thyroid axis, therefore 
it is not surprising that drug-thyroid interactions will vary among species.  In humans, 
several drugs may cause marked changes in the results of thyroid function tests, leading 
to difficulty in interpretation, but only rarely lead to clinical features of thyroid 
dysfunction. The effects of many of these drugs have not yet been studied in dogs.  
Therefore, chapters 2 and 3 will focus on the effects of some very commonly used drugs 
in canine practice on thyroid function test results. 
 To further assess the possible influence of some very common clinical situations 
on thyroid function test results, the possible effects of obesity and weight loss on canine 
thyroid function will be assessed in chapter 4. Obesity and weight loss have been shown 
to alter thyroid hormone homeostasis in humans. In dogs, obesity is the most common 
nutritional problem encountered and weight loss is the cornerstone of its treatment, 
therefore it is important to clarify how obesity and weight loss can affect thyroid 
function test results in dogs.   
 
Clinical manifestations of hypothyroidism are nonspecific; this further 
complicates the diagnosis of canine hypothyroidism.  Several diseases have a clinical 
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presentation that can be similar to hypothyroidism.  The most striking example is the 
symmetrical flank alopecia frequently observed in hypothyroidism but also a 
characteristic feature of a recently documented dermatological disease: canine recurrent 
flank alopecia (CRFA).  During the last decades, many dogs have been erroneously 
diagnosed with hypothyroidism when they in fact were suffering from CRFA.  Canine 
recurrent flank alopecia is a recently recognized skin disorder of unknown etiology, 
characterized by episodes of truncal hair loss that often occurs on a recurrent basis.  
Typically, this alopecia affects adult dogs on a yearly seasonal basis and resolves 
spontaneously without treatment within several months.  The episodes do not always 
reoccur annually.  In chapter 5 we shall evaluate thyroid function in dogs with CRFA.  
 
SCIENTIFIC AIMS 
 5
SCIENTIFIC AIMS 
 
 6
SCIENTIFIC AIMS 
 7
 
Hypothyroidism is the most common endocrine disease in dogs, but also the 
most over diagnosed.  Indeed, clinical evaluation of thyroid function in dogs is not 
always straightforward.  First, numerous factors such as the presence of systemic 
disease or the administration of drugs can affect thyroid homeostasis and frequently 
used thyroid function tests. Many of those factors have not yet been well evaluated in 
dogs.  Second, clinical manifestations of hypothyroidism, such as lethargy, alopecia and 
obesity, are nonspecific. Several diseases have a clinical presentation that can be similar 
to hypothyroidism.  The most striking example is the symmetrical flank alopecia 
frequently observed in hypothyroidism but also a characteristic feature of canine 
recurrent flank alopecia (CRFA).   
 
The aim of this study is to clarify, if and how, some commonly observed clinical 
situations could affect thyroid homeostasis, in order to avoid an erroneous diagnosis of 
hypothyroidism resulting in inappropriate treatment. 
 
Specific aims:  
 
1/ To evaluate the effects of some very commonly prescribed drugs on canine thyroid 
function test results. 
1a. To evaluate the effects of prednisone and phenobarbital on canine thyroid function. 
 
1b. To evaluate the effects of acetylsalicylic acid and ketoprofen on canine thyroid 
function test results. 
 
2/ To investigate the influence of obesity and weight loss on thyroid homeostasis in 
dogs. 
 
Obesity and weight loss have been shown to alter thyroid hormone homeostasis 
in humans. In dogs, obesity is the most common nutritional problem encountered and 
weight loss is the cornerstone of its treatment, therefore it is important to clarify how 
obesity and weight loss can affect thyroid function test results in dogs.   
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3/ To examine thyroid function in dogs with canine recurrent flank alopecia. 
 
The symmetrical alopecia described in canine recurrent flank alopecia can easily 
mislead one to a diagnosis of hypothyroidism.  The etiology of this disease is still 
largely unknown. 
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I. Physiology of the hypothalamic-pituitary-thyroid axis 
 
 An understanding of the basic physiology of the hypothalamic-pituitary-thyroid 
axis is critical to appreciating the various ways in which diseases or drugs can interact 
with this system and influence thyroid hormone concentrations. Figure 1 shows a 
schematic representation of the hypothalamic-pituitary-thyroid axis. 
 
 
 
Figure 1: schematic representation of hypothalamic-pituitary-thyroid axis.  T4: thyroxine, 
fT4: free thyroxine, T3: triiodothyronine, fT3: free triiodothyronine, rT3: reverse 
triiodothyronine, TSH: thyrotropin, TRH: thyrotropin-releasing hormone. 
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 Iodine metabolism 
Thyroid hormones are the only iodinated organic compounds in the body with the 2 
major secretory products of the thyroid gland, being thyroxine (T4) and 3,5,3'-
triiodothyronine (T3).  Ingested iodide is absorbed from the gastrointestinal tract into the 
circulation. Dogs have plasma iodide concentrations of 5 to 10 Pg/dl, which are 10 to 20 
times concentrations in human plasma.  In the thyroid gland, iodide is concentrated or 
"trapped" by active transport mechanisms of the thyroid follicular cell resulting in 
intracellular iodide concentrations, which are 10 to 200 times those of serum. This process 
is stimulated by the interaction of TSH with follicular cell surface receptors leading to 
stimulation of cyclic AMP.  
Iodide trapping can be inhibited by other anions such as thiocyanate (SCN-) and 
perchlorate (ClO4
-). Thiocyanate is a metabolic product of some naturally occurring 
compounds in plants (e.g. cyanogenic glucosides found in sweet potatoes or lima beans) 
and may result in goitrogenic (antithyroid) activity of the plant. Another naturally 
occurring goitrinogen is goitrin found in plants of the genus Brassica (Ferguson, 2001). 
Oral administration of perchlorate after the administration of a tracer dose of radioiodine 
can be used to diagnose congenital defects in the thyroidal organification of iodide 
(Taurog, 1996). 
 
Thyroid hormone synthesis 
Thyroglobulin (Tg), an iodinated glycoprotein with a molecular weight of 
660,000 daltons, serves as a synthesis and storage site for thyroid hormone and its 
precursors in the thyroid follicle.  Once inside the thyroid cell, iodide diffuses down a 
concentration gradient to the apical surface of the cell where it is oxidized by the 
enzyme thyroid peroxidase (TPO) to iodine.  It then is incorporated into tyrosine 
residues of Tg in a process called organification, forming monoiodotyrosine (MIT) and 
diiodotyrosine (DIT).  Thyroxine then is formed by coupling 2 DIT molecules, and T3 is 
formed by coupling 1 MIT molecule with 1 DIT molecule. When iodine intake is 
adequate, production of T4 is favored. However, in iodine-deficient states and 
impending thyroid failure, the intrathyroidal synthesis of T3 is preferred over that of T4.   
By this autoregulation, the thyroid gland produces the most active thyroid hormone (T3 
is 3 to 10 times more potent than T4) while using less iodide (Taurog, 1996). 
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The Wolff-Chaikoff effect, another intrathyroidal regulatory mechanism, is key to 
understanding the potential acute antithyroid effect of large amounts of ingested iodide.  
Mediated via inhibition of the thyroid peroxidase (TPO) enzyme, iodide decreases the rate 
of its own relative and absolute organification.   In humans, this effect is transient and 
"escape" is seen within several weeks. This inhibitory effect may represent a mechanism 
by which the organism is protected from massive thyroid hormone release after a large di-
etary iodine load. In puppies, increasing the iodine content of the diet results in a fall in 
total and free T4 concentration (Castillo et al., 2001). 
Iodide derived from iodine-containing drugs (e.g. amiodarone, radiographic 
contrast agents) or nutrients may influence thyroid gland function by similar mechanisms 
(Wolff, 1989). 
 
Thyroid hormone secretion 
Thyroid hormone secretion is initiated as the epithelial follicular cells take up 
thyroglobulin in colloid droplets by a process called pinocytosis. Degradation of 
thyroglobulin by the lysosomal proteolytic enzymes produces both the iodotyrosines (MIT 
and DIT) and iodothyronines (T4 and T3).  Little of the released MIT and DIT enters the 
circulation because the iodine is removed from these substances by a specific dehalogenase 
enzyme. Some of this iodine is recycled internally for iodination of new tyrosine residues 
in thyroglobulin, but in carnivores much iodine is released to the circulation. Enzymes 
present within the thyroid gland, however, can deiodinate T4 to either T3 or 3',5',3-T3 
(reverse T3).
  Whereas T3 is the biologically active hormone, rT3 has no biological 
activity. As a result, although the T4:T3 ratio stored in the gland is 12:1 in the canine 
thyroid, the ratio of secreted products is 4:1.  Production rates of the thyroid hormones in 
the dog have been estimated to be 8 Pg/kg/day for T4 and 0.8 to 1.5 Pg/kg/day for T3 
(Kaptein et al., 1990; 1993; 1994). The production rates observed in dogs, are more than 
twice those observed for TT4 and TT3 in humans (Kaptein et al., 1993; 1994).   
 
Hypothalamic-pituitary-thyroid axis 
Thyrotropin, a glycoprotein produced in the thyrotropes of the pituitary pars 
distalis, has a stimulatory effect on thyroid hormone synthesis and secretion.  In 
addition, TSH stimulates thyroid growth and function. The effects of TSH on the 
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thyroid gland are mediated by interaction with a specific TSH follicular cell surface 
receptor leading to stimulation of adenylate cyclase. Thyrotropin has a molecular weight 
of about 30,000 and consists of an D and E subunit. The D subunit is identical to the D 
subunit of the other glycoprotein pituitary hormones (e.g. luteinizing hormone [LH], 
follicle stimulating hormone [FSH]), whereas the E subunit is species specific and 
specific to the TSH molecule. The structure of the hormone-specific E subunit of TSH 
recently has been reported for the dog (Yang et al., 2000). 
The negative feedback effect of thyroid hormones (in the free or unbound form) 
is the principal mechanism regulating TSH secretion. Tonic stimulation by thyrotropin-
releasing hormone (TRH) has a permissive role in TSH secretion.  The pituitary 
thyrotrope cell completely deiodinates T4 (derived from the plasma) to T3 which 
subsequently inhibits TSH synthesis and secretion by alteration of nuclear receptor 
binding, mRNA transcription, and protein synthesis. Circulating T4 taken up by the 
pituitary gland is the preferred source of T3 in the pituitary gland, at least in the rat (Larsen 
et al., 1981; Reichlin, 1986; Magner, 1990; Fish et al., 1997). 
 
Metabolism of thyroid hormone  
The metabolically active thyroid hormones are the iodothyronines, T4 and T3. 
Thyroxine is the main secretory product of the normal thyroid gland, but, T3, which is 
about 3 to 10 times more potent than T4, and smaller amounts of inactive 3,3',5'-L-
triiodothyronine (reverse T3) and other deiodinated metabolites  are secreted also. 
Although all T4 is secreted by the thyroid gland, a considerable amount (40 to 60 % in the 
dog) of T3 is derived from extrathyroidal enzymatic 5'-deiodination of T4.
  Therefore, 
although it also has intrinsic metabolic activity, T4 has been called a "prohormone" because 
of its conversion to the more potent T3 in a step regulated by peripheral tissues (Belshaw et 
al., 1974; Inada et al., 1975; Laurberg, 1980; Ferguson, 1984; Kaptein et al., 1993; 1994). 
Peripheral deiodination of T4 into T3 occurs intracellularly.  The identification of 3 
distinct types of 5'-deiodinase (5'-D) enzymes has underscored the importance of the 
regulation of T3 production from T4 in individual tissues. Type I  5'-D is found in most 
peripheral tissues, but has its highest activity in liver, kidney, muscle and thyroid gland. 
This enzyme is now known to be a selenoenzyme requiring trace quantities of selenium for 
optimal activity.  Muscle, although it has low enzyme activity, may produce as much as 
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60% of the body's T3 solely because of its large mass. The physiological role of Type I 5'-
D is the provision of circulating T3. This enzyme is capable of "outer ring" and "inner ring" 
deiodination and can deiodinate T4 with a high capacity and is sensitive to propylthiouracil 
(PTU).  Type II 5'-D is found in the central nervous system (CNS), pituitary gland, brown 
fat, placenta and skin (dog) and its physiological role is provision of intracellular T3.   This 
enzyme acts on T4 and other compounds with outer ring iodine at concentrations within the 
physiological range and is resistant to PTU.  Type III 5'-D is present in placenta, CNS, skin 
(not in the dog), and fetal liver and has as its physiologic role inactivation  of T4 and T3 by 
inner ring  (i.e. ring closest to the amino acid moiety) deiodination, with preference for T3 
as a substrate (Ferguson, 2001). 
 
Plasma hormone binding of thyroid hormone and free hormone fraction  
Thyroxine and T3 are water insoluble lipophilic compounds. Their ability to 
circulate in plasma is dependent upon binding by specific binding proteins, thyroxine-
binding globulin (TBG) and thyroxine-binding prealbumin (TBPA; transthyretin), as well 
as by albumin itself. Thyroid hormone binding proteins provide a hormone reservoir in the 
plasma and "buffer" hormone delivery into tissue. These transport proteins act to provide 
a continuously available source of hormone while keeping the free or active fraction of 
the hormone within a tight range. Thyroxine-binding prealbumin, and possibly albumin, 
also may serve as intermediary carriers for specific uptake of the hormone by individual 
tissues. Dogs do have a high affinity thyroid hormone binding protein comparable to TBG 
in humans, but plasma concentrations of TBG in the dog are only 15 % of those observed 
in humans.  In addition to TBG, TBPA, and albumin, circulating T4 in canine plasma 
appears to bind to certain plasma lipoproteins. The cat does not appear to have a high 
affinity thyroid binding protein (such as TBG) but has only TBPA and albumin as serum 
thyroid hormone binding proteins.   Partly as a result of weaker serum protein binding, 
total T4 concentrations are lower, the unbound or free fraction of circulating T4 is higher, 
and hormone metabolism is more rapid in most domestic animals than in humans (Bigler, 
1976; Larsson et al., 1985). This observation explains in part why dosages for thyroid 
hormone replacement therapy are higher in dogs than in humans.  
The free hormone hypothesis states that it is the unbound fraction of hormone, 
which is available to tissues and therefore proportional to the action, metabolism, and 
CHAPTER 1 
 18
elimination of that hormone (Robbins & Rall, 1960; Mendel, 1989). Most evidence 
suggests that the free hormone fraction predicts the amount of hormone that is available 
to tissues at equilibrium. Plasma proteins buffer hormone delivery into tissue and 
provide a hormone reservoir. While normal variation in the free fraction of thyroxine 
(FFT4) is fairly small, ranging from 0.05-0.15%, this binding relationship may change 
in response to drugs or illness (Ferguson & Peterson, 1992).  Partly as a result of weaker 
serum protein binding in the dog compared to humans, total T4 concentrations are 
lower, and the unbound or free fraction of circulating T4 is higher (0.1 vs. ~0.03% in 
humans) (Bigler, 1976; Larsson et al., 1985; Kaptein et al., 1994). 
Evidence also exists that certain cell types actively transport or exchange thyroid 
hormone from the plasma into the cytosol, and that these transport and exchange systems 
may be targeted by some drugs.  However, some investigators believe that serum-binding 
proteins, especially albumin and TBPA, may serve to distribute hormones to specific 
tissues. Most theories of thyroid hormone exchange have assigned a passive "reservoir" 
role to cytosolic thyroid hormone binding proteins, proteins that retain thyroid hormone in 
a predominantly bound state inside the cell (Pardridge, 1981; Mendel, 1989; Burrow et al., 
1989). 
Most evidence suggests that thyroid hormone uptake by tissues is proportional 
to, but not limited to, the free or unbound fraction of circulating hormone. Approximately 
50 to 60 % of the body's T4 and 90 to 95 % of the body's T3 is located in the intracellular 
compartment (Fish et al., 1997).  Certain organs, especially the liver and kidney, can 
concentrate thyroid hormones and exchange hormone rapidly with the plasma.  In humans, 
about 60 % of the intracellular T4 is in rapidly equilibrating tissues (e.g., liver, kidney) 
whereas only 6 % of the intracellular T3 is in these tissues.
  About 80 % of all 
extrathyroidal T3 is located in slowly equilibrating tissues (e.g., muscle, skin), whereas 
only 20 % of intracellular T4 is in this compartment.  As a result, most of the body's T4 is 
located in plasma, interstitial fluid, liver and kidney. The majority of the body's 
extrathyroidal T3 is in the cells of the muscles and skin and in a conjugated form in the 
intestinal tract.   
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 Metabolic clearance rates 
 The plasma half-life of T4 in the dog has been estimated to be 8 hours (Kaptein et 
al., 1993; 1994) or 10-16 hours (Fox & Nachreiner, 1981) compared to a plasma half-life 
of about 7 days in humans.   Similarly, the plasma half-life of T3 in the dog has been 
estimated to be 5 to 6 hours, compared to 24 to 36 hours in humans. These figures reflect 
plasma disappearance rates and do not necessarily indicate extent or duration of biological 
action. The shorter half-life of T4 explains why when treating hypothyroidism a twice-
daily administration of synthetic T4 will more consistently normalize serum T4 
concentrations (Nachreiner et al., 1993). In most hypothyroid dogs, however, once daily 
administration of thyroxine often leads to good clinical control of the disease (Ferguson, 
2001). 
 
 
II. Etiology of canine hypothyroidism  
 
 Although dysfunction anywhere in the hypothalamic-pituitary-thyroidal axis 
may result in thyroid hormone deficiency, more than 95 per cent of clinical cases of 
hypothyroidism in dogs result from destruction of the thyroid gland itself (i.e., primary 
hypothyroidism) (Scott-Moncrieff & Guptill-Yoran, 2000). The 2 most common causes 
of adult-onset primary hypothyroidism in dogs are lymphocytic thyroiditis and 
idiopathic atrophy of the thyroid gland, each accounting for about one-half of the cases 
of hypothyroidism (Gosselin et al., 1981). Other rare forms of canine hypothyroidism 
include iatrogenic conditions, neoplastic destruction of thyroid tissue and congenital 
hypothyroidism. Hypothyroidism occasionally also may result from impaired ability of  
the pituitary gland to synthesize and secrete TSH, resulting in secondary thyroid 
follicular atrophy. Secondary hypothyroidism can be caused by pituitary tumors, 
congenital pituitary malformation, isolated TSH deficiency, or pituitary trauma or 
surgery and accounts for less than 5 % of clinical cases of hypothyroidism (Rijnberk, 
1996; Scott-Moncrieff & Guptill-Yoran, 2000).  
Congenital hypothyroidism is rare compared to acquired hypothyroidism.  
Possible etiologies include:  dysgeneses of the thyroid gland, an enzymatic deficit in 
thyroid hormone synthesis or a central problem (most frequent) (Rijnberk, 1996).  There 
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are some reports of congenital hypothyroidism in the literature; a young Boxer, a family 
of giant Schnauzers (central hypothyroidism) and young German Shepherds suffering 
from dwarfism (Greco et al., 1991; Mooney & Anderson, 1993; Kooistra et al., 2000b). 
German Shepherds with pituitary dwarfism, a recessive inheritable disease, suffer from 
a combined deficiency in growth hormone, TSH and prolactin (Kooistra et al., 2000b). 
 The lymphocytic thyroiditis can occasionally be seen with other autoimmune 
diseases. Schmidt syndrome or polyglandular autoimmune disease is well described in 
humans, but is also described in dogs.  This disease is characterized by the presence of 2 
or more endocrine diseases, e.g. hypoadrenocorticisme, autoimmune thyroiditis and 
insuline-dependant diabetes mellitus. The association of several endocrine diseases can 
be a diagnostic and therapeutic challenge (Kintzer, 1992). 
 
 
III. Clinical signs of hypothyroidism in dogs 
 
 Thyroid hormones have an effect on all levels of metabolism and their 
deficiency can lead to dysfunction of several organs. Clinical signs of hypothyroidism 
are vague and insidious in onset. Furthermore, many diseases, such as canine recurrent 
flank alopecia (CRFA) or any systemic condition can lead to clinical signs suggestive of 
hypothyroidism. This disease is most commonly observed in middle sized to large breed 
dogs and occurs preferably between 3 and 8 years of age.  A few breeds, such as the 
Doberman, Golden Retriever, de Irish Setter, Airedale Terrier, Great Dane, Bobtail and 
Beagle seem predisposed (Feldman & Nelson, 1996).  Primary acquired hypothyroidism 
is infrequent under the age of 2 years. Table 1 gives a summary of the clinical signs that 
can be observed with hypothyroidism.  
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Table 1: Summary of the most common clinical signs observed in dogs with 
hypothyroidism  
 
Frequent 
 
Less frequent 
 
Doubtful relationship 
 
Lethargy/weakness 
 
Neuropathy, vestibular 
syndrome 
 
Male infertility 
 
Obesity 
 
Female infertility  
 
Dilated cardiomyopathy 
 
Alopecia/hypotrichosis 
 
Myxoedema 
 
Larynx paralysis 
 
Seborrhea 
 
Lipid keratopathy 
 
Megaoesofagus 
 
Pyodermia or recurrent otitis  
  
 
 
 Twenty to 76% of the hypothyroid dogs are presented to their veterinarian with 
complaints of weakness, lethargy or exercise intolerance (Panciera, 1997; Dixon et al., 
1999; Scott-Moncrieff & Guptill-Yoran, 2000).  Sometimes the disease is so insidious 
in onset that the owners only note after initiating the therapy how lethargic their pet 
was. 
 
 Dermatological changes such as a dry skin, changes in coat quality or color, 
alopecia or seborrhoea are described in 60-80 % of hypothyroid dogs (Panciera, 1997; 
Dixon et al., 1999; Scott-Moncrieff & Guptill-Yoran, 2000).  The alopecia can be 
observed in areas undergoing friction (neck or tail) or have a bilateral symmetrical 
distribution (thorax or flank) sparing the limbs.  Alopecia can occur because thyroid 
hormones are essential to initiate the anagen phase (growth) of the hair follicles. 
Hyperpigmentation can sometimes be observed.  A predisposition for recurrent bacterial 
pyoderma or external otitis and Malassezia infections can be seen. Alopecia is a 
common clinical sign of hypothyroidism; 25% of hypothyroid dogs have been reported 
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to present with symmetrical bilateral endocrine alopecia (Feldman & Nelson, 1996).  
The symmetrical alopecia described in canine recurrent flank alopecia (CRFA) can 
easily mislead one to a diagnosis of hypothyroidism. Canine recurrent flank alopecia is 
a recently recognized skin disorder of unknown etiology, characterized by episodes of 
truncal hair loss that often occurs on a recurrent basis.  It has been described under 
several synonyms: seasonal flank alopecia, canine idiopathic cyclic flank alopecia, 
cyclic follicular dysplasia, and follicular dysplasia.   Typically, this alopecia affects 
adult dogs on a yearly seasonal basis and resolves spontaneously without treatment 
within several months.  The episodes do not always reoccur annually.  A breed 
predisposition seems to exist for CRFA, with boxers (may account for approximately 
half of all reported cases), Airedale terriers, schnauzers, and English bulldogs being the 
more frequently cited breeds (Scott, 1990; Miller & Dunstan, 1993; Curtis et al., 1996). 
However, it has been reported in several other breeds (Fontaine et al., 1998). 
Interestingly, the same breeds are suspected to be predisposed for hypothyroidism 
(Feldman & Nelson, 1996). Furthermore, the recognition of CRFA as a separate 
dermatological condition became clear only in the 1990s (Scott, 1990).  Therefore, 
some dogs previously classified as hypothyroid based on the presence of flank alopecia 
resolving with thyroid supplementation might very well have been dogs suffering from 
CRFA.  Another explanation is that the breeds cited earlier are predisposed to both 
hypothyroidism and CRFA.  Both diseases are more frequent in young to middle-aged 
dogs.  Several hypotheses, such as photoperiod and melatonin deficiency, have been 
proposed to explain the disease, but the etiology remains unclear (Scott, 1990; Curtis et 
al., 1996; Fontaine et al., 1998; Paradis, 2000). Thorough assessment of thyroid 
function in dogs with CRFA has not been reported to our knowledge and will be further 
explored in chapter 4. 
 
Obesity is observed in more than 40 % of dogs with hypothyroidism in several 
studies (Kaelin et al., 1986; Panciera, 1994; Feldman & Nelson, 1996; Dixon et al., 
1999). Therefore, many dogs in practice are tested and/or treated for hypothyroidism 
because they are overweight. Obesity, however, is a common nutritionally related 
problem in dogs and many dogs with obesity are not hypothyroid. It is estimated in the 
general population that between 21 and 30 % of dogs seen in practice are obese 
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(Laflamme et al., 1994). Many obese hypothyroid dogs are mildly to moderately obese 
but occasionally the obesity can be very outspoken.  Obesity and weight loss have been 
shown to alter thyroid hormone homeostasis in humans. In dogs, obesity is the most 
common nutritional problem encountered and weight loss is the cornerstone of its 
treatment, therefore it is important to clarify how obesity and weight loss can affect 
thyroid function test results in dogs.  This will be further evaluated in chapter 5.  
 
 Some other complaints such as myxoedema, reproduction, neurological, 
cardiovascular or ophthalmologic problems can be present but less frequently.   
 Myxoedema gives the patient a typical tragic expression and is caused by the 
accumulation of hyaluronic acid in the dermis around the face (Scott-Moncrieff & 
Guptill-Yoran, 2000). The most severe and extremely rare presentation for 
hypothyroidism is myxoedema coma. This leads to impairment of mental status, 
thermoregulation and cardiorespiration.  Dobermans seem to be predisposed. 
Thyroid hormones, through stimulation of the myocytes, have a positive chrono- 
and inotrop effect on the hart.  This is partly due to increased transcription of the heavy 
myosin chains, an increase in calcium ATPase pumps and increased amount of E 
receptors (Panciera, 2000). The cardiovascular effects of thyroid hormone 
concentrations are most pronounced in cats with hyperthyroidism (excessive thyroid 
hormone concentrations), these animals can develop a hypertrophic cardiomyopathy. In 
cases of canine hypothyroidism, the cardiovascular consequences are subtler, but can 
include, decreased cardiac output, bradycardia, and a decrease in the R wave amplitude 
on ECG (Panciera, 2000). Hypothyroidism was observed more frequently in a group of 
dogs with atrial fibrillation (Gerritsen et al., 1996). Hypothyroidism might predispose a 
dog, with an already existing cardiac disease, to develop atrial fibrillation. A causative 
effect between hypothyroidism and the development of dilated cardiomyopathy is still 
controversial. 
  
The lipid keratopathies sometimes observed in dogs with hypothyroidism are 
most likely a consequence of the hyperlipidemia frequently observed in this condition.  
But the association between corneal lipid deposits and hypothyroidism has been poorly 
documented yet in dogs. 
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 In some cases the patients are brought in with neurological signs.  Most of these 
dogs also show classical signs of hypothyroidism.  Generalised peripheral neuropathies 
or localised neuropathies (vestibular disease, facial paralysis, laryngeal paralysis, 
megaoesofagus) were described in hypothyroid dogs (Jaggy & Oliver, 1994; Jaggy, 
2000). A direct causative link is controversial, especially concerning the megaoesofagus 
or the laryngeal paralysis. A decreased activity of the sodium/potassium pump, 
atherosclerose and myxoedema have been proposed as possible mechanisms (Jaggy, 
2000). 
 Reproduction abnormalities have been considered as a classical feature for dogs 
with hypothyroidism in the past. A recent study has not shown a decrease in 
reproduction capacity in male dogs with hypothyroidism (Johnson et al., 1999). With 
advanced hypothyroidism bitches could show infertility, shortened oestrus or prolonged 
anoestrus.  A direct causative effect has however not been shown.  Intact hypothyroid 
bitches, through stimulation of prolactin secretion by the increased TSH concentrations, 
can sometimes show galactorrhea (Cortese et al., 1997). 
 Thyroid hormones are essential in the young age for the development of tissues 
and skeleton.  In addition to the clinical signs seen with acquired hypothyroidism, dogs 
with congenital hypothyroidism can show lameness, macroglossia, delayed tooth 
eruption and disproportionate dwarfism.  On radiographs a typical epiphyseal 
dysgenesis can be observed (Greco et al., 1991; Mooney & Anderson, 1993). Young 
German shepperd dogs with pituitary dwarfism typically have a proportionate dwarfism, 
an abnormal coat with retention of secondary hairs, an absence of primary hairs and a 
symmetrical bilateral alopecia.  Male dogs often have cryptorchidism and bitches can 
sometimes show a persistent oestrus (Kooistra et al., 2000b). 
 
 
IV. Non-specific laboratory changes observed in canine hypothyroidism 
 
 Finding a hypercholesterolemia and a non-regenerative anemia on a blood 
analysis can increase the suspicion for hypothyroidism. Hypercholesterolemia is 
observed in approximately 75% of the cases and would be due to a decreased clearance 
and hepatic use combined with an increased hepatic production of cholesterol (Feldman 
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& Nelson, 1996; Christopher, 1997; Scott-Moncrieff & Guptill-Yoran, 2000). The 
animal has to be fasted for at least 12 hours before taking the sample in order to avoid 
postprandial hypercholesterolemia.  The hypercholesterolemia is often pronounced in 
hypothyroid dogs with some dogs showing values in excess of 10 mmol/L.  
Unfortunately, hypercholesterolemia is observed in many other diseases such as 
hyperadrenocorticism, diabetes mellitus, glomerulopathies and liver diseases.   
 Normocytic normochromic anemia is observed in 30% of dogs with 
hypothyroidism, but the packed cell volume typically remains above 25%. This anemia 
could be due to a decreased stimulation of erythropoiesis by erythropoietin and thyroid 
hormones.  Occasionally, target cells can be seen on a blood smear. These are thought to 
be the result of cholesterol overload of the erythrocyte membrane (Feldman & Nelson, 
1996). 
 Thrombocytosis can be observed and platelets are sometimes smaller (Sullivan 
et al., 1993). A few years ago, it was thought that hypothyroidism could lead to a 
decrease in von Willebrandfactor and bleeding tendencies.  Recent studies have 
however shown that this was not the case (Panciera & Johnson, 1994). It is interesting 
to note that some breeds, such as the Dobermans, which are predisposed for 
hypothyroidism, also are predisposed for von Willebrands disease. 
 Frequently, the dermatological abnormalities observed suggest an endocrine 
origin but are seldom specific for hypothyroidism.  Skin biopsies are unnecessary in 
most cases suspected of canine hypothyroidism. Cutaneous changes that would support 
a diagnosis of hypothyroidism, are hypertrophy and a vacuolisation of the musculi 
erectori around the hair follicle (controversial), dermal mucinosis and a thickening of 
the dermis with the presence of myxoedema (Miller & Dunstan, 1993; Scott et al., 
1995). 
 
 
V. Specific thyroid tests used in dogs 
 
 Because of the vague clinical signs and the absence of specific abnormalities on 
a routine blood test, the diagnosis should be confirmed through a specific evaluation of 
the thyroid gland.  These tests should always be run on a dog with a clinical suspicion 
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for hypothyroidism, and not as a screening test in dogs without any clinical signs 
suggestive of the disease. It is indeed important to mention that the positive predictive 
value of a diagnostic test increases when the prevalence of the disease increases.  A 
thorough clinical examination of the patient, knowledge of the advantages and 
disadvantages of all available tests and knowledge of the factors that can influence the 
results, will allow the veterinarian to correctly diagnose the disease. Table 2 contains a 
summary of the advantages and disadvantages of the most commonly used thyroid 
hormone tests in dogs.  
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Table 2: Advantages and disadvantages of the most commonly used tests to 
evaluate thyroid function in dogs   
Test Advantages Disadvantages 
TT4 Easy 
Not expensive 
Readily available 
Normal values allow 
exclusion of 
hypothyroidism  
Decreased with SNTD 
Decreased after 
administration of certain 
drugs 
A decreased T4 alone does 
not allow a reliable 
diagnosis of hypothyroidism 
(low specificity) 
TSH Easy 
Not expensive 
Available 
1/4 of hypothyroid dogs 
have TSH values within the 
reference range (low 
sensitivity) 
Always use in combination 
with T4  
FT4 Is less influenced by SNTD 
or through drug 
administration than TT4 
The only reliable method is 
through equilibrium dialysis 
Not readily available in 
Europe 
T3 Theoretically interesting  Few clinical interest 
because of overlapping 
values between 
hypothyroid, euthyroid and 
sick dogs  
TSH stimulation test Was and still is considered 
as the gold standard  
Bovine TSH is not easily 
available anymore 
Expensive 
4 to 6 hours lasting test  
Anaphylactical reactions 
were described  
TRH stimulation test 
   *with T4 determination 
   *with TSH determination 
 
 
Allows diagnosis of primary 
hypothyroidism 
Interesting for the diagnosis 
of secondary 
hypothyroidism  
 
Not reliable 
No extra benefit compared 
to combination of TT4 and 
TSH determination 
Expensive  
Possibly vomiting, 
salivation and tachycardia  
 
SNTD: systemic non-thyroid disease 
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 Until very recently, veterinarians have been required to choose from a variety of 
diagnostic tests of thyroid function, with no single test being optimal. Following 
development of canine-specific TSH assays and further experience with free thyroxine 
by equilibrium dialysis (FT4ED), the benefits of these assays have become apparent, 
but so also have their limitations.  Experience with canine TSH assays, has not 
increased estimates of thyroid failure secondary to deficiency of pituitary TSH 
secretion; but, it has helped confirm the goitrogenic effect of some commonly used 
drugs (Campbell et al., 1995; Scott-Moncrieff & Nelson, 1998). Specificity, sensitivity 
and accuracy of FT4 and TSH determinations for the diagnosis of canine 
hypothyroidism are summarized in table 3.  
 
Table 3: Thyroid diagnostic test comparisons in dog (%) 
Test TT4            TT3 FT4D       TSH   TT4/TSH    FT4D/TSH
Sensitivity 89/100      10            98/80        76/86.7       67/86.7       74/80 
Specificity 82/75.3       92   93/93.5     93/81.8       98/92.2       98/97.4 
Accuracy 85             55 95 84               82 86                
 
Data from Peterson et al (Peterson et al., 1997) and Dixon et al (Dixon & Mooney, 
1999b). If only 1 number listed, from Peterson et al.. 
Sensitivity is the percentage of hypothyroid dogs that had abnormal test results. 
Specificity is the percentage of euthyroid dogs that had normal test results. 
Accuracy is the percentage of cases that are neither falsely positive nor falsely negative. 
 
 Thyroid hormones kept in plastic tubes, remain stable for 5 days at room 
temperature, and can be kept frozen for years.  Serum concentrations of total thyroxine 
(TT4) and free thyroxine (FT4) will increase if they are kept in glass tubes for 5 days at 
37 q C (Behrend et al., 1998). Furthermore, glass tubes break easier during transport.  
Hemolysis and lipemia do not interfere with measurement of thyroid hormones 
measured by radioimmunoassay (RIA) (Behrend et al., 1998; Scott-Moncrieff & 
Guptill-Yoran, 2000). 
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Total thyroxine 
 Canine thyroid function is most frequently evaluated in practice through 
measurement of a baseline serum TT4, which is easy and not expensive.  But it is 
important to realise its limitations.  Indeed, numerous factors such as systemic diseases 
or the administration of medications can influence the TT4 serum concentrations and 
will be discussed further.  Furthermore there is an important overlap between the TT4 
serum measurements observed in euthyroid and hypothyroid dogs.  A study indicates 
that basal TT4 measurements observed in 62 normal dogs varied between 12,8 and 42,5 
nmol/L and from not detectable to 19,3 in 51 hypothyroid dogs (Nelson et al., 1991). 
The measurement of a baseline TT4 alone to evaluate thyroid function is insufficient, 
except when the TT4 measurement falls well within the reference limits, this allows 
exclusion of the diagnosis of hypothyroidism in the majority of cases (high sensitivity 
of the test).  When TT4 serum concentrations are under the reference range, further 
testing is indicated.  
 The methods for detection used are also of importance.  Canine TT4 serum 
concentrations are only 10 to 25% of those observed in humans. Therefore it is 
preferable to use canine kits to perform the measurements.  Radioimmunoassay (RIA) is 
the most commonly used test.  The presence of anti-thyroxine antibodies in some dogs 
with lymphocytic thyroiditis can interfere with the measurement of TT4 through RIA.  
Consequently, false low or more commonly falsely elevated TT4 measurements can be 
observed (Thacker et al., 1992).  
 
Endogenous thyrotropin 
 With primary hypothyroidism, an increase in TSH serum concentrations would 
be expected because of the lack of negative feed back mechanism of the thyroid 
hormones on the pituitary.  In human medicine, measurement of serum TSH is 
recommended to evaluate thyroid function. An increase will confirm a diagnosis of 
primary hypothyroidism.  It is important to note that in human medicine, third 
generation kits for TSH measurements are very sensitive and allow detection of small 
variations in TSH concentrations. This would not be the case yet for the kits used in 
dogs.  The measurement of canine endogenous TSH has only been available for a few 
years now.  Sometimes, a euthyroid dog can have increased TSH values (Scott-
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Moncrieff et al., 1998; Dixon & Mooney, 1999b).  But, more problematic is the fact that 
approximately one fourth of the dogs with hypothyroidism show TSH serum 
concentrations within the reference range (Peterson et al., 1997; Scott-Moncrieff et al., 
1998; Dixon & Mooney, 1999b). Several hypotheses have been suggested:  fluctuation 
of the TSH serum concentration, the non detection of all isoforms of TSH, some dogs 
might suffer from secondary or tertiary hypothyroidism, or finally that with time TSH 
decreases in dogs with primary hypothyroidism (Ramsey et al., 1997; Peterson et al., 
1997; Kooistra et al., 2000a). In other words, because of the weak sensitivity of the 
TSH measurement for the diagnosis of hypothyroidism, this test cannot be 
recommended solely.  To reliably evaluate canine thyroid function, a T4 measurement 
(FT4 or TT4) is always combined with a TSH measurement.  A serum sample with 
decreased T4 and increased TSH serum concentrations (>0,6 ng/ml) will confirm with 
confidence the diagnosis of primary hypothyroidism (Scott-Moncrieff et al, 1998; 
Kantrowitz et al., 1999). When the measurements of T4 and TSH give contradictory 
results, it is recommended to repeat measurements 4-8 weeks later.  
 
Free thyroxine 
 Only the free fraction of T4 (not bound to transport proteins) can enter the cells, 
link to the receptors and lead to a biological effect. In theory, the measurement of FT4 
should reflect more precisely thyroid function.  But the low FT4 serum concentrations 
(<1% of TT4) render the measurement more difficult. The most reliable technique used 
to measure FT4 is equilibrium dialysis, only available in some laboratories and more 
expensive then measurement of a TT4.  In this technique, a semi-permeable membrane 
allows passage of small FT4 molecules and not of transport proteins; this allows 
isolation and measurement of FT4.  One-study reports a sensitivity of 98%, when the 
measurement of FT4 is used alone for the diagnosis of hypothyroidism (Peterson et al., 
1997). However, another study concludes that measurement of FT4 by equilibrium 
dialysis only added minimal supplementary information compared to measurement of 
TT4 serum concentrations (Dixon & Mooney, 1999b). Other methods used for 
determination of FT4 such as chemoluminescence and RIA seem less reliable and offer 
no advantage over the simple dosage of TT4 levels by RIA (Nelson et al., 1991; Scott-
Moncrieff & Guptill-Yoran, 2000). Free T4 serum concentrations seem less influenced 
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by non-thyroidal illnesses then TT4 (Peterson et al., 1997). Measuring FT4 seems 
therefore more interesting to evaluate thyroid function, if measurement is performed 
through equilibrium dialysis.  
 
Triiodothyronine 
 Determination of total or free triiodothyronine (TT3, FT3), the hormone active at 
the cellular level, would be interesting, at least in theory.  However there is an important 
overlap between values observed in euthyroid dogs, hypothyroid dogs and dogs 
suffering from a systemic illness.  Therefore, determination of TT3 concentration is not 
very interesting in the evaluation of thyroid function in practice (Nelson et al., 1991; 
Miller et al., 1992). 
 
Thyrotropin stimulation test 
 Canine thyroid stimulation with bovine TSH is less affected by the presence of 
non-systemic thyroid diseases then is a baseline TT4 measurement. Therefore the 
bovine TSH stimulation test has long been considered as the gold standard for thyroid 
evaluation in dogs (Scott-Moncrieff & Guptill-Yoran, 2000). Today, the bovine TSH 
stimulation test is less used for several reasons: expense, 4-6 hour test, bovine TSH is 
difficult to obtain and endogenous TSH measurements are available. Measurement of 
TT4 and TSH are readily available, but in non-unfrequent cases with controversial 
results, performing a TSH stimulation test would still be very interesting.  A recent 
study showed that recombinant human TSH would stimulate the thyroid gland of 
euthyroid beagle dogs (Sauvé & Paradis, 2000). Clinical studies to evaluate its clinical 
usefulness are underway.  
 
Thyrotropin-releasing hormone stimulation test 
 Because bovine TSH was difficult to obtain, studies were performed to evaluate 
the use of TRH stimulation tests (thyrotropin-releasing hormone) as an alternative.   
Thyrotropin-releasing hormone should stimulate the secretion of TSH by the pituitary; 
induce a stimulation of the thyroid gland and an increased release of T4.   But the 
increase in TT4 or FT4 after injection of TRH is less pronounced than with a TSH 
stimulation test.  Indeed, a study revealed that the TRH stimulation test is not useful in 
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the diagnosis of hypothyroidism (Frank, 1996). Determination of TSH levels, instead of 
TT4, after stimulation with TRH, allows differentiation between hypothyroid and 
euthyroid dogs (Meij et al., 1996; Scott-Moncrieff & Nelson, 1998),  but this test did 
not offer any advantage over the classical combination of TT4 and TSH measurement. 
The TRH-stimulation test can be useful in the diagnosis of secondary hypothyroidism 
(pituitary origin).  The administration of TRH can lead to undesirable effects such as 
vomiting, diarrhea and tachycardia. For all those reasons, this test is seldom used in 
practice in the evaluation of thyroid function in dogs.  
 
Antibodies against thyroid hormones  
 Antibodies against thyroid hormones can sometimes by found in dogs. Thyroid 
hormones are haptens that are minimally immunogenic. However it seems that 
thyroglobulin (TG), which is released with lymphocytic thyroiditis, provides the 
antigenic stimulus and presents T3 and T4 to the immune system (Gaschen et al., 1993). 
Therefore, finding those antibodies suggests the presence of a lymphocytic thyroiditis.  
However, the presence of these antibodies does not reflect thyroid function, as 75% of 
the thyroid gland must be destroyed in order to lead to decreased T4 blood levels. 
Furthermore, anti-T3 and anti-T4 antibodies are only observed in approximately 30% of 
the hypothyroid dogs. Therefore their clinical use is limited (Thacker et al., 1992). 
These antibodies can interfere with radioimmunoassay determination of T3 or T4, and 
lead to falsely increased values as a consequence. In this case, measurement of FT4 by 
equilibrium dialysis is recommended, as this test is not affected by the presence of anti-
T4 antibodies.  
 The measurement of anti-thyroglobulin antibodies (ATG) was evaluated as a 
diagnostic tool but high percentages of false positive were found especially in dogs with 
systemic diseases (Thacker et al., 1992). This limited their clinical use. More reliable 
measurement methods and interpretation criteria were recently published.  However, 
these ATG are found only in 36 to 60% of hypothyroid dogs (Nachreiner et al., 1998; 
Dixon & Mooney, 1999a; Daminet & Paradis, 2000). The presence of ATG in euthyroid 
dogs (fals positives) is now only observed in less then 5% of healthy dogs (Nachreiner 
et al., 1998; Dixon & Mooney, 1999a). A diagnosis of hypothyroidism could never be 
based on the finding of those antibodies alone, as they do not reflect thyroid ability to 
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synthesise thyroid hormones.  But if hypothyroidism was already diagnosed, then 
finding ATG can confirm the presence of a lymphocytic thyroiditis as a cause of the 
hypothyroidism. The presence of antibodies in combination with normal thyroid 
hormone values can be an indication that hypothyroidism might develop. Clinical 
studies evaluating the development of hypothyroidism in dogs positive for ATG are 
lacking.  It is interesting to note that the measurement of ATG is part of the screening 
required by the OFA  (Orthopedic Foundation for Animals) for reproduction animals.  
 
Diagnostic therapy 
 Response to therapy as a sole method of diagnosing hypothyroidism is not 
recommended for several reasons.  Even if the primary complaints improve with the 
administration of synthetic thyroid hormones, many intermittent disorders will improve 
with the administration of thyroid hormones (e.g. canine recurrent flank alopecia or just 
general stimulation of the animal). The consequence will be an unnecessary and 
expensive therapy, potential side effects or the delay in the diagnosis of the real 
problem.  
 
Scintigraphy 
 Scintigraphy is a very useful method for evaluation of thyroid function. It is 
more commonly used in the evaluation of feline hyperthyroidism than in the evaluation 
of canine hypothyroidism. Unfortunately, because of the need for specialised equipment 
and the use of radioactive products, it is not widely available. Furthermore, very often 
the patient needs to be anaesthetized.  
 
 
VI. Influence on thyroid function tests  
 
 Numerous diseases and medications can influence thyroid function. Besides this, 
many other physiological factors such as, age, breed and fluctuating serum 
concentrations can influence the results.  Therefore the interpretation of the laboratory 
result alone will lead to overdiagnosis of hypothyroidism.  
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A. Physiological influences  
 Thyroid hormone concentrations vary opposite to age.  At birth, thyroid 
hormone concentrations observed are very close to adult values. Gradually after birth 
they increase. In puppies younger than 6 weeks of age, thyroid hormone serum 
concentrations are 2 to 5 times higher than in adult dogs.  From 6 to 12 weeks of age, 
TT4 values are comparable to those observed in adult dogs (Reimers et al., 1990). Half 
of the dogs older then 6 years of age have lower TT4 serum values.  Thyrotropin 
stimulation test results are also less pronounced in older dogs.  The exact cause for these 
differences in thyroid hormone levels with age is unknown, but highlights the 
importance of having specific reference values for each age category. 
 Small breed dogs have TT4 values that are somewhat higher then mid- or large 
breed dogs.  Their average TT4 value remains well within the reference range (Reimers 
et al., 1990). Therefore, from a clinical point of view these changes are not very 
relevant.  
 Greyhounds have TT4 values that are clearly lower (half) than in other breeds.  
Thyroid function test results in this breed should therefore be interpreted very cautiously 
(Gaughan & Bruyette, 2001).  Newfoundland dogs are also sometimes mentioned as a 
breed with lower TT4 values, but in one study, TT4 and TSH serum concentrations 
were comparable to values observed in other breeds (Sauvé et al., 1997). If some other 
breeds could have decreased thyroid hormone concentrations remains to be studied.   
 Globally, there are no differences in thyroid hormone concentrations between 
male and female dogs.  But, pregnant bitches or bitches in dioestrus (progesterone 
influence) have TT4 serum concentrations that are higher then a non-selected 
population (Reimers et al., 1990).  
 Daily random fluctuations in thyroid hormone concentrations have been 
described in euthyroid dogs (Miller et al., 1992).  
 A pronounced protein deficit and fasting can decrease thyroid hormone values, 
but the influence of obesity has not yet been well documented in dogs and will be 
evaluated in chapter 5 (van Haasteren et al., 1996).  
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B. Effects of drugs on canine thyroid function 
Table 4 shows drugs affecting thyroid function in humans with some proposed 
mechanisms of action. Table 5 summarizes the effects of some studied drugs on thyroid 
function in dogs.   
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Table 5: Summary of the effects of drugs on canine thyroid function test results.  
The symbols , , =, indicate that the measurements may be increased, decreased 
or unchanged, respectively. 
 
Drugs TT4 FT4 TSH 
TSH stimulation 
test 
Glucocorticoids 
(immunosuppressive 
dosage) 
p Not studied Not studied 
Blunted at high 
doses and 
durations 
Sulfonamides (30 
mg/kg q12h) 
p p n p 
Propranolol = = = = 
Carprofen p = (p) p Not studied 
Potassium bromide = = = = 
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Glucocorticoids 
 Studies performed on humans and rats have demonstrated that endogenous or 
exogenous glucocorticoids directly inhibit the hypothalamic-pituitary-thyroid axis and 
also influence peripheral metabolism of thyroid hormones (Davies & Franklyn, 1991; 
Kaptein et al., 1992; Wenzel, 1996). More precisely, in humans, glucocorticoids inhibit 
pituitary secretion of TSH, impair peripheral 5-deiodination of T4, and decrease TBG 
serum concentrations.  As a result, decreased serum concentrations of TT4, FT4, TT3 
and TSH and increased concentrations of rT3 can be observed in humans receiving 
glucocorticoid therapy (Cavalieri, 1991; Rubello et al., 1992; Samuels et al., 1994; 
Surks & Stievert, 1995; Hangaard et al., 1996). Mechanisms advocated to explain 
increased rT3 include reduced rT3 clearance and inhibition of 5-deiodination (Davies 
& Franklyn, 1991; Moore et al., 1993).  
 High endogenous cortisol concentrations in dogs with hyperadrenocorticism 
markedly lowered baseline serum TT4 concentration in 57 % of affected dogs and 
significantly blunted post-TSH T4 measurements (Peterson et al., 1984). Total T4 
concentrations normalized after treatment of the hyperadrenocorticism.  Decreased TSH 
secretion, changes in thyroid hormone binding and alterations in peripheral thyroid 
hormone metabolism were suggested in this study to explain the decreased thyroid 
hormone concentrations observed. 
 As glucocorticoids are very commonly used in canine medicine, the potential 
effects of exogenous corticosteroid administration on canine thyroid function test results 
will be further evaluated in chapter 2.  
 
 Phenobarbital 
 In rats, phenobarbital markedly alters thyroid function by increasing the rate of 
clearance of T4.  Increased hepatic deiodination of thyroid hormones, biliary clearance, 
and fecal excretion result in decreased concentrations of circulating thyroid hormones.  
Decreased concentrations of thyroid hormones, in turn, increase TSH secretion by the 
classical negative feedback pathway (McClain et al., 1989; Curran & Degroot, 1991; 
Johnson et al., 1993; Barter & Klaassen, 1994). Increased conversion of T4 to T3 in 
peripheral tissues also may play a role (Gieger et al., 2000). Phenobarbital also could 
have additional central effects on the hypothalamus-pituitary-thyroid axis 
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(Theodoropoulos & Zolman, 1989; Liu et al., 1995). Most studies in rats report 
decreased T4 with normal or, more often, increased TSH concentrations (Ohnhaus et 
al., 1981; Theodoropoulos & Zolman, 1989; Attia & Aref, 1991; Curran & Degroot, 
1991; DeSandro et al., 1991; Deda et al., 1992; Barter & Klaassen, 1994; Verma & 
Haidukewych, 1994). 
 In veterinary medicine, phenobarbital has long been listed as a drug that 
potentially can decrease serum TT4 concentrations in dogs, but this hypothesis has only 
been verified in the last few years and will be further discussed and evaluated in chapter 
2.   
 Further complicating the clinical evaluation of a dog tested for hypothyroidism 
and administered phenobarbital, is that weight gain (due to polyphagia), lethargy and 
hypercholesterolemia are reported in dogs on phenobarbital treatment, but are also 
commonly observed in dogs with hypothyroidism (Chrisman, 1991; Scott-Moncrieff & 
Guptill-Yoran, 2000; Gieger et al., 2000). 
 
 Potassium bromide 
 For years, phenobarbital has been considered the most effective initial treatment 
for dogs with epilepsy (Chrisman, 1991). Recently, many veterinary neurologists have 
started using potassium bromide (KBr) as the initial therapy of choice for dogs with 
epilepsy.  Bromide is a halide chemically related to iodide and potentially could interact 
with iodine in the thyroid gland.  In rats, bromide produces a relative iodine deficiency, 
thereby interfering with iodine uptake, iodine transport and iodination of tyrosine and 
tyrosyl residues on thyroglobulin (Velicky et al., 1998). A dose-dependent decrease in 
total T4 concentration, and morphological changes of the thyroid gland have been 
shown after KBr administration to rats (Loeber et al., 1983; van Leeuwen et al., 1983; 
Velicky et al., 1997; Velicky et al., 1998). Some of these effects already were noticed in 
thyroid glands of rats with small dosages of bromide (i.e. dosages encountered in the 
environment), and questions have been raised regarding the potential deleterious effects 
of environmental bromide on the human thyroid gland. No major effects were noted 
however on thyroid hormone concentrations after oral KBr administration in healthy 
humans (Sangster et al., 1983). A single case report of KBr overdose does however 
describe transient hypothyroidism in a human (Mizukami et al., 1988). 
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In one study, epileptic dogs receiving KBr alone (n=8) had normal thyroid 
function test results (Kantrowitz et al., 1999). Similar results were obtained in another 
study where thyroid function (TT4, TSH, FT4 and TRH stimulation) remained 
unchanged in healthy dogs receiving KBr over a 6-month period (Paull et al., 2000). In 
summary, administration of KBr does not seem to significantly affect thyroid function 
in dogs when used at usual dosages.   
 
 Sulfonamides 
 Sulfonamides can markedly interfere with thyroid hormone synthesis in rats by 
reversible inhibition of thyroid peroxidase, an enzyme essential for iodination (Comby 
et al., 1993; Doerge & Decker, 1994). Sulfonamides therefore are goitrogens, leading 
secondarily to diminished thyroid hormone synthesis and secretion. By reduced 
negative feedback, an increase in pituitary secretion of TSH occurs which induces 
proliferative changes in the thyroid gland (Cohen et al., 1981; Comby et al., 1993; 
Capen, 1994). Long-term administration of sulfonamides and prolonged stimulation of 
the thyroid gland by TSH have been associated with thyroid neoplasia in rats (Doerge & 
Decker, 1994). Considerable interspecies variation however exists with respect to 
thyroid peroxidase inhibition by sulfonamides (Doerge & Decker, 1994; Capen, 1994). 
For example, only mild effects of sulfonamides are observed on human thyroid function 
(Cohen et al., 1980). When a combination of sulfonamides and trimethoprim is used, it 
is the sulfonamide component which is responsible for thyroid inhibition, and 
trimethoprim alone failed to cause detectable alteration of thyroid function in rats 
(Cohen et al., 1981) or dogs (Lagler et al., 1976).  
Several prospective studies have evaluated the effects of sulfonamide 
administration on thyroid function in dogs.  Trimethoprim-sulfadiazine administered at 
a dosage of 15 mg/kg q12h to healthy dogs for 4 weeks had no effect on serum TT4, 
TT3, or FT4 concentrations or results of TSH stimulation tests (Panciera & Post, 1992). 
When trimethoprim-sulfadiazine was administered in the second half of gestation to 
pregnant bitches, no effects were noticed on thyroid hormone concentrations or thyroid 
gland morphology in the newborn puppies (Post et al., 1993). However, when 
trimethoprim-sulfadimethoxazole was administered to dogs suffering from pyoderma 
for 6 weeks at a higher dosage of 30 mg/kg q12h (a dosage frequently recommended in 
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veterinary dermatology), serum TT4, TT3 and FT4 concentrations decreased (Hall et 
al., 1993). Half of the dogs in this study had serum TT4 concentrations below the 
reference range at the end of the treatment period, which could have resulted in the 
inappropriate diagnosis of primary thyroid failure. Furthermore, 3 dogs had decreased 
responsiveness to bovine TSH stimulation at the end of the 6-week treatment.  In one 
dog, TSH stimulation results normalized 8 weeks later, whereas in another dog 
normalization took 12 weeks.  In 2 other studies, a similar dosage of trimethoprim-
sulfadimethoxazole was given to healthy dogs for several weeks, and serum 
concentrations of thyroid hormones were markedly decreased and endogenous TSH 
increased as soon as 7 days after initiation of the treatment (Campbell et al., 1996; 
Williamson et al., 2002). Furthermore, radionuclide thyroid imaging showed increased 
uptake of pertechnetate, and thyroid gland biopsies disclosed hyperplasia of thyroid 
follicles and absence of colloid production (Campbell et al., 1995). These findings 
further support the concept that sulfonamides act as goitrogens resulting in primary 
hypothyroidism and secondary changes associated with the proliferative effects of TSH. 
 
Clearly, the effects of sulfonamides on thyroid function are species-specific, and 
dosage- and duration-dependent.  Normalization of thyroid function test results in dogs 
after cessation of sulfonamide administration can take 8 to12 weeks.  If the clinician is 
not aware of the effects of sulfonamides on thyroid function, an inappropriate diagnosis 
of hypothyroidism can easily be made in a dog receiving sulfonamides.   
 Not only can sulfonamides alter thyroid function test results, but they also can 
lead to clinical hypothyroidism in some dogs (i.e. sulfonamide-induced iatrogenic 
hypothyroidism) (Torres et al., 1996; Gookin et al., 1999). The dogs described in these 
2 papers received a dosage of 24 mg/kg of trimethoprim-sulfadiazine for periods 
ranging from 30 to 126 days.  Thyroid gland function tests in these dogs were 
indistinguishable from those seen in dogs with endogenous hypothyroidism in both 
situations decreased TT4 and FT4, increased TSH and decreased response to TSH 
stimulation test are observed.  Thyroid scintigraphy was helpful in distinguishing 
endogenous from sulfonamide-induced hypothyroidism in one report (Gookin et al., 
1999). Uptake of pertechnetate by the thyroid gland should be normal or increased in 
dogs with sulfonamide-induced hypothyroidism, but should be minimal in dogs with 
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endogenous hypothyroidism.  The hypothyroid state (i.e. clinical signs and tests results) 
resolves gradually (i.e., 7 days to several months) after the withdrawal of sulfonamides.   
 
 Non steroidal anti-inflammatory drugs 
Many non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to alter 
thyroid function tests in humans, because circulating thyroid hormones are highly 
protein bound, and various NSAIDs can displace thyroid hormones from serum protein 
binding sites (Davies & Franklyn, 1991; Bishnoi et al., 1994; Wenzel, 1996). These 
effects are most important in humans treated with salicylates, fenclofenac and 
phenylbutazone (Davies & Franklyn, 1991). Short-term administration of therapeutic 
dosages of salicylates led to a transient increase in unbound hormone concentrations and 
suppression of TSH concentrations in most studies (Davies & Franklyn, 1991; 
McConnell, 1999). For example, administration of a single dose of aspirin acutely 
increases free thyroid hormone concentrations by 2- to 3-fold (Larsen, 1972). During 
long-term treatment with salicylates, a new steady state is reached reflecting increased 
T4 turnover rate (Davies & Franklyn, 1991). Decreases in serum TT4 concentrations of 
20 to 40 % have been reported (McConnell, 1992; Surks & Stievert, 1995). Free T4 
concentrations can be unchanged or decreased (Surks & Stievert, 1995; McConnell, 
1999). Thyrotropin concentrations return to the reference range within a few weeks of 
treatment (McConnell, 1992).  
Salicylates alter thyroid function primarily by competition with low-affinity 
binding sites on serum thyroid hormone-binding proteins, but other mechanisms such as 
inhibition of hepatic 5-monodeiodination and competition with plasma membrane, 
cytosolic or nuclear membrane binding also have been postulated (Chalmers et al., 
1993; Barlow et al., 1996; Lim  et al., 1996). The contribution of these disturbances on 
peripheral thyroid hormone metabolism however is uncertain (McConnell, 1999).  
Other NSAIDS have less pronounced effects on thyroid function in humans.  
Naproxen, diclofenac and ketoprofen induced a decrease in TT3 concentrations, but had 
no effect on TT4 and TSH concentrations (Bishnoi et al., 1994; Carlson et al., 1999). 
These results may be explained by the fact that, in humans, T3 is less avidly bound to 
transport proteins and is more easily displaced than T4 (Carlson et al., 1999). Ibuprofen, 
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piroxicam and indomethacin had no effects on thyroid function test results in human 
patients (Bishnoi et al., 1994).  
Thyroid hormone binding to serum carrier proteins and hormone metabolic rates 
vary among species. Therefore, it seems reasonable to think that the effects of NSAIDS 
on thyroid hormones might be different between dogs and humans. Affinity of thyroid 
hormones for their serum proteins is lower in dogs than in humans (Larsson et al., 1985; 
Larsson, 1987). Therefore it is possible that effects of different NSAIDS are more 
pronounced in dogs than in humans.  Further studies on the effects of other NSAIDS on 
canine thyroid function are necessary and will be discussed and evaluated in chapter 3.   
 
 Propranolol 
 Propranolol may alter thyroid hormone metabolism in humans. Small decreases 
in T3 are observed, but TSH concentrations remain unchanged.  In euthyroid beagle 
dogs, however, T4 and T3 measurements and TSH stimulation test results remained 
unchanged after 4 weeks of oral propranolol administration (TSH was not measured) 
(Center et al., 1984). Propranolol does not seem to significantly affect serum thyroid 
hormone concentrations in dogs. 
 
 
C. Systemic non-thyroid diseases  
 
 The presence of a systemic non-thyroidal disease (SNTD), such as diabetes 
mellitus, liver disease, hyperadrenocorticism and renal- or hart failure, is a frequent 
cause for decreased thyroid hormone concentrations.  This phenomenon is referred to as 
the "euthyroïd sick syndrome" (Ferguson, 1997). These changes probably reflect a 
physiological adaptation of the organism leading to a decrease in tissue energy 
requirements.  The administration of synthetic thyroid hormones to these patients is not 
recommended.  The pathogenesis is complex but would include:  change in the 
deiodinases activity, a decrease in thyroid hormone binding to their transport proteins, a 
decrease in TSH and thyroid hormone secretion (Nicoloff & LoPresti, 1995). Cytokines 
such as interleukine-1 (IL-1), IL-2, tumor necrosis factor-D and interferon, also seem to 
be involved. The administration of IL-2 to dogs has lead to a marked decrease in thyroid 
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hormone concentrations (Panciera et al., 1995). In the presence of a SNTD, serum 
thyroid hormone concentrations can be decreased in a range compatible with 
hypothyroidism.  For example, 57% of dogs with hyperadrenocorticism, showed a 
decrease in TT4 serum concentrations (Peterson et al., 1984). Free T4 can also be 
decreased but often to a lesser extend (Scott-Moncrieff & Guptill-Yoran, 2000). The 
response to a TSH stimulation test can also be blunted, but usually is less affected then a 
baseline TT4.  Therefore, it is indicated, whenever possible to treat the SNTD before 
testing thyroid function (Ferguson, 1997).  
 
 
VII. Diagnostic approach 
 
 Diagram 1 gives a possible approach for a patient suspected of having 
hypothyroidism. 
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Diagram 1: Proposed algorithm for the evaluation of thyroid gland in practice 
 
Dog with clinical signs suggestive of hypothyroidism 
 
 
 
Hematological and biochemical results compatible with hypothyroidism and which exclude 
the presence of systemic disease 
 
                                                                                           
       TT4 < 15 nmol/L 
           
         
     determine TSH  
                                              
TT4 p ( 15 nmol/L) 
and 
TSH n (! 0.6 ng/ml) 
   Contradictory      
   results 
   TT4 p, TSH N 
 
  
 -Repeat tests 4-8 
weeks later and/or 
  -TSH stimulation test 
and/or 
TT4 ! 15 nmol/L 
 
 
 
 
 
      Euthyroid  
(hypothyroidism very unlikely) 
   Hypothyroidism  -Combination of  
FT4 and TSH and/or 
    -Eventually 
determine ATG 
 
TT4: total thyroxine (reference range 15-45 nmol/L), FT4: free thyroxine (10-35 
pmol/L), TSH: Thyrotropin (0-0.6 ng/ml), ATG: anti-thyroglobuline antibodies.  Every 
laboratory should ideally determine its own reference values.   
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VIII. Treatment of canine hypothyroidism 
 
 Treatment of hypothyroidism consists in life long administration of synthetic 
levothyroxine (L-T4) in order to: approximate the secretion of thyroid hormones by the 
thyroid gland, resolve clinical signs and avoid thyrotoxicosis.  A normal thyroid gland 
secretes principally T4, which is thereafter transformed in T3 through peripheral 
deiodination.  The administration of a medication containing T3 and T4 is 
contraindicated because both hormones have very different half-times and in 
consequence their frequency of administration is very different. Treatment with 
liothyronine T3 is also contraindicated because it should be administered 3 times a day 
and more easily lead to thyrotoxicosis, presumably because the organism cannot 
regulate deiodination of T4 into T3.  The use of an original preparation ("brandname"), 
and a veterinary preparation should be prioritised, because biological availability of 
generic or human products varies in dogs (Nachreiner & Refsal, 1992). Dosages used to 
treat dogs are higher than in human medicine.  This is explained by a difference in 
metabolism between the two species.  In dogs, fecal excretion is higher and intestinal 
reabsorption less (10-50% compared to 50-80% in humans) (Ferguson, 1986). 
Therefore, half-time of T4 in dogs (18 hours) is shorter than in humans (7days).  Initial 
treatment dosages varies from 11 to 22 Pg/kg q 12 hour according to the author, with a 
maximum of 0,8 mg of L-thyroxine q 12 hour (Rijnberk, 1996; Greco, 2000; Scott-
Moncrieff & Guptill-Yoran, 2000). The patient is revaluated 1 to 2 months after 
initiating therapy and dosage is adjusted based on clinical response and results of the T4 
serum concentration.  The pharmacokinetics of levothyroxine after oral administration 
varies from patient to patient, therefore an individual adjustment of the dosage is needed 
(Nachreiner et al., 1993). After some time, in most dogs, once daily administration 
will be sufficient.  If the owner or veterinarian wishes to use generic products, 
revaluation of serum concentrations is recommended 1 to 2 months later.  Successful 
therapy is first of all assessed by a good clinical examination.  Lethargy should resolve 
within 2 weeks of initiating therapy.   Hair regrowth will be more progressive, but an 
improvement should be noticed within 4-6 weeks.  Blood abnormalities should be 
normalised within 4-6 weeks.  The non-resolution of the clinical signs within 6-8 weeks 
can have several origins such as; poor owners compliance with treatment, the dosage 
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used is not optimal, diagnosis could be wrong or an additional disease could be present.  
Most commonly treatment is evaluated through measurement of TT4.  When 
interpreting the result of TT4 measurement, time of sampling compared to the 
administration of the medication, should be taken into consideration. When a blood 
sample is taken just before administration of the medication (pre-tablet test), nadir 
concentrations are measured.  Most commonly blood is taken 4 to 6 hours after the last 
medication is administered (post-tablet test) and peak concentrations are measured.  In 
this case, TT4 is expected to be within the reference range (upper half limit), but a TT4 
value just above the reference range is accepted (Greco, 2000). Free T4 measurements 
can also be used to assess therapy. The recommendations concerning time of sampling 
and interpretation of results are similar as for TT4 (Scott-Moncrieff & Guptill-Yoran, 
2000). In human medicine, a combination of TSH and FT4 determinations is used to 
assess optimal therapy.  In humans and in dogs, the administration of an excess of 
levothyroxine can lead to thyrotoxicosis.  In human medicine, a small overdosage 
(subclinical thyrotoxicosis) can already lead to more hidden, but serious complications 
such as osteoporosis, increased liver enzymes or an occult cardiac hypertrophy (Greco, 
2000). This is accompanied by a decrease in TSH serum concentrations under the 
reference range. On the contrary, dogs only seldom suffer from clinical thyrotoxicosis 
(polyuria/polydipsia, polyphagia, weight loss, panting, hyperactivity). This is probably 
related to the more rapid elimination of thyroid hormones in dogs compared to humans. 
It is not clear whether the dog can, as observed in humans, suffer from subclinical 
thyrotoxicosis with side effect noted on the mid to long term.  In theory, the best way to 
assess optimal therapy would be to asses whether the pituitary-thyroid axis is 
sufficiently inhibited by the thyroid hormones, this through showing normalisation of 
initially elevated TSH values.  For the 18 to 38% hypothyroid dogs showing no initial 
increase in TSH values, normalisation of TSH serum concentrations cannot be used to 
assess therapy.  Furthermore the tests available to measure TSH concentrations are very 
reliable to detect an increase in TSH values but not to detect decreases in the lower 
range.   The use of endogenous TSH in the monitoring of therapy, allows detection of a 
dog which is insufficiently treated (TSH remains high).  But it does not allow to 
differentiate an over treated dog from a well-controlled dog.   Therefore, follow-up 
through TT4 serum concentrations (cheap and easy to perform) remains the most 
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commonly used parameter for the follow-up of a treated hypothyroid dog. However, 
additional TSH determinations can be valuable for the monitoring of therapy in some 
patients.   
 
Conclusion 
 Treatment of hypothyroidism is relatively simple, but obtaining a reliable 
diagnosis can sometimes be more difficult. Numerous factors can influence thyroid 
homeostasis. Knowledge of these factors can contribute to decreasing the misdiagnosis 
of hypothyroidism. Non-thyroidal diseases and the administration of medications can 
lead to decreased thyroid hormone concentrations. The effects of several commonly 
used medications, obesity and weight loss on canine thyroid function will be studied in 
this thesis. Furthermore, thyroid function will also be evaluated in dogs with CRFA, a 
disease with a presentation suggesting hypothyroidism.  
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Introduction to chapter 2 
 
 Some drugs affect thyroid function. The list of drugs known to alter thyroid 
function or thyroid function test results in humans is much more extensive than those 
evaluated in dogs.  The lack of information about possible influence of medications on 
canine thyroid function contributes to the over-diagnosis and over-interpretation of 
thyroid hormone results in dogs. This eventually can lead to misdiagnosis of 
hypothyroidism. Prednisone is widely used in veterinary medicine for its 
immunosuppressive or anti-inflammatory properties to treat a variety of disorders.  
Phenobarbital is the first line anticonvulsant of choice for treatment of canine epilepsy.  
Both drugs are extensively used in veterinary medicine.  In this second chapter the 
short-term effects of prednisone and phenobarbital on canine thyroid function test 
results will be assessed. 
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Summary 
 
The short-term effects of prednisone and phenobarbital on serum total thyroxine (TT4), 
free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were evaluated in 
euthyroid dogs.   
Twenty-six beagles were randomly divided into 3 groups, receiving respectively, a 
placebo, prednisone (1.2 to 2 mg/kg body weight, per os, every 12 hours) for 3 weeks or 
phenobarbital (1.8 to 3 mg/kg body weight for 1 week, then 2.7 to 4.5 mg/kg body 
weight, per os, every 12 hours for 2 weeks).  Blood samples taken over a 6-week period 
were assayed for serum TT4, FT4, and TSH.  Phenobarbital therapy in our study did not 
affect serum TT4, FT4, or TSH concentrations.  Prednisone therapy, however, 
significantly decreased serum TT4 and FT4, but did not affect serum TSH 
concentrations.   
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Introduction 
 
 The measurement of serum concentrations of total thyroxine (TT4) is frequently 
used to assess thyroid function in dogs.  Serum TT4 concentrations are influenced by 
many factors, including daily fluctuations, severe non-thyroidal diseases, and certain 
drugs (1-3).  Because of these influences, the measurement of a basal TT4 concentration 
is frequently unreliable as an indicator of thyroid function in dogs.  Theoretically, free 
thyroxine (FT4) concentrations should be less subject to these variations (4).  The most 
reliable assay for FT4 is by equilibrium dialysis, which is becoming more readily 
available from diagnostic laboratories (5).  Until recently, the easiest and most reliable 
test to evaluate canine thyroid function was the thyroid-stimulating hormone (TSH) 
stimulation test.  However, bovine TSH used to perform this test is no longer 
commercially available.  Recently, methods to evaluate canine endogenous TSH have 
become available and seem promising for accurate assessment of canine thyroid 
function (6-9). 
 
 Several drugs have been shown to alter thyroid function in humans, rats, and 
dogs (2,10).  Drugs frequently used in canine practice and known to alter thyroid 
function in man and rats include glucocorticoids and phenobarbital.  Studies performed 
with humans and rats have demonstrated that endogenous or exogenous glucocorticoids 
directly inhibit the hypothalamic-pituitary-thyroid axis and also influence peripheral 
metabolism of thyroid hormones (11-14).  Although several studies in dogs have 
reported the effects of exogenous or endogenous glucocorticoids on TT4, and 
triiodothyronine (T3), their effects on endogenous TSH are unknown (15-19).   
 In rats, phenobarbital alters thyroid function by affecting the peripheral 
elimination of T4 (10, 20).  Indeed, increased hepatic deiodination of thyroid hormones, 
increased biliary clearance, and increased fecal excretion result in decreased 
concentrations of circulating thyroid hormone, which, in turn, increase TSH secretion 
through the classical negative feedback pathway (20-22).  Phenobarbital could also have 
additional central effects on the hypothalamus-pituitary-thyroid axis (23, 24).  Most 
studies in rats report decreased T4 with normal or, more often, increased TSH  
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concentrations (21, 23, 25).  In humans, phenobarbital increases the metabolic clearance 
of T4 through increased deiodination and biliary clearance of thyroid hormones, as well 
as by an enhanced hepatocellular binding (26, 27).  In veterinary medicine, 
phenobarbital is often listed as a drug that can potentially decrease canine TT4 levels (1, 
2), but to our knowledge, there are no published studies available on the effects of 
phenobarbital on thyroid function in dogs.   
 The objective of this study was to evaluate the influence of short-term oral 
prednisone and phenobarbital on canine thyroid function. 
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Materials and methods 
 
Dogs 
Twenty-six, sexually intact, adult beagles (11 females, 15 males; 2 to 3 years old) were 
assessed as healthy based on results of physical examination, complete blood count and 
biochemical profile, and normal serum TT4, FT4, and TSH concentrations.  The dogs 
were randomly divided into 3 groups.  Group 1 consisted of 8 dogs, 3 females and 5 
males.  Group 2 contained 9 dogs, 4 females and 5 males.  Group 3 consisted of 9 dogs, 
4 females and 5 males.  The mean body weights of these dogs were 11.07 kg +/- 0.59, 
11.4 +/- 0.76, and 10.7 +/- 0.7 for groups 1, 2, and 3, respectively.  All dogs were 
housed indoors, in 6 runs containing 4 to 5 dogs each.  A one-week acclimatisation 
period was allowed before starting the experiment.  Environmental conditions, such as 
photoperiod (12 hours on, 12 hours off), ventilation, and temperature were kept constant 
throughout the study.  The dogs were fed a standard commercial maintenance pellet diet 
twice daily and water was available ad libitum.  
 
Experimental protocol 
Dogs in group 1 received a placebo
 
 (Lactose, Odan Ltee Laboratories, Montreal, 
Quebec) for 3 wk.  Dogs in group 2 were given prednisone
 
 (Apotex, Weston, Ontario) 
at a dosage ranging from 1.2 to 2 mg/kg body weight (BW), PO, q12h for 3 wk.  Dogs 
in group 3 were given phenobarbital (Parke-Davis, Scarborough, Ontario) at a dosage  
ranging from 1.8 to 3 mg/kg BW, PO, q12h for the first wk, then from 2.7 to 4.5 mg/kg 
BW for the next 2 wk.  Monitoring was continued for 6 wk, with the treatments 
administered during the first 3 wk of the study. 
 Blood samples (18 mL) were taken by jugular venipuncture before initiating 
therapy (T0), at 48 h, and after 1, 3, 4, 5, and 6 wk.  All blood samples were taken 
between 0800 and 0900.  Blood samples were immediately centrifuged and serum was 
frozen in 4 aliquots at -20
0
C, until assayed.   
 The protocol was approved by the Ethics Committee of the Faculté de Médecine 
Vétérinaire of the University of Montreal, and procedures were performed in 
accordance with the recommendations of the Canadian Council on Animal Care. 
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Assays for TT4, FT4 and TSH 
Assays for TT4, FT4, and TSH were performed on all samples.  Total thyroxine 
concentrations were determined by using a commercially available solid-phase 
radioimmunoassay
 
(Coat-A-Count canine T4, Diagnostic Products, Los Angeles, 
California, USA) previously validated for canine serum (15).  Assays for FT4 
concentrations by equilibrium dialysis were performed using a commercial assay kit 
(Free T4 by equilibrium dialysis Nichols Institute Diagnostics, San Juan Capistrano, 
CA) at the Endocrine Section, Animal Health Diagnostic Laboratory, Michigan State 
University.  Assay procedures were performed as per the manufacturer's instructions.  
The manufacturer of the kit reported negligible crossreactivity of other iodothyronines 
(range of 0.044% to 0.001%) in the assay.  For estimates of assay repeatability, 3 pools 
of canine serum were established.  In canine serum with a mean concentration of 15, 37, 
or 96 pmol/L, the interassay coefficient of variation (CV) was 18.6%, 14.2%, and 6.9%, 
respectively (n=10 assays).  In the same serum pools, intraassay CV was 14.5%, 10.2%, 
and 6.6%, respectively (10 replicates).  Canine serum with a concentration of FT4 of 
111 pmol/L was diluted with "0" standard prior to placement in the dialysis chamber.  In 
serum diluted with standard at rates of 1:1, 1:2, or 1:4, 100%, 74%, and 70% of 
expected concentrations of FT4 were measured in the assay.  Thyroxine was added in 
varying amounts to aliquots of dialysate harvested after prior incubation with canine 
serum.  The concentration of FT4 in the dialysate was 11 pmol/L after incubation with 
serum and before addition of exogenous T4.  When T4 was added to dialysate at 
concentrations of 13, 26, 52, or 77 pmol/L, 92%, 95%, 99%, and 92% of added T4, was 
respectively measured in the assay.  The sensitivity of the assay, defined as the 
concentration of FT4 at the point of 90% of total specific binding, was 1.8 pmol/L 
(mean of 10 assays).  Serum TSH concentrations were determined by using a 
commercially available solid-phase radioimmunoassay (Coat-A-Count canine TSH 
IRMA, Diagnostic Products) recently validated in the dog (7, 9).  The intra- assay CV 
was 7% for samples with a TSH concentration below 1 ng/mL, and 0.8% for samples 
with a TSH concentration above 1 ng/mL.  The inter-assay CV was 7% for samples with 
a mean TSH concentration of 3 ng/mL, and 26% for samples with a mean TSH  
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concentration of 0.11 ng/mL.  Dilutional parallelism, evaluated through assaying serum 
at 4 dilutions, was respected.  The limit of detection was 0.03 ng/mL. 
 
Serum phenobarbital concentrations 
Serum concentrations of phenobarbital were determined for dogs in group 2, in samples 
from wk 1 and 3, by using an enzymatic technique
 
(Cedia Phenobarbital, Boehringer 
Manheim, Indianapolis, Indiana, USA) at a commercial laboratory (Vita-Tech, Ontario).  
 
Data analysis 
Data were analyzed by two-way analysis of variance for repeated measures.  When 
there were significant time by treatment interactions, a Dunnett's procedure was used to 
compare the groups at each time period.  Data are presented as means +/- standard error 
of the mean (SX).  Results were considered significant at P < 0.05. 
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Results 
 
Total thyroxine concentrations 
There was a significant effect of time on TT4 concentrations in the control and the 
prednisone groups (Figure 1, P < 0.05).  There was a significant interaction between 
time and group; therefore, differences between groups were analyzed at each time 
period.  After 1 and 3 wk of treatment, TT4 concentrations were significantly lower in 
the prednisone group compared with the control group (week 1; 12 +/- 2 nmol/L and 
28.1 +/- 4 nmol/L, respectively; week 3; 15.8 +/- 2 nmol/L and 38.3 +/- 4.4, 
respectively).  Phenobarbital therapy did not significantly affect TT4 values at any time 
(Figure 1). 
 
Free thyroxine concentrations 
There was a significant effect of time on FT4 concentrations in the control and the 
prednisone groups (Figure 2, P < 0.05), and a significant interaction between time and 
group.  A significant decrease in FT4 concentrations was found at 3 wk in the 
prednisone group when compared with the control group (19.7 +/- 3.1 pmol/L and 31.4 
+/- 3.5 pmol/L, respectively).  Phenobarbital did not significantly affect the FT4 
concentrations at any time (Figure 2). 
 
Serum TSH concentrations 
There was a significant effect of time on TSH concentrations in all 3 groups (Figure 3, 
P < 0.05 ).  There was neither significant effect of group, nor an interaction between 
time and group.  All concentrations for TSH levels were within the normal reference 
range throughout the study (< 0.7 ng/mL). 
 
Serum phenobarbital concentrations 
Measurement of serum phenobarbital concentrations after 1 wk of therapy revealed that 
the recommended therapeutic level of phenobarbital (65 to 150 Pmol/L) had been 
obtained in 6 out of 9 dogs (28).  Most dogs had serum concentrations towards the 
lower end of the therapeutic range (71.4 +/- 4.4 Pmol/L).  After the dosage of  
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phenobarbital had been increased by 50% in all dogs for the next 2 wk, the serum 
phenobarbital concentrations were again at the lower end of the therapeutic range (67.4 
+/- 5.6 Pmol/L).  There was no correlation between serum phenobarbital levels and 
serum concentrations of TT4, FT4, or TSH.  Side effects from phenobarbital 
administration, such as ataxia or lethargy, were not noticed.   
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Figure 1-Mean (+/- SX) TT4 concentrations in beagles during and after placebo, 
prednisone (1.2 to 2 mg/kg BW, PO q12h) or phenobarbital (1.8 to 3 mg/kg BW 
for 1 wk, then 2.7 to 4.5 mg/kg BW PO, q12h) administration.  Medications were 
administered during the first 3 wk of the experiment. *=significantly different 
from control group (P < 0.05). 
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Figure 2-Mean (+/- SX) FT4 concentrations in beagles during and after placebo, 
prednisone (1.2 to 2 mg/kg BW PO, q12h) or phenobarbital (1.8 to 3 mg/kg BW 
for 1 wk, then 2.7 to 4.5 mg/kg BW PO, q12h) administration.  Medications were 
administered during the first 3 wk of the experiment. *=significantly different 
from control group (P < 0.05). 
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Figure 3-Mean (+/- SX) TSH concentrations in beagle dogs during and after 
placebo, prednisone (1.2 to 2 mg/kg BW PO, q12h) or phenobarbital (1.8 to 3 
mg/kg BW for 1 wk, then 2.7 to 4.5 mg/kg BW PO, q12h) administration.  
Medications were administered during the first 3 wk of the experiment (P < 0.05). 
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Discussion 
 
  The effects of prednisone on canine endogenous TSH and the effects of 
phenobarbital on thyroid function in dogs are unknown.  Our finding that, prednisone 
given at an immunosuppressive dosage significantly suppressed TT4 at 1 and 3 wk and 
FT4 levels after 3 wk of therapy is in agreement with a previous study by Torres et al 
(15) but contrasts with that by Moore et al (18).  Torres et al, reported a decrease in 
canine TT4 and FT4 levels at 24 h and 3 wk after initiating oral prednisone therapy at 
an immunosuppressive dosage.  However, serum thyrotropin concentrations were not 
determined and FT4 concentrations were not assayed by equilibrium dialysis, which is 
now considered the most reliable technique to determine FT4 levels (5, 29, 30).  Moore 
et al later reported that 1 mo of oral prednisone did not affect basal TT4 levels in 
normal dogs, but a lower antiinflammatory dose of prednisone was used.  The effects 
of glucocorticoids have previously been documented to be dependent on the dosage, 
route of administration, duration of treatment, and chemical form used (15, 31). 
  The fact that, in our study, serum TSH concentrations were not significantly 
affected by prednisone administered orally at an immunosuppressive dosage during a 
3-week period, suggests that the measurement of TSH concentrations in euthyroid dogs 
receiving short-term prednisone therapy may be a more reliable tool than that of TT4 to 
evaluate thyroid function.  However, this is in contrast to studies with humans, in 
which TSH concentrations were decreased by exogenous or endogenous 
glucocorticoids (11, 12, 32-35).  It is possible that a suppression of TSH secretion is 
less easily detected in dogs compared with humans, because euthyroid dogs have TSH 
concentrations very close to the limit of detection of the current assay.  It is also 
possible that there is a species difference between dogs and humans in the pituitary 
response to glucocorticoids.  In the clinic, TSH measurement is frequently used in 
combination with TT4 or FT4 to evaluate thyroid function in dogs (8).  Further studies 
to assess the effects of glucocorticoids on hypothyroid dogs with high TSH levels are 
needed.  
  The mechanism of action of glucocorticoids on thyroid function  appears 
complex, with suppression of TSH release reported in humans (12-14, 32, 36-38) and  
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rats (37, 38), and disturbed T3 and T4 partition, clearance rates, and metabolism 
reported in humans (13, 39), rats, and dogs (15-17, 31).  Our study was not designed to 
determine the mechanism of action of glucocorticoids on thyroid function. 
  Another commonly used drug that may affect thyroid function is phenobarbital.  
In rats, phenobarbital increases biliary thyroid hormone excretion, which decreases 
serum TT4 levels with normal or more often, increased TSH levels (20-25, 40). There 
are no published studies on the effects of phenobarbital on thyroid function in dogs, 
but, by extrapolation, phenobarbital is often listed as a drug that can potentially affect 
canine thyroid function (1, 2).  Recently, 2 short communications have suggested that 
long-term administration of phenobarbital influences canine thyroid function (41, 42).  
Surprisingly, in our study, phenobarbital did not significantly affect TT4, FT4, or TSH 
concentrations.  Interestingly, most studies in rats report decreased levels of TT4 and 
increased levels of TSH, but the dosages administered to these rats were extremely 
high (100 mg/kg BW/d) and serum levels of phenobarbital were not determined (20, 
23, 25).  Hepatic enzyme induction and decreased concentrations of TT4 in rats 
receiving phenobarbital are dose-related (24).  Most studies in humans report no 
significant changes of TT4 and TSH levels in epileptic patients taking phenobarbital 
(10, 26, 27, 43).  Dosages of phenobarbital administered to human patients range from 
1 to 5 mg/kg BW/day, a dose similar to the recommended initial dosage for 
phenobarbital in dogs. 
  In the present study, serum phenobarbital concentrations after 1 wk of treatment 
were at the lower end of the therapeutic range in group 2 dogs.  As the elimination half-
life of phenobarbital in beagles is much shorter than in other breeds, serum steady-state 
concentrations should be achieved after 1 wk, instead of 2 to 3 wk (44-46).  To reach 
higher therapeutic concentrations, the initial dosage of phenobarbital was increased by 
50 % in all dogs of group 2 for the next 2 wk.  Despite these higher doses of 
phenobarbital, serum concentrations of phenobarbital were somewhat lower than 
expected.  This suggests that short-term administration of phenobarbital, at 
antiepileptic dosages, does not affect thyroid function in dogs.  
  There was a significant effect of time on TT4, FT4, and TSH concentrations in 
the control group.  Several factors can influence basal TT4 and less severely, FT4  
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concentrations in dogs (3).  Factors such as photoperiod, ambient temperature and body 
weight were constant throughout the experiment, making it unlikely that they were 
responsible for the variation of the hormone concentrations in the control group.  Also, 
the dogs were allowed to acclimatize for a period of 1 wk.  It has been reported that, in 
females, increased progesterone levels can increase TT4 levels (47), although another 
study suggests no difference in TT4 concentrations between male and female dogs (48).  
The females in our study were in anestrus, based on the absence of clinical signs 
compatible with proestrus and estrus throughout the study.  Furthermore, the tendency 
toward increased concentrations of TT4 after 1 and 3 wk of treatment was noted in both 
the female and male dogs of the control group.   
   
Conclusion 
 In conclusion, oral prednisone administered over a 3-week period at 
immunosuppressive dosages significantly suppressed TT4 and FT4 concentrations, but 
did not affect TSH concentrations.  Short-term administration of phenobarbital does not 
significantly alter canine thyroid function.   
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Introduction to chapter 3 
 
 In the previous chapter we demonstrated a significant effect of prednisone on 
TT4 serum concentrations.  To further investigate the influence of drugs on canine 
thyroid function tests, we will, in the following chapter, evaluate the possible influence 
of some commonly used NSAIDs.  Indeed, as the importance of recognising and 
treating pain in dogs grows, so does the use of NSAIDs.  
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Summary 
 
Many factors including drugs can influence thyroid function in humans, rats and 
dogs. Studies in humans report significant effects of non-steroidal anti-inflammatory 
agents (NSAIDs) on thyroid function test results, which can lead to misinterpretation of 
the results and inappropriate therapeutic decisions. As NSAIDs are used more and more 
frequently in dogs, it is important to know whether they affect thyroid function test 
results.  
The objective of this study was to determine whether acetylsalicylic acid (ASA) 
or ketoprofen (Keto) influence thyroid function test results in dogs. Eighteen spayed 
female beagle dogs were randomly assigned to three treatment sequences in a 3x3 cross 
over study design with treatments consisting of ASA (25 mg/kg BW q 12 h), Keto (1 
mg/kg BW q 24 h) or placebo administered for a one-week period with a three-week 
washout period between treatment periods. Blood samples for determination of total 
thyroxine (TT4), free thyroxine (FT4), total triiodothyronine (TT3), thyrotropin (TSH), 
reverse triiodothyronine (rT3), Keto and ASA concentrations were taken during each 
treatment period on days 0, 1, 3 and 7. During the washout period samples were taken 
weekly. 
A significant decrease in TT4 was observed as soon as 24 h after ASA 
administration, whereas the decrease in TT3 was less pronounced and differed 
significantly with placebo only after one week of the ASA administration. No 
significant effects were found for free T4 and TSH with ASA administration. No 
significant effects on thyroid results were found for Keto administration. The results 
indicate that TT4 can be markedly decreased by ASA therapy and until the results of 
further studies are available, thyroid function test results should be interpreted 
cautiously in dogs on NSAIDs therapy. 
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Introduction 
 
Hypothyroidism is the most diagnosed and probably also the most over-
diagnosed endocrine disease in dogs.  Evaluation of thyroid function in dogs is not 
always straightforward as clinical manifestations of hypothyroidism are nonspecific and 
no single thyroid function test is fully reliable to confirm the diagnosis (Peterson et al., 
1997; Scott-Moncrieff et al., 1998; Dixon & Mooney, 1999). Furthermore, numerous 
nonthyroidal factors such as the presence of systemic disease (euthyroid sick syndrome) 
or the administration of drugs can affect thyroid function (Ferguson, 1988; Ferguson, 
1997).  Drugs frequently used in canine practice and known to alter thyroid function in 
dogs include glucocorticoids, phenobarbital and sulphonamides (Daminet & Ferguson, 
2003). Changes in thyroid hormone concentrations induced by drugs can be confusing 
and lead to an erroneous diagnosis of hypothyroidism resulting in inappropriate 
treatment. 
Currently, the combined use of measurement of thyroxine (T4) and thyrotropin 
(thyroid stimulating hormone; TSH) serum concentrations seems to be the easiest and 
most reliable way to assess canine thyroid function in a clinical setting (Scott-Moncrieff 
et al., 1998). The measurement of free thyroxine (FT4), especially by equilibrium 
dialysis (FT4ED), is thought by many authors to be valuable because it is less 
influenced by non-thyroidal diseases than determination of a total thyroxine (TT4) 
(Peterson et al., 1997; Scott-Moncrieff & Guptill-Yoran, 2000),  although other studies 
have not confirmed this finding (Dixon & Mooney, 1999).    
Non-steroidal anti-inflammatory agents (NSAIDs) are used increasingly 
frequently in dogs. The possible gastro-intestinal and renal side effects of NSAIDs have 
been extensively described in the literature (Mathews, 1996), but studies on the effects 
of NSAIDs on canine thyroid function have not been reported to our knowledge other 
than in 2 abstracts (Ferguson et al., 1999; Sauvé et al., 2002). 
There are, however, reports of the effect of NSAIDs on thyroid function in 
humans and horses.  Non-steroidal anti-inflammatory agents can alter thyroid function 
in humans, since circulating thyroid hormones are protein bound, and various NSAIDs 
can displace thyroid hormones from serum protein-binding sites (Davies & Franklyn,  
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1991; Bishnoi et al., 1994; Wenzel, 1996). These effects are most important in humans 
treated with salicylates (e.g. salsalate, acetylsalicylic acid), or fenclofenac and 
phenylbutazone (Davies & Franklyn, 1991).   Several studies in horses have shown that 
phenylbutazone markedly affects TT4 and to a lesser extend FT4 serum concentrations 
in this species (Sojka et al., 1993; Ramirez et al., 1997). 
It is, however, important to study the effects of NSAIDs on thyroid function in 
the dog separately because the results found in humans cannot be extrapolated to dogs 
for the following reasons. Firstly, thyroid hormones are lipophilic compounds and, as 
such, need to be transported by specific binding proteins, thyroxine-binding protein (TBG), 
thyroxine-binding prealbumin (TBPA; transthyretin) and albumin. Plasma concentrations 
of TBG in the dog are only 15 % of those in man and the affinity of thyroid hormones for 
their transport proteins is also less than in humans (Larsson et al., 1985; Kaptein et al., 
1994). Secondly, and partly as a result of this weaker serum protein binding, TT4 
concentrations are lower, the unbound or free fraction of circulating T4 is higher (0.1 
versus ~0.03% in man), and hormone metabolism is more rapid in most domestic animals 
than in humans (Bigler, 1976). It is the unbound (free) fraction of the hormone, which is 
available to tissues and therefore the concentration is proportional to the action, 
metabolism, and elimination of that hormone (Robbins & Rall, 1960; Mendel, 1989). 
While the normal variation of the free fraction of thyroxine (FFT4) is fairly small, 
ranging from 0.05-0.15%, this binding relationship may change in response to drugs or 
illness (Ferguson & Peterson, 1992). Because of reduced affinity of thyroid hormones 
for their carrier proteins in dogs compared to humans, the effects of different NSAIDs 
may be more pronounced in dogs than in humans.   
In our study, the effects of two different NSAIDs on thyroid function was  
investigated. Acetylsalicylic acid (ASA), a salicylate, has been the cornerstone of 
analgesic therapy in humans and dogs for decades.  Newer, more potent NSAIDs are 
now available but ASAs low cost and historical usage still make its use widespread in 
practice.   Acetylsalicylic acid is highly protein bound (50-70%) to plasma transport 
proteins, especially albumin (Davis & Westfall, 1972; Boothe, 1995).  Following 
several doses of ASA of 25 mg/kg q 12 h, Boothe (1995) reported a plasma elimination 
half-life of 7.5 h in dogs.  Plasma salicylate concentrations < 50 µg/mL are considered  
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to be subtherapeutic in the dog and concentrations > 300 µg/mL are considered 
potentially toxic (Nap et al., 1991).  
Ketoprofen (Keto), a propionic acid derivate with well-established analgesic 
properties, is another NSAID increasingly used in dogs, horses and humans.  The 
molecule is highly (99%) bound to transport proteins, principally albumin (Boothe, 
1995). Peak plasma concentrations in dogs are reported to occur 0.8 +/- 0.6 h after oral 
administration and the drug has a plasma elimination half-life of 4 +/- 1 h (Schmitt & 
Guentert, 1990; Mathews, 1996).  Maximal plasma concentration after oral 
administration has been reported to be 2.8 +/- 1.3 µg/mL (Schmitt & Guentert, 1990).  
The objective of the present study was to assess the effect of ASA and Keto, on 
thyroid function tests in dogs through determination of TT4, FT4, TSH, TT3 and rT3 
serum concentrations.  
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Materials and methods 
 
Dogs 
Eighteen spayed female Beagles, weighing from 10 to 14 kg (median: 12) and 
aged between two and three years were used.  The study was approved by the Ethical 
Committee of the Faculty of Veterinary Medicine, Ghent University, Belgium.  All dogs 
were assessed as healthy based on physical examination, normal complete blood count 
and biochemistry and a TT4 serum concentration above 15 nmol/L.  Anti-canine 
thyroglobulin autoantibodies (TgAA) by ELISA were negative (ELISA, Oxford 
Biomedicals) (Nachreiner et al., 1998) .  The dogs were kept in the same conditions 
throughout the study and were fed twice a day with a standard maintenance diet (08:00 
and 20:00 h).   
 
Study design 
A 3x3 crossover study design was used to evaluate differences between three 
treatments: placebo, acetylsalicylic acid and ketoprofen. Each dog received each of the 
treatments in one of the three treatment periods with a three-week washout period 
between treatment periods. Six dogs were randomly assigned to each of the three 
treatment sequences.  A treatment period consisted of seven days with daily drug 
administration. The placebo (lactose monohydrate 200 Mesh) was administered orally q 
24 h during one week.   Acetylsalicylic acid powder, (Federa), was weighed, placed in 
hard gelatine capsules and administered at a dosage of 25 mg/kg BW PO q 12 h over the 
one week trial period.  Ketoprofen (Ketofen, Merial) was given at a dosage of 1 mg/kg 
BW orally q 24 h for one week. Ketofen tablets were pulverised and to allow the 
accurate administration of 1 mg ketoprofen/kg BW, the exact amount of powder was 
calculated, weighed and placed in hard gelatine capsules. 
During the treatment periods, all medications were administered at 08:00 h and 
for the ASA group also at 20:00 h, except on day zero of each treatment period where 
medications were given after blood sampling at 09:00 h (T0).  Food was given twice a 
day to all dogs at 08:00 h and 20:00 h, except on the mornings of blood sampling, when 
food was given after blood sampling at 09:00 h. Capsules were administered with one  
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tablespoon of highly digestible canned food (Hills, Prescription Diet, canine i/d) in 
order to reduce the risk of gastro-intestinal irritation and vomiting.   
Dogs were examined daily and potential side effects noted.  Faecal testing for occult 
blood (Hexagon OBScreen, Human) and weighing were both performed weekly 
throughout the study. 
Blood samples were taken by jugular venipuncture, serum samples allowed to 
clot, and, after centrifuging the serum or plasma aliquots were frozen at 20C in plastic 
tubes until assayed.  Blood samples for determination of serum TT4, TT3, rT3, FT4, 
TSH and for plasma Keto and ASA concentrations were taken at 09:00 h during the 
treatment periods on days 0 (T0), 1 (T1), 3 (T3) and 7 (T7). During the washout periods 
sampling was performed once a week (T14, T21, T28).   Before initiating the project, 
encapsulated ASA and Keto were administered each to two dogs and blood sampled 
every 15 min in order to evaluate the time to obtain drug peak plasma concentrations.   
 
Thyroid hormone assays 
Determinations of TT4 and TSH serum concentrations were performed using 
previously validated radioimmunoassays (Clinical Assays Gammacoat M Total T4 125I 
RIA Kit, Diasorin; Coat-A-Count canine TSH IRMA, Diagnostic Products Corp).  Total 
T3 concentrations were measured through a validated in-house charcoal separation 
assay (Panciera et al., 1990). Determinations of free T4 (FT4) serum concentrations by 
equilibrium dialysis (FT4ED) were performed using a validated commercial assay kit 
(Nichols Institute Diagnostics) (Daminet et al., 1999). Reverse T3 serum concentrations 
were also measured using a validated radioimmunoassay method (Biodate S.p.A.) 
(Center et al., 1984). Serum TgAA concentrations, were determined once in all dogs 
(ELISA, Oxford Biomedicals).  A positive result was defined as at least twice (200 %) 
the optical density of the negative control sample (Nachreiner et al., 1998). Analyses 
were performed at the Endocrine Section, Animal Health Diagnostic Laboratory, 
Michigan State University.  
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Salicylate and ketoprofen assays 
Salicylate and ketoprofen plasma concentrations were quantified by high-
performance liquid chromatography with ultraviolet detection (HPLC-UV method) at 
the Department of Pharmacology, Pharmacy and Toxicology, Faculty of Veterinary 
Medicine, Ghent University.  In brief, the method involved the addition of internal 
standard (50 µL of a fenoprofen solution of 100 µg/mL) to 500 µL of dog plasma for 
the Keto analysis, or 25 µL of plasma for the salicylic acid analysis. Next, a protein 
precipitation step was performed by adding 100 µL of HCl 1 M. Thereafter, 3 mL of 
ethyl acetate was added and the sample was extracted for 20 min on a horizontal roller 
bank. The sample was centrifuged at ± 2500 rpm for 10 min and the organic layer was 
evaporated under N2 at ± 40 °C. The dry residue was dissolved in 250 µL of HPLC 
water and vortex mixed for 15 s. Finally, the residue was transferred to an autosampler 
vial and 100 µL were injected into the HPLC-UV system. A reversed-phase C18 column 
(type Hypersil, 100 x 3 mm i.d., 5 µm, Varian) was used in combination with a 
reversed-phase guard column (10 x 2 mm i.d., Varian). The mobile phase contained 1% 
(v/v) glacial acetic acid in HPLC grade water (A) and methanol (B). A gradient solvent 
program with the following conditions was run: 0-4 min: 50% A, 50% B; 4.5-15 min: 
30% A, 70% B; 15.5-25 min: 50% A, 50% B. The flow rate was set at 0.5 mL/min. The 
UV trace was monitored at O=305 nm between 0-6 min to detect salicylic acid, at O=259 
nm between 6-10.5 min for ketoprofen and at O=236 nm from 10.5 min onwards to 
detect fenoprofen.  
By using this method it was possible to quantify Keto and salicylic acid concentrations 
in plasma at levels as low as 0.1 µg/mL ketoprofen and 2 µg/mL salicylic acid. 
Calibration curves were linear in the range of 0.1 to 10 µg/mL for ketoprofen 
(r>0.9991) and 2 to 200 µg/mL for salicylic acid (r>0.9961).  
Quality control (QC) samples were included in each run to check the sample preparation 
and chromatographic procedure. Quality control samples were prepared from drug free 
dog plasma spiked at a level of 1.0 µg/mL of Keto and 20.0 µg/mL of salicylic acid. 
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Statistical analyses 
A mixed model with DOG as random effect and TREATMENT and PERIOD as 
fixed effects was used to analyze the crossover trial (SAS, version 8).  Ketoprofen and 
salicylic acid were compared with placebo separately on days 1, 3 and 7 of the treatment 
period using as response variable the difference between the hormone concentrations at 
the particular day with day 0. With a family confidence coefficient equal to 95%, each 
of the six individual comparisons (two drug comparisons at three time points) were 
tested at a significance level of 0.00833 (Bonferonis multiple comparisons adjustment). 
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Results 
 
Results for mean TT4, FT4, TT3, and TSH serum concentrations within the 
treatment period are shown in Fig. 1.  A significant decrease in serum TT4 was 
observed as early as 24 h following ASA administration (P=0.0008) and persisted 
during the ASA treatment (Fig. 1a).  Total T4 values then normalized within one week 
of ASA withdrawal (Fig. 2).  Results for the TT3/TT4 ratio and the free fraction of T4 
(FT4/TT4) are shown in Fig. 3 and for rT3 serum concentrations in Fig. 4.  During Keto 
treatment, no statistically significant changes were observed compared to the control 
group (Fig. 1).   
 The number of samples with TT4 serum concentrations < 15 nmol/L, a range 
compatible with hypothyroidism, were counted during the treatment periods (T1, T3 
and T7) for each group.  During ASA treatment, 30 measurements of TT4 of 54 (55%) 
were lower than 15 nmol/L, 10 of 54 (18%) in the Keto group and five of 54 (9%) in the 
placebo group. 
The decrease in TT3 serum concentrations was less pronounced than for TT4 but 
differed significantly with placebo one week after the ASA administration (P=0.0006).   
No significant differences between Keto and placebo groups were observed (Fig. 1b).  
No significant changes were found for FT4 concentrations in the ASA 
(P=0.1998 at day 1, P=0.1794 at day 3, P=0.4033 at day 7) or the Keto group (P=0.9349 
at day 1, P=0.9349 at day 3, P=0.9349 at day 7) (Fig. 1c). Neither drug significantly 
affected TSH serum concentrations (Fig. 1d).  
The free fraction of T4 (FFT4) was significantly higher in the ASA group 
compared with the control group, at two time periods (P=0.0003 at day 1, P=0.0243 at 
day 3, P=0.0001 at day 7). Free fraction of T4 did not significantly differ between the 
Keto and control groups (Fig. 3a). 
 
Total T3/TT4 ratio was significantly increased during ASA treatment (Fig. 3b).  
This was statistically significant at T1 in the ASA group (P=0.0035 at day 1, P=0.0449 
at day 3, P= 0.04 at day 7). 
Therapeutic plasma concentrations were obtained for both drugs in all animals 
(except for one measurement of ASA with a concentration of 36 µg/mL).  During ASA  
CHAPTER 3 
 99
 
treatment, plasma salicylate concentrations ranged from 36 to 177 µg/mL (mean value 
at T1: 96.5; at T3: 105.3 and at T7: 76.2 µg/mL).  During Keto treatment, plasma 
concentrations ranged from 1.2 to 7.5 µg/mL (mean value at T1: 3.9; at T3: 4.3 and at 
T7: 3.8 µg/mL).  Mean values for plasma concentrations expressed in µmol/ml were for 
ASA:  T1: 0.698, at T3: 0.762 and at T7: 0.552 µmol/mL; for Keto: T1: 0.0153; at T3: 
0.0169 and at T7: 0.0149 µmol/mL. In the pilot study performed on 4 dogs before 
initiating the experiment, peak plasma concentrations of both drugs were obtained after 
approximately 1 hour. 
Salicylic plasma levels and TT4 serum concentrations correlated negatively, 
with the Pearson correlation coefficient equal to -0.43 at day 1, -0.53 at day 3 and -
0.059 at day 7.  
All dogs remained generally healthy throughout the study, weight remained 
stable and no serious side effects were noted.  Faecal testing for occult blood occurred 
weekly and three of 18 tested positive for occult blood one week after ASA 
administration, and four dogs of 18 tested positive one week after Keto administration. 
None of the placebo dogs tested positive for occult blood at any time during treatment 
periods.  During the washout periods, all dogs tested negative except for one animal, 
which remained positive one week after discontinuing ASA administration. This dog 
had also tested positive after one week of treatment with ASA and had bloody diarrhoea 
during this treatment.  Overall, bloody diarrhoea was observed in one dog during Keto 
treatment and in two dogs during ASA therapy.    
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Fig. 1. Mean total thyroxine (TT4) (a), total triiodothyronine (TT3) (b), free 
thyroxine (FT4) (c), and thyrotropin (TSH) (d) serum concentrations from dogs 
administered a placebo, acetylsalicylic acid (ASA) or ketoprofen (Keto) for seven 
days. * Indicates significant differences with placebo group. P < 0.00833. 
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Fig. 2. Mean total thyroxine (TT4) serum concentrations from dogs administered a 
placebo, ASA or Keto shown over a four-week period.  Treatments were 
administered for seven days. * Indicates a significant difference with control 
group. P < 0.00833. 
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Fig. 3. Mean percentages for free fraction of T4 (FFT4) and TT3/TT4 ratio are 
represented. * Indicates a significant difference with control group. P < 0.00833. 
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Fig. 4.  Mean reverse triiodothyronine (rT3) serum concentrations from dogs 
administered a placebo, ASA or Keto for seven days. * Indicates significant 
differences with control group. P < 0.00833. 
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Discussion 
 
Our results support previous studies in humans and horses that have shown that 
treatment with certain NSAIDs can significantly affect thyroid function test results 
(Sojka et al., 1993; Surks & Stievert, 1995; Ramirez et al., 1997). In our study, a 
decrease in TT4 serum concentration was observed as soon as 24 h after initiating 
treatment with ASA and TT4 concentrations remained decreased throughout the one-
week treatment period. Total T4 serum values normalized one week after discontinuing 
treatment.  Free T4 serum concentrations, measured by equilibrium dialysis, were less 
affected by ASA treatment than TT4 concentrations.   
With ASA treatment, TT4 serum concentrations decreased, FT4 concentration 
remained normal and the free fraction of T4 increased. These changes probably reflect 
displacement of thyroid hormones from their serum transport-binding site.  The negative 
correlation we found between ASA plasma concentrations and TT4 levels also favors 
the competition for serum binding sites as the major mechanism accounting for our 
observations.  An increase in FT4 values was not observed. It might be postulated that 
the unbound hormone was cleared more rapidly or that the pituitary responded quickly 
to an increase in FT4 resulting in a lowering of T4 secretion.  Reverse T3 serum 
concentrations remained unchanged, and there was no net change of free T4 
concentration and no significant effect of ASA on peripheral 5 mono-deiodination of 
T4. It may be postulated that ASA affects the clearance of thyroid hormones, suppresses 
TSH synthesis, affects thyroid hormone synthesis, or alters the sensitivity of the thyroid 
gland to TSH. In humans, salicylates alter thyroid function primarily through 
competition with low-affinity binding sites on serum thyroid hormone-binding proteins, 
but other mechanisms such as decreased uptake of iodine by the thyroid gland, 
inhibition of the hepatic 5-monodeiodination, and competition with plasma membrane, 
cytosolic or nuclear membrane binding have also been postulated (Lim et al., 1996; 
McConnell, 1999). However, the contribution of these disturbances on peripheral 
thyroid hormone metabolism in humans is uncertain (McConnell, 1999). Some drugs 
such as furosemide and fenclofenac are potent competitors for thyroid hormones and 
share some structural similarities with thyroid hormones (Munro et al., 1989). 
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Total T3 and FT4, the hormones responsible for feedback regulation of TSH 
secretion, were not significantly affected by ASA or Keto administration; this may 
explain why dogs in this study had normal TSH concentrations.  Therefore one could 
argue that T3 and TSH concentrations should be used to assess thyroid function in dogs 
on NSAIDs therapy.  Unfortunately, serum T3 and TSH are less useful for the diagnosis 
of hypothyroidism. In one study, serum T3 and TSH concentrations remained within 
reference limits in 90 and 24 % of dogs with hypothyroidism, respectively (Peterson et 
al., 1997). Therefore, measurement of T3, although less affected by drugs in our study 
and several other studies, is of limited benefit in the evaluation of thyroid function in 
clinics (Kantrowitz et al., 1999; Müller et al., 2000).  No significant changes were 
observed in TSH serum concentrations in our study after ASA or Keto administration, 
supporting euthyroidism in the ASA-treated animals.  However, most euthyroid dogs 
have TSH values in the lower end of the reference range (Kooistra et al., 2000).  
Therefore, changes in TSH concentrations in this low reference range might be more 
difficult to detect. Furthermore the limit of detection of the canine TSH assay is 0.03 
ng/mL with some dogs having undetectable TSH serum concentrations.  Further studies 
are needed to confirm the mechanism by which ASA affects thyroid homeostasis in 
dogs. 
 Ketoprofen administered for one week did not significantly affect TT4, TT3, 
FT4, rT3, or TSH serum concentrations.  A study in humans reports no effect of 
ketoprofen at therapeutic dosages on thyroid function (TT4 and TSH) except on TT3 
(Bishnoi et al., 1994; Carlson et al., 1999).  It is interesting to see from our data that the 
hormone most affected by ketoprofen is also serum TT3.  Our findings might be 
explained by the fact that as well in humans as in dogs, T3 is less avidly bound to 
transport proteins and in consequence more easily displaced than T4 (Carlson et al., 
1999).  This finding also raises the question as to why TT3 was not more affected than 
TT4 by ASA administration.   
Our study revealed a marked influence of ASA but only a minor effect of Keto 
on TT4 serum concentrations despite the fact that ASA is somewhat less bound to 
serum transport proteins than Keto, and that affinity constant values (Ka) of Keto for 
albumin are somewhat higher then Ka values of ASA for albumin (Ka respectively 3.8 x  
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106 and 1.6 x 106 M-1) (Carter & Ho, 1994; Sowell et al., 2001). Our observations may 
reflect the much higher molar concentrations obtained with ASA treatment than with 
Keto treatment.  Ketoprofen molar plasma concentrations represented approximately 2 
% of ASA molar plasma concentrations.  Displacement of T4 from its serum transport 
protein binding sites could also, at least in part, be favoured by the fact that ASA plasma 
concentrations (around 698 000 nmol/L) are much higher than TT4 concentrations 
(around 20 nmol/L).  
Also, ASA binds to the two major drug-binding sites (site I of subdomain IIA 
and site II of subdomain IIIA) of albumin, whereas Keto only binds to albumins site II 
(Rahman et al., 1993; Carter & Ho, 1994; Chuang et al., 1999). In humans, the high-
affinity binding sites for T3 and T4 molecules are located in subdomain IIA of the 
albumin molecule (Robbins, 2000). Interestingly, Wang (1999) has shown that 
salicylates, although their principal serum binding site is albumin, also displace T4 from 
TBG, TTR and albumin in human serum (Wang et al., 1999).  
In our study, the effects of short-term administration of two NSAIDs are 
described, but potential changes in thyroid homeostasis after long-term administration 
of NSAIDs in dogs might be different.  For example, in humans short-term 
administration of therapeutic dosages of salicylates leads to a decrease in TT4 serum 
concentration, a transient increase in unbound hormone levels and suppression of TSH 
concentrations in most studies (Davies & Franklyn, 1991; McConnel, 1992; McConnell, 
1999) However, during long-term treatment with salicylates, a new steady state is 
reached reflecting an increased T4 turnover rate, mildly decreased serum TT4 
concentrations and unchanged or decreased FT4 concentrations are observed (Davies & 
Franklyn, 1991; McConnell, 1992; Surks & Stievert, 1995; McConnell, 1999).  
Thyrotropin concentrations return to the reference range within a few weeks of 
treatment (McConnell, 1992).   
Carprofen, another propionic acid derivate, is another commonly used NSAID in 
dogs and is highly protein bound (Isaacs, 1999).  One abstract reports a mild decrease in 
TT4 and TSH measurements after administration of carprofen to dogs (2.2-3.3 mg/kg 
BW q 12 h for 5 weeks).  Free T4 also decreased mildly but this was not statistically  
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significant (Ferguson et al., 1999).  The proposed mechanism includes displacement of 
T4 from serum binding sites; displacement of pituitary intracellular binding of thyroid  
hormone may explain the persistence of TSH suppression.  As serum samples in this 
study were taken at 0, 2 and 5 weeks, it is possible that the more rapid increases in FT4, 
as seen in humans, may not have been observed.  
 Our protocol for administration of ASA and Keto was based on knowledge of 
the clinical use of these drugs as well as on our desire to obtain samples for thyroid 
hormone concentrations at drug maximal plasma concentration. Dosages used for both 
drugs in this study were common dosages used in practice and were likely to lead to 
therapeutic concentrations of these drugs (Mathews, 1996). As the mechanism 
traditionally believed to be involved to explain effects of NSAIDs on thyroid function in 
humans and horses was displacement of T4 from transport proteins, samples were taken 
at the maximal serum concentration of both drugs.  Samples were not taken at other 
moments during the day to evaluate if this decrease in TT4 persisted throughout the day. 
Interestingly, in a study in horses, decreased TT4 concentrations were observed after 
phenylbutazone administration, and sampling did not occur at maximal serum 
concentration in this study (Ramirez et al., 1997). But many protocols for ASA therapy 
in dogs will lead to stable plasma concentrations, therefore, our observations are likely 
to be valid throughout the day (Lipowitz et al., 1986). 
Few side effects were observed in our study following ASA and Keto 
administration. The mild gastro-intestinal side effects seen in a few dogs are not likely 
to have influenced our results. Despite the abnormal thyroid function test results 
observed in the dogs on ASA therapy, no clinical signs compatible with hypothyroidism 
were observed in any of the dogs during the study.  
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Conclusion 
 
There are several clinical implications to this study.  Firstly, as observed in 
human studies and corroborated in our study, the importance of the effects of NSAIDs 
on thyroid function can be marked, but varies from drug to drug.  Therefore, until 
further studies on the potential effects of NSAIDs on thyroid function are published, 
caution is advised when interpreting thyroid function test results in a dog on NSAIDs 
therapy.  Secondly, a seven-day treatment with ASA resulted in a decrease in TT4-
potentially sufficient to lead to the misinterpretation of the thyroid profile and 
misdiagnosis of hypothyroidism in more than half of the dogs.  Thirdly, FT4 measured 
by equilibrium dialysis and TSH serum concentrations were less affected by ASA and 
Keto administration than TT4. Therefore, a diagnosis of hypothyroidism, in a dog on 
NSAIDs therapy, should not be based on a TT4 measurement only.  Fourthly, after 
short-term (one-week) administration of ASA, and maybe other NSAIDs as well, we 
advise a minimal seven-day period before thyroid function testing in dogs. 
This study revealed that ASA can rapidly and significantly affect thyroid 
homeostasis in dogs. The effect was most pronounced on TT4 serum concentration and 
probably reflected the displacement of thyroid hormones from serum protein binding 
sites.  
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Introduction to chapter 4 
 
Some factors can influence thyroid hormone test results in humans and dogs, 
contributing to the difficulty in evaluation of thyroid function.  In chapters 2 and 3 we 
investigated the effects of commonly used drugs on canine thyroid function.  To further 
investigate the possible influence of common clinical situations on thyroid function 
tests, the effects of obesity and weight loss will be assessed in the following chapter. 
Indeed, in dogs, obesity is the most common nutritional problem encountered and 
weight loss is the cornerstone of its treatment, therefore it was important to clarify how 
obesity and weight loss can affect thyroid function test results in dogs. 
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Summary 
 
Obesity and weight loss have been shown to alter thyroid hormone homeostasis 
in humans. In dogs, obesity is the most common nutritional problem encountered and 
weight loss is the cornerstone of its treatment. Therefore it is important to clarify how 
obesity and weight loss can affect thyroid function test results in that species.  The 
objectives of this study were to compare thyroid function in obese dogs and in lean dogs 
and to explore the effects of caloric restriction and weight loss on thyroid hormone 
serum concentrations in obese dogs. 
  In the first experiment, 12 healthy lean beagles and 12 obese beagles were 
compared.  Thyroid function was evaluated by measuring serum concentrations of total 
thyroxine (TT4), free thyroxine (FT4), total triiodothyronine (TT3), thyrotropin (TSH), 
and reverse triiodothyronine (rT3) as well as a TSH stimulation test using 75 µg IV of 
recombinant human TSH.  
In the second experiment, eight obese beagles were fed an energy-restricted diet 
(average 63 % MER) until optimal weight was obtained.  Blood samples for 
determination of TT4, FT4, TT3, TSH, and rT3, were taken at the start and then weekly 
during weight loss. 
Only TT3 and TT4 serum concentrations were significantly higher in obese dogs 
as compared to lean dogs.  In the second experiment, weight loss resulted in a 
significant decrease in TT3 and TSH serum concentrations.  Thus obesity and energy 
restriction significantly alter thyroid homeostasis in dogs, but the observed changes are 
unlikely to affect interpretation of thyroid function test results in clinics. 
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Introduction  
 
 Hypothyroidism is the most common, but probably also the most over diagnosed 
endocrine disease in dogs, partially because clinical manifestations of hypothyroidism 
are vague and insidious. Obesity is observed in more than 40 % of dogs with 
hypothyroidism in several studies (Dixon et al., 1999b; Feldman et al., 1996; Kaelin et 
al., 1986; Panciera,1994).  Therefore, many dogs in practice are tested and/or treated for 
hypothyroidism because they are overweight. Obesity, however, is a common 
nutritionally related problem in dogs and many dogs with obesity are not hypothyroid. It 
is estimated in the general population that between 21 and 30 % of dogs seen in practice 
are obese (Laflamme et al., 1994).  Gosselin et al. (1980) reported that thyroid hormone 
concentrations in obese beagle dogs were increased in comparison to euthyroid lean 
dogs, but this statement was based on only 6 dogs. Furthermore tests available then to 
assess canine thyroid function were less reliable than current ones. Nevertheless, the 
effect of obesity on canine thyroid function is frequently cited in the literature (Peterson 
et al., 1989; Scott-Moncrieff et al., 2000) and for the reasons mentioned above (small 
sample size and reliability of diagnostic tests) it is worthwhile to further investigate this 
issue. 
 
 Fasting or weight loss has been reported to decrease thyroid hormone 
concentrations in humans and rats (Drent and van der Veen, 1995; Glass and Kushner, 
1996). However, information on possible effects of energy restriction on canine thyroid 
function test results is scarce.  Energy restriction is the cornerstone for the treatment of 
obesity. Obese dogs are frequently tested for hypothyroidism in practice when they have 
been fed a calorie restricted diet and the veterinarian or owner feel that weight loss is 
not sufficient. Therefore, studies clarifying the possible influence of weight loss or 
energy restriction on thyroid hormone concentrations in dogs are warranted.   
 
Currently, the combined use of serum thyroxine (T4) and TSH concentrations 
seems to be the easiest and most reliable way to assess canine thyroid function (Scott-
Moncrieff et al., 1996).  The measurement of FT4, especially by equilibrium dialysis 
(FT4ED) is thought by many authors to be superior because it is less influenced by non- 
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thyroidal diseases than is determination of TT4 (Peterson et al., 1997; Scott-Moncrieff 
et al., 2000).  Results of TSH stimulation tests using bovine TSH (bTSH) are less 
influenced by the presence of non-thyroidal systemic diseases than is the measurement 
of baseline T4. Therefore this dynamic test is still considered the gold standard to assess 
thyroid function in dogs (Scott-Moncrieff et al., 2000).  Since the withdrawal of 
pharmaceutical grade of bTSH from the market, TSH stimulation tests have been 
infrequently used in dogs.  A recent study has shown that recombinant human TSH 
(rhTSH) did significantly increase thyroid hormone concentrations in euthyroid beagle 
dogs (Sauvé and Paradis, 2000). Therefore, it could be an interesting alternative to the 
use of bTSH.   
 
 The objectives of this study were to compare thyroid function in obese and lean 
control dogs and to evaluate the effects of calorie restriction and weight loss on thyroid 
hormone concentrations in obese dogs. Thyroid function was evaluated by the 
determination of TT4, TT3, FT4ED, rT3, TSH serum concentrations and through 
performing a TSH stimulation test. 
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Materials and methods 
 
First experiment: Effect of obesity on serum thyroid hormone concentrations 
Twenty-four Beagle dogs (control and obese groups) aged between 1 and 9 years 
were used for the first experiment. All dogs were assessed as healthy (except for 
obesity) based on physical examination, normal complete blood count (CBC) and serum 
biochemistry profile.  Body condition score was assessed according to a validated nine-
point body condition scoring system (Laflamme et al., 1994). All dogs were kept in 
similar conditions throughout the study and fed once a day (9 AM) with a standard 
maintenance diet (Royal Canin Premium Croc adult) for at least one month before 
entering the study. All dogs had access to outside runs for several hours each day.  
Metabolic energy requirements were individually adjusted if needed in order to ensure 
stable weight, and ranged between 480 kJ kg 
(0.75)
 and 522 kJ kg 
(0.75)
.  Weight in both 
groups was stable for at least 1 month before the experiment. 
  
The lean control group consisted of 12 beagle dogs, 4 females (2 spayed and 2 
in anoestrus) and 8 neutered males, weighing between 10.8 and 17.55 kg (mean 13.15 
kg, median 12.1 kg) and aged between 1 and 9 years.  Body condition score was 
between 4 and 5 on the nine-point scale at the time of evaluation.  
 
The obese group consisted of 12 obese beagle dogs, 4 females (2 spayed and 2 
in anoestrus) and 8 neutered males. Age ranged from 3 to 9 years and weight from 17.8 
to 25.9 kg (mean 21.5 kg, median 20.7 kg). At the time of evaluation, all dogs in this 
group had a body condition score between 6 and 8 on the nine-point scale. Obesity had 
been induced through allowing ad libitum food intake over a period of 10-15 months. 
The dogs were already obese for 6 months at the time of evaluation.  
 
Blood samples for determination of TT4, TSH, TT3, rT3, thyroglobulin auto 
antibodies (TgAA) and FT4ED were taken from all dogs at 9 AM after a 12-hour fast.  
Samples were taken through jugular venipuncture and allowed to remain at room 
temperature for approximately 20 minutes prior to centrifugation. Serum aliquots were 
frozen at 20°C in plastic tubes until assayed.  A TSH stimulation test using 75 µg of  
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human recombinant TSH (Thyrogen®, Genzyme Corporation) was performed in all 
dogs. One vial of rhTSH (0.9 mg) was reconstituted with 5 ml of sterile injection water. 
Serum samples for determination of TT4 were taken before (T0) intravenous injection 
(i.v.) of rhTSH and 4 (T4) and 6 (T6) hours later.  
 
Second experiment: Effect of weight loss due to caloric restriction on thyroid function 
In the second experiment, the effect of weight loss on thyroid function was 
evaluated in eight chronically obese dogs following a protocol established by Diez et 
al..  These dogs were different from the obese dogs in the first experiment and consisted 
of 4 neutered males and 4 intact females, aged from 4 to 7 years.  Before inclusion in 
the study, dogs were determined to be healthy based on physical examination, CBC, 
serum biochemistry profile and urinalysis. All dogs tested negative for TgAA.  At the 
beginning of the experiment, weight ranged from 17.3 to 23.45 kg and all dogs had a 
body condition score of at least 6 on a nine-point scale (Laflamme et al., 1997). Dogs 
were at least 30% (30-72%) overweight for a minimum period of one year before 
entering the study. Initial energy requirements for weight loss were based on the 
individual previous food consumption of the dog.  An average of 72% of maintenance 
energy for optimal body weight was required to induce weight loss and was decreased 
as needed by increments of 10% as needed to ensure a weekly weight loss of around 2 
%.  Dogs were fed with either a high-protein diet (%DM: crude protein, 47.5%; starch, 
5.3%; total dietary fiber, 30.8%; ash, 7% and metabolizable energy, 11.6 kJ/g as fed) or 
with a commercially available weight reduction diet (%DM: crude protein, 23.8%; 
starch, 23.9%; total dietary fiber, 38.6%; ash, 5.2% and metabolizable energy, 9.8 kJ/g 
as fed). Each dog received one diet throughout the experiment (n=4 in each group). 
Water was provided ad libitum.  Blood samples to assess TT4, TSH, FTED, TT3 and 
rT3 were taken every 4 weeks as described above.  Dogs were examined daily and body 
weight was recorded weekly. The protocol was terminated when dogs optimal body 
weight was obtained. Optimal and thus target body weight was defined as a body 
condition score of 5/9.  
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The experiments were approved by the Ethical Committee of the Faculty of 
Veterinary Medicine, Ghent University, Belgium and/or by the Animal Use and Care 
Advisory Committee of the University of Liège, Belgium. 
 
Assays 
Serum TT4 and TSH serum concentrations were determined using 
radioimmunoassays previously validated for the dog (Clinical Assays Gammacoat M 
Total T4 125I RIA Kit, Diasorin, Stillwater, MN; and Coat-A-Count canine TSH 
IRMA, Diagnostic Products Corp, Los Angeles, CA, USA, respectively) (Sauvé et al., 
2003).  Reference range for TT4 and TSH serum concentrations was 15-67 nmol/L and 
0-0.68 ng/ml respectively.  Determination of FT4 serum concentrations by equilibrium 
dialysis (FT4ED) was performed using a commercial assay kit (Nichols Institute 
Diagnostics, San Juan Capistrano,CA) (Daminet et al., 1999).  The reference range for 
FT4ED serum measurements was 6-42 pmol/L.  Total T3 concentrations were measured 
through a validated in-house charcoal separation assay (Panciera et al., 1990). The 
reference range for TT3 serum concentrations was 1.0-2.4 nmol/L.  Reverse T3 serum 
concentrations were measured through a validated radioimmunoassay method (Biodate 
S.p.A., Rome, Italy) (Center et al., 1984). Reference range for rT3 was 0.41-0.95 
nmol/L.  Thyroglobulin AA were determined through a previously validated technique 
(Nachreiner et al., 1998). All thyroid hormone analyses were performed at the 
Endocrine Section, Animal Health Diagnostic Laboratory, Michigan State University. 
 
Statistical analysis 
For the first experiment, the obese group was compared with the control group 
for the different hormones by analysis of variance with D=0.05. 
Furthermore, a mixed model was fitted to TT4 concentrations with dog as random effect 
and time after TSH stimulation (0, 4 and 6 hours) as a categorical fixed effect. At each 
of the three timepoints, the obese group was compared with the normal group at the 
0.017 significance level in order to ensure an overall 5% type I error rate (Bonferronis 
multiple comparisons technique with comparisons at three different timepoints). 
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For the second experiment, a mixed model was fitted to each of the different 
hormone concentrations with dog as random effect and the fraction overweight 
((starting weight-normal weight)/normal weight), as a continuous fixed effect. The diet 
group and its interaction with fraction overweight was also added to the model, but in 
case of non significance of these terms, they were dropped from the model. Based on 
these mixed models, the hypothesis was tested whether the slope, describing the linear 
effect of the weight fraction on the hormone concentrations, was equal to zero or not. 
 
Finally, the influence of the TT4 and TT3 concentrations at the start and the end 
of the diet on the time needed to return to normal weight was studied by linear 
regression, with the hypothesis test based again on the slope being equal to zero or not. 
 
Results 
 
First experiment: Effect of obesity on serum thyroid hormone concentrations 
Results for mean basal TT4, TSH, FT4ED, TT3 and rT3 serum concentrations 
(+/- SEM) are shown in table 1. Total T4 and TT3 serum concentrations were 
significantly higher in the obese group compared with the lean control group 
(P<0.0001) although basal TT4 serum values always remained within the reference 
range for euthyroid dogs (range from 15 to 67 nmol/L). No significant differences 
between groups were found for TSH, FT4ED and rT3. 
 
Results for the TSH stimulation test using rhTSH are shown in figure 1.  Total 
T4 serum concentrations increased markedly after the injection of rhTSH in both 
groups. Increases in TT4 concentrations were more pronounced 6 hours after TSH 
injection then after 4 hours in both groups. Total T4 serum concentrations were not 
statistically different between the two groups at 4 and 6 hours after TSH stimulation.  
No adverse reactions were noted after the i.v. injection of rhTSH in any of the dogs. 
 
All dogs tested negative (< 200 % optical density) for TgAA.  
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Second experiment: Effect of weight loss due to caloric restriction on thyroid function 
All 8 dogs remained healthy during the weight loss study.  Time required to 
reach ideal body weight varied greatly between dogs and ranged from 12 to 26 weeks.  
Average percent body weight loss per week was 2.15 % +/- 0.14 (Mean +/- SEM). 
Initial energy allowance was 675.6 +/- 13 kJ kg 
(0.75)
/day and to reach optimal body 
weight, energy requirement had to be decreased to mean levels of 63 % of maintenance 
energy requirement (MER=550 kJ kg 
(0.75)
). 
 
No differences were found between the 2 diets groups and the interaction 
between time and diet group was also nonsignificant, so that diet could be removed 
from the model.  
 
Serum TT3 and TSH concentrations decreased significantly over time during 
weight loss (P<0.0001) (Table 2, Figure 2). Total T3 serum concentration decreased 
significantly over time during weight loss, each 10% decrease in overweight 
corresponding to a decrease of 0.059 nmol/L. The mean TT3 concentration was equal to 
1.65 at the start and 0.95 nmol/L at the end of the experiment. Total TSH serum 
concentration also decreased significantly over time during weight loss, each 10% 
decrease in overweight resulting in a decrease of 0.025 ng/ml. The mean TSH 
concentration was equal to 0.45 at the start and 0.15 ng/ml at the end of the experiment. 
Although TT4 concentrations decreased also as a function of fraction overweight, this 
effect was not statistically significant (P=0.26). Total T3 concentrations at the start of 
the diet influenced the time to return to normal weight significantly (P=0.013) but no 
such relationship was found for TT4 (Table 3). Dogs having a higher initial serum TT3 
concentration required more time to lose weight. Total T4 and TT3 concentrations at the 
end of the experiment did not correlate with the time required to return to normal weight 
(Table 3). 
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Table 1. Experiment 1: Mean basal serum hormone concentrations (+/- SEM) in 
the obese (n=12) and lean control (n=12) groups. Values denoted by an asterix, *, 
indicate a significant difference between obese and control group ( =0.05). 
 
Hormone Obese Control P-value 
TT4 (nmol/L) 47.00 +/- 2.38 31.00 +/- 2.38 <0.0001* 
FT4 (pmol/L) 18.75 +/- 1.34 17.34 +/- 1.34 0.46 
TT3 (nmol/L) 1.62 +/- 0.07 1.09 +/- 0.07 <0.0001* 
TSH (ng/ml) 0.27 +/- 0.03 0.23 +/- 0.03 0.41 
rT3 (nmol/L) 0.67 +/- 0.05 0.63 +/- 0.05 0.61 
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Figure 1: Experiment 1: Results of the TSH stimulation test using 75 µg of rhTSH 
in obese dogs (n=12) and in control dogs (n=12).  Box plots for TT4 measurements 
are shown on T0 and 4 and 6 hours after rhTSH administration. 
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Table 2. Experiment 2: Evolution of different serum thyroid hormone 
concentrations as a function of the fraction overweight. Slope denotes the linear 
change of the hormone concentration when overweight goes from 100 to 0%. 
*Indicates a significant linear effect of fraction overweight on hormone 
concentration ( =0.05). 
 
Hormone Mean 
value at 
start 
Mean 
value at 
end 
Difference 
(SEM) 
Slope 
(SEM) 
P-value 
TT4 (nmol/L) 32.38 27.26 -4.75 (4.52) -5.22(4.62) 0.26 
TT3 (nmol/L) 1.65 0.95 -0.7 (0.11) -0.59 (0.12) <0.0001* 
FT4 (pmol/L) 20.50 22.25 +1.75 (4.21) +1.12 (3.03) 0.71 
TSH (ng/ml) 0.45 0.15 -0.30 (0.08) -0.25 (0.05) <0.0001* 
rT3 (nmol/L) 0.55 0.59 +0.04 (0.05) +0.03 (0.06) 0.62 
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Figure 2: Experiment 2: Evolution of serum TT4 (a), TSH (b), TT3 (c), FT4 (d) 
and rT3 (e) concentrations over time during weight loss. The thick line 
corresponds to the overall relationship; the thin lines correspond to the individual 
dogs. 
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Table 3. Experiment 2: Effect of TT4 and TT3 serum concentrations at the start 
and the end of the experiment on the time to normalization. Slope denotes the 
linear change on time to normalization for a 1-unit change (TT4) or 0.1-unit 
change (TT3) in hormone concentration. The second column shows the mean 
hormone concentrations of the 8 dogs for which 152 days are required for 
normalization. * Indicates a statistically significant difference. 
 
 
Hormone Mean value  Slope (SEM) P-value 
TT4 at start (nmol/L) 32.4 0.405 (1.02) 0.71 
TT3 at start (nmol/L) 1.65 19.25 (5.52) 0.013* 
TT4 at end (nmol/L) 27.6 0.16 (1.55) 0.92 
TT3 at end (nmol/L) 9.5 0.58 (5.54) 0.92 
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Discussion 
 
Serum TT3 and TT4 concentrations were significantly higher in obese dogs.  
However the magnitude of the observed elevation in TT4 and TT3 serum concentrations 
was not clinically significant as both hormones always remained well within the 
reference range. 
 
In obese humans, thyroid function generally remains normal, with most studies 
reporting normal TT4, TT3, rT3 and TSH serum concentrations (Drent and van der 
Veen, 1995; Glass and Kushner, 1996; Roti et al., 2000). However one-study reported 
increased TT4 levels (Scriba et al., 1979). The exact cause for a similar observation in 
our study is not known.  Some studies in humans have documented increased serum 
thyroid binding globulin concentrations which could be responsible for the increased 
TT4 serum concentrations (Scriba et al., 1979).   
 
Some studies also reported increased TT3 levels in obese humans (Bray et al., 
1976; Scriba et al., 1979; Stichel et al., 2000). The exact cause of this observation is 
controversial but hypotheses include increased conversion of T4 into T3, decreased 
numbers of T3 receptors in obese patients or caloric overfeeding rather than obesity 
itself (Glass and van der Veen, 1996; Stichel et al., 2000). However in the first 
experiment the obese dogs were fed their maintenance energy requirements for one 
month before the time of evaluation, therefore, overfeeding should not be responsible 
for the increased serum TT3 concentrations observed in our study.  In the second 
experiment however, initial energy allowance was higher (675.6 +/- 13 kJ kg 
(0.75)
/day), 
therefore, this initial overfeeding could have contributed to the higher serum TT3 
concentrations observed at the start of the second experiment. 
 
In veterinary practice, finding a baseline serum TT4 concentration within the 
reference range is commonly used to exclude hypothyroidism in dogs (Scott-Moncrieff 
et al., 2000). Many factors, especially illnesses and some drugs, can significantly 
decrease thyroid hormone concentrations and lead to misdiagnosis of hypothyroidism  
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(Scott-Moncrieff et al., 2000). Our study showed that obese dogs are euthyroid and have 
slightly higher TT4 values than lean dogs. Therefore exclusion of hypothyroidism in an 
(euthyroid) obese but otherwise healthy dog, based on a baseline TT4 measurement 
should be straightforward.  
 
Whereas TT4 values were significantly increased in obese dogs, FT4 values 
measured through equilibrium dialysis were similar in obese and lean dogs.   Therefore, 
FT4ED is reliable to evaluate thyroid function in obese dogs, which is in accordance 
with several studies showing that FT4ED is less influenced by non-thyroidal factors 
than TT4 measurements (Peterson et al., 1997; Scott-Moncrieff et al., 2000). The free or 
unbound fraction of thyroid hormones is biologically active.  If the increased TT4 
concentrations observed in our study were due to increased levels of thyroid binding 
globulin, normal FT4 and increased TT4 levels would be expected.   Thyroglobulin AA 
are observed in 36 to 60 % of dogs with hypothyroidism and support a diagnosis of 
autoimmune thyroid disease (Daminet et al., 2000; Dixon et al., 1999a; Nachreiner et 
al., 1998).  All our dogs, including the 20 dogs with obesity, tested negative for the 
presence of TgAA.   
 
One intact female beagle had high serum TT4 (74 nmol/L) concentration one 
month after initiating weight loss (visible in figure 2).  Serum progesterone 
concentration at that time was 43 nmol/L, which is compatible with dioestrus and could 
be responsible for this increased TT4 serum concentration (Reimers et al., 1990). 
 
Reverse T3, produced by peripheral 5-deiodination of T4, is the biologically 
inactive form of T3.  In humans with obesity rT3 levels remain unchanged in most 
studies (Roti et al., 2000), which corresponds to our findings.  
  
As T3 and T4 are major regulators of energy metabolism, a defect in the thyroid 
function is frequently associated with changes in body weight.  None of the 20 obese 
beagles (12 from the first experiment and 8 from the second experiment before weight 
loss) used in this study had results compatible with thyroid dysfunction.  Interestingly, 2  
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obese dogs from the second experiment had high TSH serum concentrations before 
caloric restriction (0.86 and 0.72 ng/ml) in combination with normal TT4 serum 
concentrations.  These results could suggest subclinical hypothyroidism where an early 
thyroid failure is compensated by increased stimulation of TSH secretion. Moreover, 
approximately 10% of euthyroid dogs have an increased TSH into the hypothyroid 
range. Further follow-up of these 2 dogs during a one-year period excluded the 
possibility of hypothyroidism based on the absence of clinical signs, normal TT4 and 
TSH measurements, negative TgAA evaluation and a normal TSH stimulation test (one 
dog).  Most studies in obese humans report normal basal serum TSH concentrations, 
although a recent study reported high TSH levels in some obese children and adults 
(Pinkney et al., 1998; Stichel et al., 2000).  High leptin levels observed in obese humans 
might contribute to this finding through stimulation of thyrotropin-releasing hormone 
(TRH) release (Pinkney et al., 1998; Stichel et al., 2000). 
 
The study of Sauvé and Paradis in 2000 was the first to report the use of rhTS to 
perform a TSH stimulation test in euthyroid beagle dogs. These authors concluded that 
the intravenous use of 50 µg of rhTSH was clinically useful and that sampling for serum 
TT4 determination 4 and 6 hours after rhTSH injection was adequate. Based on further 
discussion with these authors and personal clinical experience with this molecule, a 
slightly higher dose (75 µg) was used to perform the TSH stimulation tests in our study. 
The use of 75 µg of rhTSH for dogs weighing between 10.8 and 25.9 kg (but obese) in 
our study allowed optimal stimulation of the thyroid gland.  All dogs (lean and obese) 
met the criteria suggested by Sauvé&Paradis to confirm euthyroidism (post TSH TT4 
value greater than 45 nmol/L or an increase in TT4 of at least 24 nmol/L) (Sauvé and 
Paradis, 2000). Furthermore with the aforementioned dose of rhTSH, TT4 results at 6 
hours were higher than at 4 hours, suggesting that, with 75  µg of rhTSH, sampling 6 
hours after the injection of rhTSH is more optimal than the 4-hour sample.  It is 
interesting to mention that the reference values for the assay used to measure TT4 
measurements in our study were higher than the reference range for the assay used in 
the study of Sauvé and Paradis. 
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Diet changes are the mainstay in the treatment of obesity. Therefore, it is 
important to recognize how changes in dietary intake affect thyroid hormone physiology 
and results of thyroid hormone testing. One study in dogs reported a decrease in serum 
TT3 concentrations in dogs undergoing several weight loss protocols, but FT4, TSH and 
rT3 serum concentrations were not evaluated in that study (Laflamme et al., 1997).  
Percentage of maintenance energy requirement (MER) used in our study was similar to 
% MER used in the study of Laflamme in 1997.  Our study showed that feeding an 
energy restricted diet (average 63 % of MER) to obese dogs led to a significant decrease 
of serum TT3 concentrations but that TT4, FT4ED, and rT3 remain normal. Such levels 
of restriction are routinely used in clinics to promote weight loss.  In clinical practice, 
TT4 measurements are more routinely used to evaluate thyroid function than are TT3 
serum concentrations because the latter show much greater overlapping results between 
normal, hypothyroid and sick dogs (Miller et al., 1992).  Our results are in agreement 
with the observations in obese humans where decreased levels of TT3 are observed after 
caloric restriction in most studies; this is referred to as the low T3 state of 
undernutrition (Cavallo et al., 1990; Glass and van der Veen, 1996). A decreased 
peripheral conversion of T4 into T3, through inhibition of a type I deiodinase, is the 
proposed mechanism (Glass and van der Veen, 1996; Roti et al., 2000; Vagenakis et al., 
1977). The decreased concentration of T3 is believed to protect the organism during 
periods of fasting or calorie restriction by lowering the metabolic rate (Cavallo et al., 
1990; Drent and Kushner, 1995; Shetty,1990).  
 
A decrease in serum TT3 concentrations is also the hallmark of the euthyroid 
sick syndrome observed in humans or dogs suffering from a systemic nonthyroid 
illness (Ferguson,1997).  Anorexia and decreased energy intake frequently seen in 
association with systemic illness might play a role. 
In humans losing weight parallel to the decrease in TT3 serum concentrations, 
an increase in rT3 levels due to diminished clearance is reported (Glass and van der 
Veen, 1996; Roti et al., 2000). Reverse T3 serum concentrations did not change 
significantly in our study.   
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Thyrotropin levels in our study decreased during caloric restriction, but 
remained within the reference range. Decreased or normal baseline serum TSH levels 
have also been documented in humans undergoing fasting or calorie restriction (Beer et 
al., 1989; Glass and van der Veen, 1996). Whether calorie-restriction could suppress the 
high TSH levels of a hypothyroid dog into the reference range and therefore leading to a 
diagnostic challenge remains a question. 
 
The decline in TT3 that accompanies caloric-restriction would theoretically be 
expected to be associated with an increase in serum TSH concentrations.  However this 
is not the case. One possible explanation is that intracellular pituitary concentrations 
remain constant, because they are maintained by intracellular deiodination of the 
unchanged TT4 levels.  Altered sensitivity of the hypothalamic-pituitary-thyroid axis or 
inhibition through inhibitors of TSH secretion might also play a role.  But clearly, 
despite their low serum TT3 levels, dogs fed a calorie-restricted diet are not hypothyroid 
based on the absence of clinical signs of hypothyroidism and serum TSH and FT4 
concentrations within the reference range. 
 
Some studies have shown a correlation between TT3 values and resting 
metabolic requirements (Kiortsis et al., 1999). This could at least partially explain why 
the dogs with higher TT3 concentrations required more time to lose weight in our study.  
We found no correlation between body weight and serum TT3 concentrations. 
 
Conclusion 
 
The present study demonstrates that thyroid homeostasis is influenced by obesity 
and weight loss. Although always within their reference ranges, serum TT3 and TT4 
concentrations were somewhat higher in obese dogs when compared to lean dogs.   
Furthermore, caloric-restriction led to a decline in serum TT4, TT3 and TSH 
concentrations, but only statistically significant for TT3 and TSH.  Free T4ED and rT3 
remained unchanged.  Therefore, although significant changes in thyroid homeostasis  
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were observed in our study in obese dogs and in calorie-restricted dogs, these situations 
are unlikely to affect interpretation of usual thyroid function test results in practice. 
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Introduction to chapter 5 
 
 In chapters 2, 3 and 4, we focussed on the influence of drugs, obesity and weight 
loss on canine thyroid function test results. The awareness and knowledge of these 
influences should help the clinician to make a more reliable diagnosis of 
hypothyroidism in dogs.  Another aspect of the difficulty in the diagnosis of 
hypothyroidism in dogs is that the clinical signs are vague and non-specific.  Several 
diseases have a clinical presentation that can be similar to hypothyroidism.  The most 
striking example is the symmetrical flank alopecia frequently observed in 
hypothyroidism but also a characteristic feature of a recently documented 
dermatological disease: canine recurrent flank alopecia.  In this last chapter we shall 
evaluate thyroid function in dogs with CRFA. 
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Summary 
 
Thyroid function was assessed in euthyroid dogs (n=20), dogs suffering from 
recurrent flank alopecia (CRFA, n=18), and hypothyroid dogs (n=21).  Blood samples 
obtained from all dogs in each group were assayed for total thyroxine (TT4), thyrotropin 
(TSH), and thyroglobulin autoantibodies (TgAA) serum concentrations.  Total T4 and 
TSH serum concentrations were significantly decreased and increased, respectively, in 
the hypothyroid group compared with the other 2 groups.  No significant differences in 
TT4 and TSH serum values were found between the euthyroid and CRFA groups.  
Thyroglobulin autoantibodies were detected in 10, 11.1, and 61.9 % of euthyroid dogs, 
dogs with CRFA, and hypothyroid dogs, respectively.  In conclusion, dogs suffering 
from CRFA have a normal thyroid function, and the determination of TT4 and TSH 
serum concentrations allows differentiation of these dogs from dogs with 
hypothyroidism, in most cases.  Occasionally, both diseases can be concomitant. 
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Introduction 
 
 The diagnosis of canine hypothyroidism can be challenging for 2 main reasons: 
first, several other diseases can present with similar clinical signs, and second, there is 
no ideal test to assess canine thyroid function.   
 
 Alopecia is a common clinical sign of hypothyroidism; 25% of hypothyroid dogs 
have been reported to present with symmetrical bilateral endocrine alopecia (1).  The 
symmetrical alopecia described in canine recurrent flank alopecia (CRFA) can easily 
mislead one to a diagnosis of hypothyroidism. Canine recurrent flank alopecia is a 
recently recognized skin disorder of unknown etiology, characterized by episodes of 
truncal hair loss that often occurs on a recurrent basis.  It has been described under 
several synonyms: seasonal flank alopecia, seasonal growth hormone deficiency, 
canine idiopathic cyclic flank alopecia, cyclic follicular dysplasia, and follicular 
dysplasia.   Typically, this alopecia affects adult dogs on a yearly seasonal basis and 
resolves spontaneously without treatment within several months.  The episodes do not 
always reoccur annually.  Several hypotheses, such as photoperiod and melatonin 
deficiency, have been proposed, but the etiology remains unclear (2-5).  Assessment of 
thyroid function in dogs with CRFA through determination of endogenous thyrotropin 
(TSH) concentrations or serum thyroglobulin autoantibodies (TgAA) has not been 
reported, to our knowledge.     
 
 Overall, the assessment of canine thyroid function is also difficult because of the 
lack of one reliable test.  Since the unavailability of bovine TSH, previously used to 
perform thyroid stimulation testing, much emphasis has been placed in the recent years 
on determination of endogenous TSH concentrations.  Currently, the combined use of 
thyroxine (T4) and TSH serum concentrations seems to be the easiest and most reliable 
way to assess canine thyroid function (6,7).  Most cases of canine hypothyroidism are 
primary and the result of a lymphocytic thyroiditis.  The presence of circulating TgAA 
seems to correlate with this thyroiditis (8-11). 
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The aim of our study was to assess thyroid function of dogs affected by CRFA.  
The objectives of our study were to determine serum total thyroxine (TT4), TSH, and 
TgAA concentrations in euthyroid dogs, dogs with CRFA, and hypothyroid dogs. 
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Materials and methods 
 
 The control group consisted of 20 dogs aged from 1.5 to 14 y (median 2 y).  
Body weights ranged from 8.5 to 54 kg (median 16 kg). Ten different breeds were 
represented in this group.  These dogs were privately owned, or were part of a colony 
belonging to the Faculté de médecine vétérinaire, Université de Montréal, and were 
assessed as healthy, based on an unremarkable history and on physical examination 
findings.  None of them received medication.  A TSH stimulation test was not 
performed, as bovine TSH was not available.  To be included in this group, TT4 serum 
concentration had to be t 15 nmol/L.   
 
 A second group consisted of 18 dogs with signs compatible with CRFA.  Ages 
ranged from 2 to 12 y (median 4.5 y) and weights from 20 to 51 kg (median 27.5 kg).  
Clinical diagnosis of CRFA was based on history and clinical signs, such as breed 
predisposition, time of the year of onset of the alopecia, spontaneous regrowth in the 
alopecic area, and absence of other clinical signs suggestive of hypothyroidism or 
hyperadrenocorticism.  Seven different breeds were represented (boxer n=7, giant 
schnauzer n=2, Airedale n=5, Great Dane n=1, Dalmatian n=1, Labrador retriever n=1 
and American pit bull terrier n=1).  Of the 18 dogs in this group, 8 were spayed females, 
2 were intact males, 4 were intact females, and 4 were castrated males.  A third group 
consisted of 21 hypothyroid dogs.  Diagnosis was based on clinical history, signs 
consistent with hypothyroidism, a TT4 concentration below 15 nmol/L, and/or a serum 
TSH concentration above 0.6 ng/mL and complete resolution of clinical signs after 
thyroid supplementation in all dogs.  Ages ranged from 2 to 15 y (median 5 y), and 
weights from 5.5 to 68 kg (median 24 kg).  This group was composed of cocker spaniels 
n=5, golden retrievers n=3, Shetland sheepdogs n=3, giant schnauzers n=2, and one of 
each of the following breeds: bloodhound, Dalmatian, St-Bernard, boxer, mixed breed 
dog, Akita, weimaraner and fox terrier.   Five of these dogs were spayed females, 5 
were intact males, 2 were intact females, and 9 were neutered males.  Blood samples 
were collected by jugular venipuncture and centrifuged; each serum sample frozen in 3 
aliquots at -20q C until assayed.  Total T4 concentrations were determined using a  
CHAPTER 5 
 
 152
 
validated solid-phase radioimmunoassay (Coat-a-Count canine T4, Diagnostic Products 
Corporation, Los Angeles, California) (12).  Serum TSH concentrations were 
determined by using a validated, commercially available solid-phase radioimmunoassay 
(Coat-a-Count canine TSH IRMA, Diagnostic Products Corporation) (12,13).  Serum 
TgAA concentrations were measured at the Endocrinology Animal Health Diagnostic 
Laboratory of Michigan State University using a previously validated technique.  A 
positive result was defined as at least twice (200 %) the optical density of the negative 
control sample (11).  Data were analyzed by using a factorial ANOVA test and post hoc 
Bonferroni test, when appropriate. Results are presented as means r standard deviation 
(means, s = ) and were considered significant at P<0.05.  
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Results 
 
Total thyroxine 
 Mean basal serum TT4 concentrations were 27.5, s = 8.86 nmol/L (range 15 to 
43.32 nmol/L), 25.54, s = 11.95 nmol/L (range 7.21 to 48.5 nmol/L) and 4.16, s =  4.53 
nmol/L (range 0.05 to 14.92 nmol/L) in euthyroid, CRFA, and hypothyroid dogs, 
respectively.  There was a significant difference in serum TT4 concentrations between 
the hypothyroid group and the other 2 groups (P<0.05).  No differences in TT4 
concentrations were found between the CRFA and control groups (Figure 1).   
 
Thyrotropin 
 Mean values for TSH concentrations in the euthyroid, CRFA, and hypothyroid 
groups were 0.16, s = 0.1 ng/mL (range 0.03 to 0.39 ng/ml), 0.34, s = 0.28 ng/mL 
(range 0.03 to 1.17 ng/mL), and 3.14, s = 2.5 ng/mL (range 0.46 to 8.1 ng/mL), 
respectively. A significant difference in serum TSH concentrations was found between 
the hypothyroid group and the other 2 groups (P<0.05).  No differences were found 
between the concentrations of TSH in the CRFA and control groups (Figure 2).  Three 
dogs with CRFA had serum TSH values above 0.6 ng/mL at one point in time; the 
results for their serum TT4, TSH, and TgAA concentrations are given in Table 1.   None 
of these 3 dogs received any medication.  The first boxer was presented in May 1996 
with bilateral symmetrical flank alopecia.  His complete blood cell count and 
biochemical profile (including cholesterol values) were normal, and the dog had no 
other clinical signs suggestive of hypothyroidism.  The alopecia resolved completely 
within a few months.  The dog suffered another episode of flank alopecia 1 y later, 
which again resolved spontaneously, confirming the CRFA.  Despite the authors 
insistence, it was not possible to get a follow-up of thyroid function in this dog.  The 
second dog, a giant schnauzer, had episodes of flank alopecia in January 1996 and in 
May 1999, both episodes of alopecia resolved spontaneously without any treatment.  A 
follow-up in August 1999 revealed a normal physical examination and a healthy coat.  
According to the owner, the dog remains clinically normal.  The third dog, a Dalmatian,  
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suffered 2 episodes of CRFA; initial results of thyroid function tests suggested 
hypothyroidism, although follow-up tests revealed normal thyroid function.   
 
Thyroglobulin autoantibodies 
 Two of the 20 (10 %) control dogs were positive for serum TgAA.  Two of 18 
(11.1 %) dogs with CRFA tested positive for TgAA. Thirteen of the 21 (61.9 %) 
hypothyroid dogs tested positive for TgAA.   
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Figure 1: Mean serum TT4 concentrations in control dogs, hypothyroid dogs, and 
dogs with CRFA. Bars represent a 95 % confidence interval. 
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Figure 2: Mean TSH serum concentrations for the control group, hypothyroid 
dogs, and dogs with CRFA. Bars represent a 95 % confidence interval. 
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Discussion 
  
 As expected, TT4 serum concentrations were decreased and TSH concentrations 
were increased in most hypothyroid dogs, as compared with the control group dogs. 
Nineteen of the 21 hypothyroid dogs (90.5 %) had a TSH concentration above 0.6 
ng/mL.  Two dogs (9.5 %) with a TSH concentration of 0.46 and 0.50 ng/mL were 
included in the hypothyroid group, because their clinical signs suggested 
hypothyroidism; their serum TT4 were 1.1 and 1.57 nmol/L, respectively, in the absence 
of any concomitant disease; and all their clinical signs resolved with thyroid 
supplementation.  This finding is not surprising, as it has been reported in several 
studies that 24 % to 38 % of hypothyroid dogs have TSH values within the reference 
range (6,7).   
 
 Results from previous studies have suggested a correlation between serum 
TgAA and the presence of a lymphocytic thyroiditis (8-11).  Until recently, the methods 
used to measure serum TgAA and/or the diagnostic cut-off values used, easily yielded 
false positive results, especially in dogs with systemic disease.  This limited their 
clinical usefulness (8-10).  Nachreiner et al (11) recently published the validation of a 
reliable TgAA assay with a useful diagnostic threshold, which should increase the 
clinical utility of determining serum TgAA in some dogs.  This method for TgAA 
measurement was used in our study. We observed that 2 dogs (10 %) of the control 
group dogs tested positive for serum TgAA, whereas Nachreiner et al reported that 3.3 
% of a random population of dogs had positive results for TgAA.  One of our positive 
control dogs had only a mild-positive result with an optical density of 208 %, when the 
cut-off value for a positive sample is 200 % of the negative control result. It is, 
however, still unclear whether the presence of circulating TgAA precedes the clinical 
development of hypothyroidism, and further studies that follow dogs with circulating 
TgAA over a longer period of time are warranted. Thirteen of 21 (61.9 %) hypothyroid 
dogs tested positive for serum TgAA, which is similar to the prevalence of 42% to 59% 
for TgAA in hypothyroid dogs reported in the literature (8,10).  Therefore, our findings 
also support a correlation between lymphocytic thyroiditis and hypothyroidism.   
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 Dogs with CRFA present with dermatological signs that can be suggestive of 
hypothyroidism. Dogs of either sex and of all reproductive status can be affected.  
Canine recurrent flank alopecia is characterized by a nonscarring alopecia, most often 
confined to the thoracolumbar region.  Lesions are usually bilaterally symmetric, but in 
occasional dogs (or episodes) only one side of the body is affected, or one side is more 
affected than the other (4).  Typically, the alopecic lesions are "geographic" in shape 
with well-demarcated borders and the alopecic skin is often markedly hyperpigmented 
(2,5,14).  Mean age at the onset of the first episode around 4 y, but can be quite variable 
(range: 8 mo to 11 y).  The onset of alopecia is variable, but most commonly occurs 
between November and March in the northern hemisphere (4).  Spontaneous regrowth 
of hair occurs in 3 to 8 mo in most cases and usually consists of normal pelage density.  
Although, approximately 20 % of dogs will only have one isolated episode of flank 
alopecia in their life span, most dogs will develop recurrent alopecic episodes for years 
(4).  Other dogs have an occasional year when the alopecia does not recur.  The degree 
of alopecia is variable, with some dogs developing a virtually identical hair loss (size 
and duration) year after year, and other dogs developing larger areas and/or longer 
episodes of hair loss as years go by.  Occasionally, after several consecutive episodes of 
alopecia, some affected dogs will not experience complete hair regrowth before the 
onset of the next episode (4).   
 
The cause of CRFA remains obscure. The higher incidence of CRFA at higher 
latitudes and its seasonal nature of recurrence suggest that photoperiod may be involved 
in the pathogenesis, with melatonin and/or prolactin, 2 photo-dependent hormones, 
being potentially implicated in the process.   
 
For most cases of CRFA, the diagnosis is based on history, clinical signs, and 
rule-out of hypothyroidism (evaluation of thyroid function in dogs > 2 years of age).  
Histopathologic findings observed on skin biopsies such as atrophic, dilated, and 
troncated hair follicles with hyperkeratosis extending to secondary hair follicles (hence 
the colloquial name «witchs feet» or «octopus like hair follicles»), are suggestive of, 
but not pathognomonic, for CRFA (4,5,14).  Moreover, these findings are not always  
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present in cases of CRFA and they may be found with low frequency in other alopecic 
diseases.   
 
Hypothyroidism is an important differential diagnosis for CRFA.  Moreover, 
hypothyroidism and CRFA could both occur in the same animal.  The clinician must, 
therefore, remain vigilant, as this can represent a real diagnostic and therapeutic 
challenge.  A breed predisposition seems to exist for CRFA, with boxers (may account 
for approximately half of all reported cases), Airedale terriers, schnauzers, and English 
bulldogs being the more frequently cited breeds (2,3,14).  However, it has been reported 
in several other breeds (5).  Interestingly, the same breeds are suspected to be 
predisposed for hypothyroidism (1).  Furthermore, the recognition of CRFA or seasonal 
flank alopecia as a separate dermatological condition became clear only in the 1990s 
(3).  Therefore, some dogs previously classified as hypothyroid based on the presence of 
flank alopecia resolving with thyroid supplementation might very well have been dogs 
suffering from CRFA.  Another explanation is that the breeds cited earlier are 
predisposed to both hypothyroidism and CRFA.  Both diseases are more frequent in 
young to middle-aged dogs.  As most dogs with hypothyroidism have a lymphocytic 
thyroiditis, believed to be of autoimmune origin, the question arises whether CRFA 
could have an immune mediated origin as well?  Results of the TSH response test were 
reported in 5 dogs with CRFA and were normal, but serum TSH values and TgAA were 
not available (3).   
Results of T4 and TSH tests in our study were not significantly different 
between euthyroid dogs and dogs with CRFA. However 3 out of 18 dogs with CRFA 
were found to have results that could suggest concomitant hypothyroidism. All episodes 
of flank alopecia resolved completely without any treatment in all 3 dogs.  Their history, 
clinical presentation, and follow-up confirmed CRFA.  The increased TSH and positive 
TgAA suggested concomitant hypothyroidism due to a lymphocytic thyroiditis in dogs 
1 and 2.  None of these 3 dogs had a history or clinical signs suggestive of 
hypothyroidism, except for the flank alopecia, and they did not develop clinical 
hypothyroidism.  The reported specificity of serum TSH concentrations in the diagnosis 
of hypothyroidism ranges from 0.88 to 0.93 (6,7).  Total T4 and TSH serum  
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concentrations were repeated a year later in the second dog, and the TSH value was in 
the reference  range.  One possible explanation could be that TSH is secreted in a 
pulsatile fashion, as it is in humans (15,16).  One study reported an absence of 
significant diurnal variation of the TSH concentrations in healthy dogs and dogs with 
iodine131- induced hypothyroidism; however, dogs with naturally developing 
hypothyroidism had TSH values fluctuating in and out the reference range (17).  This 
could, at least in part, explain the low sensitivity of determination of TSH 
concentrations in the diagnosis of hypothyroidism.  The TT4 serum values in dogs 1 and 
2, with CRFA and increased TSH values, were slightly below the reference range but 
higher than expected in most dogs with hypothyroidism.  The human medical literature 
refers to subclinical hypothyroidism where an increase in TSH values maintains 
adequate thyroid hormone concentrations and few or no clinical signs of 
hypothyroidism are present (18).  Progression towards overt hypothyroidism is slow in 
humans (18).  Whether subclinical hypothyroidism exists in dogs is not known.   
 
 Our results emphasize that flank alopecia can be misleading and appropriate 
testing through a combination of T4 and endogenous TSH determinations or through a 
TSH stimulation test when available, are important to differentiate these conditions in 
some dogs.  In addition, these disorders could be concomitant in some dogs.  When a 
dog is presented with a typical presentation of CRFA a justifiable option is to wait a few 
months and see if the condition resolves spontaneously.  Results of thyroid testing 
should be interpreted in light of the history and clinical findings to avoid overtreating 
euthyroid dogs with thyroid supplementation.  Monitoring of dogs with slightly 
abnormal or equivocal results of thyroid function tests is recommended.  The etiology of 
CRFA is still unclear, but thyroid dysfunction does not seem to be a predisposing factor 
for CRFA.   
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Conclusion 
 
 In conclusion, dogs suffering from CRFA have a normal thyroid function.  
Determination of TT4 and TSH serum concentrations allows dogs with CRFA to be 
differentiated from dogs with hypothyroidism in most cases.  Hypothyroidism and 
CRFA could be concomitant in some dogs.   
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General discussion 
 
Adult onset primary hypothyroidism is a common endocrine disorder in dogs.  
However, many dogs are prescribed a life long unnecessary supplementation of thyroid 
hormones based on erroneous diagnoses of this disease. The vague and non-specific 
clinical signs of hypothyroidism and factors influencing thyroid function test results are 
greatly contributing to this problem.  The possible effects of many factors have not been 
studied yet in dogs.  Thyroid physiology, canine hypothyroidism, specific diagnostic 
tests and factors influencing thyroid homeostasis are described in chapter 1. 
 
 The aim of this study was to clarify the influence of some common clinical 
situations on canine thyroid homeostasis.  In chapters 2, 3 and 4, we evaluated the 
effects of administration of commonly prescribed drugs, obesity and weight loss on 
canine thyroid function.  In chapter 5 we thoroughly evaluated thyroid function in dogs 
with canine recurrent flank alopecia (CRFA), a dermatological disease of unknown 
origin that has been largely confused with canine hypothyroidism in the past. 
 
 The short-term effects of oral prednisone and phenobarbital were evaluated on 
canine thyroid function tests (Chapter 2).  Prednisone therapy significantly decreased 
serum TT4 and to a lesser extend FT4 serum concentrations.  Prednisone administration 
did not have a substantial effect on serum TSH concentrations in euthyroid dogs.  
However decreased TT4 levels should have resulted in increased TSH because of 
reduced negative feed back of these hormones on the pituitary gland, suggesting a 
central inhibition of the hypothalamus-pituitary axis.  We administered prednisone at a 
moderate immunosuppressive dosage for 3 weeks. Normalisation of TT4 serum 
concentrations occurred within 1 week of cessation of the therapy.  Corticoids are 
sometimes used for longer periods of time in practice.  Longer treatment may result in a 
longer duration of suppressed thyroid function.  Furthermore, previous studies have 
shown that the administration of prednisone at an anti-inflammatory dosage had no 
effects on thyroid hormone levels.  These findings emphasize that duration of treatment 
and dosage of glucocorticoids used are important.   
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Short-term phenobarbital therapy in our study did not affect serum TT4, FT4, or TSH 
concentrations. Therapeutic levels were somewhat low in our study, therefore it cannot 
be excluded that higher dosages of phenobarbital might have an influence on thyroid 
function tests even after short-term administration.  It should be mentioned that after the 
publication of our study, several other studies have investigated the effects of 
phenobarbital on canine thyroid function but after long-term administration. These 
studies revealed a significant decrease in TT4 serum values.  Furthermore, endogenous 
TSH concentrations remained within reference range (Kantrowitz et al., 1999) or were 
slightly increased (Gaskill et al., 1999; Müller et al., 2000; Gieger et al., 2000) but 
remained < 0.6 ng/ml in most dogs (the upper reference range for TSH varied between 
0.36 and 0.7 ng/ml in these studies).  Complicating clinical evaluation, weight gain (due 
to polyphagia), lethargy and hypercholesterolemia are reported in dogs on phenobarbital 
treatment, but are also commonly observed in dogs with hypothyroidism. Confirming a 
diagnosis of primary hypothyroidism in a phenobarbital treated dog can for all these 
reasons be a real challenge, especially when TSH concentrations are increased. In 
situations in which it is not clear whether the observed effects on thyroid function are 
the effect of phenobarbital therapy or due to actual hypothyroidism, potassium bromide 
(KBr) therapy could be a therapeutic option.  However, given the long duration to 
achieve steady-state (3 to 5 months) with KBr therapy, it would seem imprudent to 
switch from phenobarbital to KBr to determine whether an animal is hypothyroid or not. 
 
NSAIDs are used more and more frequently in dogs.  We evaluated whether 
acetylsalicylic acid (ASA) or ketoprofen (Keto) influence thyroid function test results in 
dogs (Chapter 3). A significant decrease in TT4 was observed as soon as 24 h after ASA 
administration, but no significant effects were found for FT4 and TSH. No significant 
effects on thyroid results were found with Keto administration. These results indicated 
that TT4 can be markedly decreased by ASA therapy and probably reflected the 
displacement of thyroid hormones from serum protein binding sites.  
A few other studies have evaluated the effects of other NSAIDs on canine 
thyroid function tests.  A mild decrease in TT4 serum concentrations was observed after 
caprofen administration, but FT4 remained unaltered (Ferguson et al., 1999).  Very  
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recently it was shown that the administration of meloxicam and etodolac had no effect 
on thyroid function test results in dogs (Sauvé et al., 2002; Panciera & Johnston, 2002).  
This is in contrast with our study where ASA had a pronounced effect on thyroid 
function test results.  This discrepancy could, at least in part, be due to the high molar 
concentrations obtained with ASA.  Comparisons of these studies clearly point out that 
effect of various NSAIDs on canine thyroid function can be very different from drug to 
drug.  
Dogs in our study did not develop any clinical signs suggestive of 
hypothyroidism when administered ASA.  Furthermore, FT4 serum concentrations were 
not significantly altered following ASA and carprofen administration.  Therefore, these 
dogs, despite decreased TT4 concentrations, were not suffering from clinical 
hypothyroidism.   
Thyroid function test results should be interpreted cautiously in dogs on NSAIDs 
therapy. A seven-day treatment with ASA resulted in a decrease in TT4-potentially 
sufficient to lead to the misinterpretation of the thyroid profile and misdiagnosis of 
hypothyroidism in more than half of the dogs. Therefore, a diagnosis of 
hypothyroidism, in a dog on NSAIDs therapy, should not be based on a TT4 
measurement only.  After short-term (one-week) administration of ASA, and maybe 
other NSAIDs as well, we advise a minimal seven-day period of drug withdrawal before 
thyroid function testing in dogs.   
 
In our studies, prednisone and ASA were the drugs most likely to affect thyroid 
function test results and potentially lead to misdiagnosis of hypothyroidism.  It is 
important to emphasize that abnormal test results were observed, but that none of these 
dogs clinically suffered from clinical thyroid dysfunction.  This is also strengthened by 
the normal FT4 measurements in several of our experiments.   
Our results emphasize that the diagnosis of hypothyroidism in dogs should not 
be based on a TT4 measurement solely.   
Furthermore, patients being tested for possible hypothyroidism should be 
carefully scrutinised for any history of recent medication administration.   
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Obesity and weight loss have been shown to alter thyroid hormone homeostasis 
in humans. In dogs, obesity is the most common nutritional problem encountered and 
weight loss is the cornerstone of its treatment.  Obesity is also a common observation in 
hypothyroid dogs, and therefore, thyroid function is frequently evaluated in practice 
because dogs are overweight.  In chapter 4, we compared thyroid function in obese dogs 
and in lean dogs and explored the effects of calorie restriction and weight loss in obese 
dogs on thyroid hormone serum concentrations.  Only TT3 and TT4 serum 
concentrations were significantly higher in obese dogs as compared to lean dogs.  It is 
generally accepted that finding a normal TT4 serum concentration in a dog, allows 
exclusion of hypothyroidism in most cases.  Therefore, exclusion of hypothyroidism in 
an obese dog based on finding a normal TT4 concentration should be straightforward.  
Weight loss resulted in a significant decrease in TT3 and TSH serum concentrations, 
but TT4 remained unaffected.  In veterinary medicine, TT4 measurements are more 
routinely used to evaluate thyroid function then TT3.  Therefore, evaluating an obese 
dog fed a calorie-restricted diet to promote weight loss, should not affect interpretation 
of thyroid function test results. 
 
Clinical manifestations of hypothyroidism are nonspecific; this further 
complicates the diagnosis of canine hypothyroidism.  Several diseases have a clinical 
presentation that can be similar to hypothyroidism.  The most striking example is the 
symmetrical flank alopecia which is frequently observed in hypothyroidism but also is a 
characteristic feature of CRFA.  During the last decades, many dogs have been 
erroneously diagnosed with hypothyroidism when they were suffering from CRFA. As 
the etiology of CRFA remains largely unknown, we decided to investigate the possible 
role of a thyroid dysfunction as a cause for CRFA.  Thyroid function was assessed in 
dogs suffering from recurrent flank alopecia in chapter 5.  The etiology of CRFA 
remains unknown but this study allowed ruling out thyroid dysfunction as a possible 
cause for this disease.  Practitioners should be aware that the clinical presentation of 
CRFA can be misleading for hypothyroidism.  Particularly in cases suspected for 
CRFA, hypothyroidism should be excluded by finding a TT4 within reference range or 
confirmed by finding a decreased TT4 combined with an increased TSH. 
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 Here follows a discussion about the different thyroid hormones measured in our 
studies. 
Total thyroxine serum concentrations were markedly decreased in more than 
half of the dogs after ASA or prednisone administration in our studies. This alteration in 
thyroid hormone concentrations can easily lead erroneously to a diagnosis of 
hypothyroidism when only a TT4 is determined.  Measuring TT4 and TSH in 
combination should avoid an erroneous diagnosis of hypothyroidism in these cases, 
because TSH serum concentrations remain within the reference range during prednisone 
and ASA administration.  On the other hand, with long term administration of 
phenobarbital and especially with sulfonamides, increased TSH serum concentrations 
can easily lead to an erroneous diagnosis of primary hypothyroidism.   
 
Free T4 measurements were less affected than TT4 serum concentrations in 
several of our studies by the administration of different drugs, or with obesity and 
weight loss.  This is in accordance with most findings in the literature.  Unfortunately, 
at the present moment, FT4 measurement by equilibrium dialysis is not readily available 
in most European laboratories. 
 
Canine-specific TSH assays were developed and are available only since 1996.  
The measurement of canine TSH levels has allowed gaining further insights in canine 
thyroid physiology, improved accuracy in the diagnosis of canine hypothyroidism and 
also helped to confirm the goitrogenic effects of some drugs.  In our studies, TSH levels 
allowed a better exploration of the hypothalamo-pituitary-thyroid axis and contributed 
to the understanding of some mechanisms involved.  Despite all these advantages, the 
limitations of TSH measurement have also become apparent in the last years.  Poor 
sensitivity of the endogenous TSH for the diagnosis of hypothyroidism contributes to 
the difficulty in confirming hypothyroidism in clinics.  
 
Reverse T3 (rT3) and T3 serum concentration measurements were used in 
several of our studies, although rT3 and TT3 are not routinely used to evaluate canine  
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thyroid gland function in practice.  These tests allowed to better explore peripheral 
mechanisms possibly involved.   
 
Thyroglobulin autoantibodies were detected in 10, 11.1, and 61.9 % of euthyroid 
dogs, dogs with CRFA, and hypothyroid dogs, respectively (Chapter 5).  In the other 
studies we performed, euthyroid dogs were all negative. These findings are similar to 
literature reports.  Measurement of TgAA can be of value in the early detection of dogs 
predisposed to hypothyroidism (breeding dogs) or in a research setting, especially 
because hypothyroidism can be a familial condition in beagle dogs.   
 
Bovine TSH stimulation test has long been considered as the gold standard for 
thyroid function evaluation in dogs, but bovine TSH is no longer commercially 
available.  Human recombinant TSH has only been used very recently in veterinary 
medicine in the evaluation of thyroid function in dogs. It proved to be a useful adjunct 
to the evaluation of thyroid function in our study (Chapter 4). No adverse reactions were 
observed and a dosage of 75 Pg proved to be a useful dosage for optimal stimulation of 
the thyroid gland.  Sampling after 6 hours seemed optimal.  This protocol was practical 
for use in a clinical research setting and was not prohibitively expensive.   
 
Our studies also allow making several recommendations to practicing 
veterinarians. 
 
1. To scrutinise patients to be tested for hypothyroidism for any history of drug 
administration is crucial.  Ideally, dogs should not be tested for hypothyroidism when 
administered drugs, and thyroid testing should be postponed to after cessation of drug 
therapy.  When this is not an option clinically (e.g. with phenobarbital administration), 
then at least the clinical picture and the results of thyroid function tests should be 
interpreted with a healthy dose of scepticism.   
If decreased TT4 serum levels are obtained in a dog administered ASA or prednisone, 
then measuring TSH serum levels can be a very useful adjunct.  With phenobarbital 
administration, even combining TT4 and TSH can be misleading in some cases. 
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2. Although we showed that some alterations occur in thyroid hormone concentrations 
with obesity and with weight loss, these changes are unlikely to mislead the 
interpretation of thyroid function test results.   
 
3. Veterinarians should be aware that CRFA exists and that its clinical presentation is 
particularly misleading for hypothyroidism.  Particularly in cases suspected for CRFA, 
hypothyroidism should be excluded by finding TT4 levels within reference range or 
confirmed by finding a decreased TT4 combined with an increased TSH.  
 
4. The findings in our work emphasize that, as with any clinicopathological test result, 
thyroid function tests should be interpreted in conjunction with a complete history and 
compatible physical examination findings. 
 
Further studies on the influence of drugs and other factors on canine thyroid 
function tests are needed.  Many questions regarding the mechanisms through which 
drugs alter canine thyroid function remain open.  Techniques for TSH measurements 
should be improved.  Research trying to clarify why some dogs with primary 
hypothyroidism have TSH serum concentrations within the reference range is essential. 
Medical imaging of the canine thyroid is still in its first steps and could lead to better 
insights into this complex but fascinating disease.  
 
Conclusion 
 
The present study contributed to the knowledge of various aspects of canine 
thyroid function.  It identified additional factors that can influence thyroid function test 
results in dogs and clearly points out that TT4 serum concentration can rapidly and 
markedly be decreased by some commonly used drugs.  The effect of weight loss was 
also significant on thyroid hormones, but the observed changes were clinically less 
relevant.  The etiology of CRFA remains unknown but this study allowed ruling out 
thyroid dysfunction as a major cause for this disease.  
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Awareness of the medications and factors that alter thyroid hormone 
concentrations should facilitate a more accurate interpretation of thyroid function test 
results, hopefully avoiding the erroneous diagnosis of hypothyroidism and subsequent 
unwarranted treatment. 
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Hypothyroidism is the most common endocrine disorder in dogs, however it is 
also the most over diagnosed.  Evaluation of thyroid function in dogs is not always 
straightforward.  The vague and non-specific clinical signs of hypothyroidism and the 
numerous factors which influence thyroid function test results, are major contributors to 
the difficulty in diagnosing this disease.  The introduction to this thesis first gives a 
detailed review of thyroid physiology and the general features of canine 
hypothyroidism.  Thereafter, specific thyroid diagnostic tests currently used in dogs are 
discussed.  Subsequently, current knowledge on influence of physiological factors, 
drugs and systemic diseases on thyroid homeostasis are reviewed (chapter 1).   
 
 In this thesis the influence of some commonly observed clinical situations, such 
as the administration of medications and obesity/weight loss, on thyroid homeostasis 
was studied. Furthermore, thyroid function was evaluated in dogs with canine recurrent 
flank alopecia, a disease commonly mistaken for hypothyroidism.  
 
 Chapters 2 and 3 evaluated the effects of some commonly used drugs in canine 
practice on thyroid function test results. The administration of medications in rats and 
humans can alter the synthesis, secretion, transport, or metabolism of thyroid hormones.  
Some drugs also directly inhibit the hypothalamic-pituitary-thyroid axis.  Species 
differences exist in all areas of the thyroid axis, therefore it is not surprising that drug-
thyroid interactions will vary among species.  In humans, several drugs may cause 
marked changes in the results of thyroid function tests, leading to difficulty in 
interpretation of the results, but only rarely causing clinical features of thyroid 
dysfunction. The effects of many of these drugs have not yet been studied in dogs.   
 
 The effects of short-term (3 weeks) administration of oral prednisone and 
phenobarbital were evaluated on canine thyroid function tests (Chapter 2).   
Phenobarbital therapy in our study did not affect serum TT4, FT4, or TSH 
concentrations. Phenobarbital serum concentrations obtained in our study were slightly 
under usual levels aimed for in clinics.  Prednisone administered at an 
immunosuppressive dosage, significantly decreased serum TT4 and, to a lesser extent,  
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FT4, but it did not affect serum TSH concentrations. One week after the administration 
of prednisone, 8 out of 9 dogs had a TT4 serum concentration below 15 nmol/L, a value 
observed in hypothyroidism.  Serum concentrations of TT4 and FT4 normalised within 
1 week of cessation of prednisone administration.   Free T4 serum concentrations were 
less affected than TT4 serum concentrations by the 3-week administration of an 
immunosuppressive dosage of prednisone. In conclusion, an immunosuppressive dosage 
of prednisone can markedly affect thyroid homeostasis in dogs and can lead to 
misinterpretation of thyroid function test results.   
 
 As NSAIDs are used more and more frequently in dogs, it was important to 
know whether they affect thyroid function test results. Therefore, we evaluated whether 
ASA or Keto influence thyroid function test results in dogs (Chapter 3). A significant 
decrease in TT4 was observed as soon as 24 h after ASA administration whereas the 
decrease in TT3 was less pronounced.  No significant effects were found for FT4 and 
TSH with ASA administration. No significant effects on thyroid results were found for 
Keto administration. The results indicate that TT4 can be markedly decreased by ASA 
therapy and probably reflected the displacement of thyroid hormones from serum 
protein binding sites. Until the results of further studies are available, thyroid function 
test results should be interpreted cautiously in dogs on NSAIDs therapy. A seven-day 
treatment with ASA resulted in a decrease in TT4, potentially sufficient to lead to the 
misinterpretation of the thyroid profile and misdiagnosis of hypothyroidism in more 
than half of the dogs.  Free T4 measured by equilibrium dialysis and TSH serum 
concentrations were less affected by ASA and Keto administration than TT4. Therefore, 
a diagnosis of hypothyroidism in a dog on NSAIDs therapy, should not be based on a 
TT4 measurement only.  After short-term (one-week) administration of ASA, and 
maybe other NSAIDs as well, we advise a minimal seven-day period before thyroid 
function testing in dogs. 
 
To further assess the possible influence of common clinical situations on thyroid 
function test results, the effects of obesity and weight loss on canine thyroid function 
were assessed in chapter 4. In dogs, obesity is the most common nutritional problem  
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encountered and weight loss is the cornerstone of its treatment. Therefore it was 
important to clarify how obesity and weight loss can affect thyroid function test results 
in dogs.  The objectives of this study were to compare thyroid function in obese dogs 
and in lean dogs and to explore the effects of calorie restriction and weight loss in obese 
dogs on thyroid hormone serum concentrations.  Total T3 and TT4 serum 
concentrations were significantly higher in obese dogs as compared to lean dogs.  
Weight loss resulted in a significant decrease in TT3 and TSH serum concentrations. In 
this study we also used recombinant human TSH to perform TSH stimulation tests.  The 
use of 75 µg of rhTSH in our study for dogs weighing between 10.8 and 25.9 kg (but 
obese) allowed optimal stimulation of the thyroid gland.  All dogs (lean and obese) met 
the criteria suggested by Sauvé and Paradis (2000) to confirm euthyroidism.  
Furthermore sampling 6 hours after the injection of rhTSH seemed optimal and the 4-
hour sample seemed not really necessary. Our findings showed that the rhTSH 
stimulation test could be a useful tool to evaluate thyroid function in dogs or in research 
setting to better explore thyroid physiology. 
In conclusion, obesity and energy restriction significantly altered thyroid 
homeostasis in dogs, but the observed changes were unlikely to affect interpretation of 
thyroid function test results in clinics. 
 
 Clinical manifestations of hypothyroidism are nonspecific; this complicates the 
diagnosis of canine hypothyroidism.  Several diseases have a clinical presentation that 
can be similar to hypothyroidism.  The most striking example is the symmetrical flank 
alopecia frequently observed in hypothyroidism but also a characteristic feature of a 
recently documented dermatological disease; i.e. canine recurrent flank alopecia 
(CRFA).  During the last decades, many dogs have been erroneously diagnosed with 
hypothyroidism when in fact they were suffering from CRFA.  The etiology of CRFA 
remains largely unknown.  In chapter 5 we evaluated thyroid function in dogs with 
CRFA. Total T4 and TSH serum concentrations were significantly decreased and 
increased, respectively, in the hypothyroid group compared with the control and CRFA 
groups.  No significant differences in TT4 and TSH serum values were found between  
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the euthyroid and CRFA groups.  Thyroglobulin autoantibodies were detected in 10, 
11.1, and 61.9 % of euthyroid dogs, dogs with CRFA, and hypothyroid dogs, 
respectively.  In conclusion, dogs suffering from CRFA had a normal thyroid function, 
and the determination of TT4 and TSH serum concentrations allowed differentiation of 
these dogs from dogs with hypothyroidism, in most cases.  
 
The present study contributes to the knowledge of various aspects of canine 
thyroid function.  It identified additional factors that can influence thyroid function test 
results in dogs and clearly points out that TT4 serum concentration can rapidly and 
markedly be decreased by some commonly used drugs.  The effect of weight loss was 
also significant on thyroid hormones, but the observed changes were clinically less 
relevant.  The etiology of CRFA remains unknown but this study allowed ruling out 
thyroid dysfunction as a major cause for this disease.  
Awareness of the medications and factors that alter thyroid hormone 
concentrations should facilitate a more accurate interpretation of thyroid function test 
results, hopefully avoiding the erroneous diagnosis of hypothyroidism and subsequent 
unwarranted treatment. 
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Hypothyroïdie is de meest voorkomende endocrinologische aandoening bij de 
hond, maar ook de meest overgediagnosticeerde.  Evaluatie van de schildklierfunctie bij 
de hond is niet altijd eenvoudig.  De vage en niet-specifieke klinische symptomen van 
hypothyroïdie en de vele factoren die de testresultaten kunnen beïnvloeden, 
bemoeilijken de diagnose van deze ziekte.  De inleiding van dit proefschrift geeft eerst 
een gedetailleerd overzicht weer van de schildklierfysiologie en de algemene 
kenmerken van hypothyroïdie bij de hond.  Daarna worden de specifieke diagnostische 
schildkliertesten die tegenwoordig gebruikt worden besproken.  Vervolgens worden de 
beschikbare literatuurgegevens over beïnvloeding van schildklierfunctietesten door 
fysiologische factoren, geneesmiddelen en systemische ziekten samengevat (hoofdstuk 
1).   
 
 In het onderzoek van dit proefschrift werd de invloed van veel voorkomende 
klinische omstandigheden, zoals het toedienen van geneesmiddelen en 
obesitas/gewichtsverlies op de schildklierhomeostase bestudeerd. Verder werd de 
schildklierfunctie geëvalueerd bij honden met recidiverende flankalopecie (CRFA), een 
dermatologische aandoening vaak verkeerdelijk gediagnosticeerd als alopecie ten 
gevolge van hypothyroïdie.  
 
 Hoofdstukken 2 en 3 beschrijven de resultaten van eigen studies.  De effecten 
van vaak gebruikte geneesmiddelen in de kleine huisdierenpraktijk op resultaten van 
schildklierfunctietesten werden onderzocht.  De toediening van geneesmiddelen bij 
ratten en mens kan de synthese, de secretie, het transport of het metabolisme van 
schildklierhormonen beïnvloeden.  Sommige geneesmiddelen kunnen ook rechtstreeks 
de hypothalamus-hypophyse-schildklieras inhiberen. Speciesverschillen bestaan op alle 
niveaus van de schildklieras. Daarom is het niet verwonderlijk dat de geneesmiddel-
schildklierinteractie interspeciesvariatie zal vertonen. Verschillende geneesmiddelen 
kunnen bij de mens uitgesproken veranderingen teweeg brengen in de resultaten van 
schildklierfunctietesten, zodat de interpretatie van deze resultaten soms moeilijk is.  Ze 
geven eerder zelden aanleiding tot klinische tekens van schildklierdysfunctie.  De  
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mogelijke effecten van veel gebruikte geneesmiddelen op de schildklierfunctietesten bij 
de hond werden nog niet nagegaan.   
 
 De effecten van kortetermijntoediening (3 weken) van orale prednisone en 
phenobarbital op de schildklierfunctietesten werden bestudeerd (hoofdstuk 2).  
Phenobarbitalbehandeling in onze studie had geen invloed op TT4 (totale thyroxine), 
FT4 (vrije thyroxine), en TSH (thyrotropine) serumconcentraties. Phenobarbital 
serumconcentraties verkregen in onze studie lagen echter iets onder de therapeutische 
plasmaspiegels. Prednisone toegediend aan een immunosuppressieve dosering 
daarentegen verminderde significant de serum TT4 en in een mindere mate FT4, maar 
serum TSH concentraties bleven onveranderd.  Een week na toediening van prednisone, 
hadden 8 van de 9 honden een TT4 onder 15 nmol/L, een waarde die gezien wordt bij 
hypothyroïdie.  TT4 en FT4 serumconcentraties normaliseerden binnen de week na 
stopzetten van de prednisonetoediening. Vrije T4 serumwaarden werden minder 
beïnvloed dan TT4 serum concentraties door de toediening van een 
immunosuppressieve dosis prednisone gedurende drie weken.  Men kan besluiten dat de 
toediening van een immunosuppressieve prednisonedosis een uitgesproken effect heeft 
op de schildklierhomeostase en kan leiden tot vals-positieve diagnoses van 
hypothyroïdie. 
 
 Niet-steroïdale ontstekingsremmers (NSAIDs) worden meer en meer gebruikt 
bij de hond. Daarom is het belangrijk om de mogelijke invloed van NSAIDs na te gaan 
op de resultaten van schildklierfunctietesten. De invloed van acetylsalicylzuur (ASA) en 
ketoprofen (Keto) op de schildklierfunctietesten bij de hond werd nagegaan (hoofdstuk 
3). Een significante daling van TT4 serumconcentraties werd vastgesteld, reeds 24 uren 
na de ASA toediening,  terwijl de daling van TT3 minder uitgesproken was.  Er werd 
geen significante invloed gevonden op FT4 en TSH serumconcentraties na ASA 
toediening. Ketoprofen toediening had geen significante invloed op de 
schildklierfunctietesten. De resultaten tonen aan dat TT4 uitgesproken verlaagd kan zijn 
door ASA therapie en dit weerspiegelt hoogst waarschijnlijk de verdringing van de 
schildklierhormonen van hun bindingsplaatsen op de serumeiwitten. Tot er meer studies  
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gepubliceerd zijn, moeten schildkliertesten met de nodige voorzichtigheid 
geïnterpreteerd worden bij honden onderworpen aan een NSAIDs behandeling.   Een 7-
daagse behandeling resulteerde in een daling van TT4, die potentieel kon leiden tot 
overdiagnose van hypothyroïdie bij meer dan de helft van de honden.  Vrije T4, bepaald 
door evenwichtsdialyse, en TSH serumconcentraties werden minder beïnvloed door 
ASA en Keto toediening dan TT4. Daarom zou de diagnose van hypothyroïdie bij een 
hond op NSAIDs therapie niet gebaseerd mogen zijn op een bepaling van TT4 alleen.  
Na een 1-week toediening van ASA, en misschien ook van andere NSAIDs, is het aan te 
bevelen een zevental dagen te wachten alvorens schildklierfunctietesten uit te voeren bij 
de hond.   
 
Om verder de mogelijke invloed van vaak voorkomende klinische 
omstandigheden op de schildklierfunctietesten na te gaan, werd de invloed van obesitas 
en gewichtsverlies geëvalueerd in hoofdstuk 4.  Bij de hond is obesitas de meest 
voorkomende nutritionele aandoening en gewichtsverlies is de hoeksteen van de 
behandeling. Daarom is het belangrijk na te gaan hoe obesitas en gewichtsverlies 
schildklierfunctietesten kunnen beïnvloeden bij de hond.  De doelstellingen van deze 
studies waren eerst de schildklierfunctie te vergelijken tussen honden met obesitas en 
slanke honden. Verder werden de effecten van calorierestrictie en gewichtsverlies op 
schildklierhormoonconcentraties nagegaan bij honden met obesitas.  Totale T3 en TT4 
serum concentraties waren significant hoger bij honden met obesitas in vergelijking met 
deze bij slanke honden.  Gewichtsverlies resulteerde in een significante daling van TT3 
en TSH serumconcentraties.  In deze studie werd ook recombinante humane TSH 
(rhTSH) gebruikt om TSH stimulatietesten uit te voeren.  Het gebruik van 75 µg rhTSH 
in onze studie voor honden met een lichaamsgewicht tussen 10,8 en 25,9 kg (maar met 
obesitas) liet een optimale stimulatie van de schildklier toe.  Alle honden (slank en met 
obesitas) voldeden aan de criteria gesuggereerd door Sauvé en Paradis om euthyroïdie te 
bevestigen.  Bovendien bleek een staalname 6 uren na het injecteren van rhTSH 
optimaal en het staal genomen na 4 uren staal niet echt noodzakelijk.  Onze bevindingen 
tonen aan dat de rhTSH stimulatietest een interessant middel is om schildklierfunctie te  
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evalueren bij honden in de kliniek of in een experimentele opzet om 
schildklierfysiologie te bestuderen.   
 
Er kan besloten worden dat obesitas en gewichtsverlies tot een significante 
verandering van de schildklierhomeostase bij de hond leiden, maar het is weinig 
waarschijnlijk dat deze veranderingen relevant zijn voor de interpretatie van 
schildklierfunctietesten in de kliniek.  
 
 Klinische tekens van hypothyroïdie zijn niet specifiek; dit bemoeilijkt de 
diagnose van hypothyroïdie bij de hond. Verscheidene ziekten hebben een klinisch 
beeld dat lijkt op hypothyroïdie.  Het meest opvallend voorbeeld is de symmetrische 
flankalopecie, frequent gezien bij hypothyroïdie maar ook een typisch kenmerk van een 
recent erkende dermatologische aandoening, namelijk recidiverende flankalopecie bij de 
hond.  De laatste decennia werden veel honden foutief gediagnosticeerd als hypothyroïd 
wanneer ze eigenlijk aan CRFA leden. De etiologie van CRFA is grotendeels onbekend.  
In hoofdstuk 5 worden de resultaten beschreven van het onderzoek naar de 
schildklierfunctie bij honden met CRFA.  Totale T4 en TSH serumconcentraties waren 
respectievelijk significant verminderd en verhoogd in de hypothyroïdiegroep in 
vergelijking met controle en CRFA groepen.  Geen significante verschillen in TT4 en 
TSH serumwaarden werden gevonden tussen de euthyroïde en CRFA groepen.  
Thyroglobuline-antilichamen (TgAA) werden gedetecteerd in respectievelijk 10, 11.1, 
en 61.9 % van de euthyroïde honden, honden met CRFA, en hypothyroïde honden.  Er 
kan besloten worden dat honden met CRFA een normale schildklierfunctie hebben, en 
dat, de bepaling van TT4 en TSH serumconcentraties in de meeste gevallen 
differentiatie toelaat tussen CRFA honden en honden met hypothyroïdie.   
 
 
De huidige studie draagt bij tot de kennis van verscheidene aspekten van de 
schildklierfunctie bij de hond.  Er werd vastgesteld dat verscheidene faktoren de 
schildklierfunctietesten kunnen beïnvloeden bij de hond en dat TT4 serumconcentraties 
snel en duidelijk verlaagd kunnen zijn door toediening van sommige vaak gebruikte  
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geneesmiddelen.  Het effect van gewichtsverlies op schildklierhormoonconcentraties 
was ook significant, maar deze veranderingen zijn klinisch weinig relevant.  De oorzaak 
van caniene recidiverende flank alopecie blijft onbekend maar in deze studie kon 
schildklierdysfunctie als voornaamste oorzaak van deze ziekte worden uitgesloten. 
Door rekening te houden met de invloed van bepaalde geneesmiddelen en 
omstandigheden op de schildklierfunctietesten, worden er hopelijk minder vals- 
positieve diagnose van hypothyroïdie gesteld en bijgevolg ook minder onnodige 
behandelingen uitgevoerd.   
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Een dankwoord is eigenlijk onvoldoende om heel veel mensen te bedanken voor hun 
hulp en steun tijdens de realisatie van dit proefschrift. Het is niet mogelijk met enkele 
woorden te vertellen hoe sommigen voor mij zo belangrijk waren en dit niet alleen voor 
de ondersteuning op professioneel vlak maar ook langs het werk om zo de nodige 
innerlijke rust te vinden die absoluut vereist is om professioneel goed te kunnen 
functioneren.  Ik hoop tevens dat dit proefschrift slechts een begin is voor nog vele 
verdere studies. 
 
Hartelijk dank aan Prof. Dr. André De Rick voor zijn wijs advies en beschikbaarheid.  
Als promotor van dit proefschrift heeft hij steeds het volste vertrouwen in dit werk 
gesteld en mij aangemoedigd wanneer het nodig was.  Zijn steun voor het realiseren van 
mijn onderzoek alsook voor het ontwikkelen van mijn klinische activiteiten in de 
Vakgroep Geneeskunde en Klinische Biologie van de Kleine Huisdieren zijn zeer 
waardevol geweest gedurende de laatste 2 jaren. 
 
Hartelijk dank ook aan Prof. Dr. Henri van Bree voor zijn ondersteuning en deskundig 
advies. Extra dank omdat hij mij tevens kon overtuigen dat dit doctoraat voor mij 
haalbaar was. Ook heb ik steeds, via hem, ook van de vakgroep Medische 
Beeldvorming van de Huisdieren op de nodige technische hulp kunnen rekenen.  Piet, 
bedankt voor alles! 
 
Het was Prof. Dr. Manon Paradis die de interesse in mij wekte voor wetenschappelijk 
onderzoek en mij begeleidde tijdens mijn eerste klinische studies. Mijn 
nieuwsgierigheid voor de schildklierproblematiek heb ik van deze fantastische vrouw 
geërfd.   
 
Erg gelukkig voor mij was er ook onze statisticus Prof. Dr. Luc Duchateau.  Luc,  
hartelijk dank voor je hulp en deskundig advies.  Het was zeker een zeer mooie bijdrage 
tot 2 van de studies in dit proefschrift, en hopelijk de basis voor vele andere studies en 
talrijke publicaties.   
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De waarde van echte vrienden is onschatbaar.  Van harte wil ik dan ook Dr. Jimmy 
Saunders danken voor zijn luisterend oor voor mijn (soms) gezaag en zijn 
onvoorwaardelijke steun, fijne samenwerking in de kliniek en onze vriendschap.  Ook 
de steun, aanmoedigingen en de gesprekken met Dr. Ingeborgh Polis hebben mij heel 
veel vooruit geholpen. 
 
Cindy, Katrien, Isabel, Dr. Karine Savary-Bataille en Gastprof. Dr. Andreas Moritz: de 
fijne samenwerking met jullie leidde tot een gezellige werksfeer die zeker bijdroeg tot 
het vlot verloop van dit doctoraat. Door mijn vertrouwen in het werk dat jullie in de 
kliniek uitvoerden kon ik geregeld met een gerust hart aan mijn doctoraat voortwerken.  
 
Tevens wil ik graag alle collegas van mijn vakgroep en van de vakgroep Medische 
Beeldvorming zeer oprecht danken voor de prettige samenwerking. Extra dank ook aan 
Olivier en Inge voor hun aanmoedigingen en hulp, en aan Yves voor zijn hulp tijdens de 
ASA/Keto proef.  Mijn ZAP collegas van de cellen Medische Beeldvorming en 
Chirurgie (Profs. van Bree, Van Rijssen, Kramer) wil ik zeker niet vergeten te danken 
voor het ter beschikking stellen van een deeltijds assistenten plaats gedurende één jaar 
om mijn klinische taken wat te verlichten. Deze mooie geste heeft zonder twijfel ook 
bijgedragen tot het vlotte verloop van dit werk. 
 
Willy Van der Leene en Frank Desmet wil ik graag danken voor hun hulp met de 
verwerking van de stalen en/of het beschikbaar maken van artikels.  Deze tijdrovende 
activiteiten werden mij dank zij jullie vaak gespaard.  Geneviève, Stefaan, Elke en 
Hubert: hartelijk dank voor de goede verzorging van de beageltjes en/of jullie hulp 
tijdens de proeven. Jullie hulp werd enorm geapprecieerd. Filip Clompen wil ik 
bedanken voor de vele keren dat hij mij uit de nood hielp met mijn computer.   
 
De financiering van de onderzoeken van dit proefschrift werden voornamelijk mogelijk 
gemaakt door de Fonds du Centenaire van de Universiteit van Montreal, Canada en de 
vakgroep Geneeskunde en Klinische Biologie van de Kleine Huisdieren, Universiteit 
Gent. 
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Dr. I. Jeusette en Dr. M. Diez wil ik graag danken voor de fijne samenwerking tijdens 
de obesitas proef en  Dr. S. Croubels en Prof. Dr. De Backer voor de steun bij het 
bepalen van geneesmiddelenconcentraties in de Vakgroep Farmacologie, Farmacie en 
Toxicologie.  Dr. Myriam Hesta dank ik voor haar uitleg en beschikbaarheid. 
 
Prof. Dr. D. Ferguson wil ik graag danken voor het corrigeren van artikels en het geven 
van uitleg waar nodig alsook zijn pertinente antwoorden op mijn multipele vragen. 
 
Dr. Rocky Di Fruscia en mijn andere ex-collegas uit Canada wil ik niet vergeten omdat 
zij een belangrijke rol hebben gespeeld in het uitbouwen van mijn loopbaan en mij 
zovele jaren gesteund hebben.   
 
Mijn eigen diertjes Babylou, Mac Intosch, Ronron en Serena die mij zo vaak hebben 
aangekeken met ogen van Awel daar zijt ge weer eens, hebt ge gezien hoe laat het is?  
wil ik speciaal danken voor hun oprechte, onbevooroordeelde en totaal onbewuste 
steun. 
 
Mijn speciale dank gaat ook in het bijzonder naar mijn broers, Pierre en Eric, mijn zus 
Christine, en mijn vriendin Marina.  Ook Rudi en André Van der Weken ben ik zeer 
veel dank verschuldigd.   
 
Mijn allerliefste Alain, jou wil ik danken voor de liefdevolle steun van de laatste 
maanden.  Jij maakt dit werk zinvol. 
 
En ten slotte wil ik hen bedanken die voor mij het allerbelangrijkst waren want zonder 
hen was dit werk gewoonweg onmogelijk geweest; mijn ouders die mij al die jaren 
gesteund hebben in alles wat ik ondernam en mij hun onvoorwaardelijke liefde gaven. 
De extra hulp die mijn mama mij de 2 laatste jaren gaf was ongetwijfeld van het 
allergrootste belang in het vlotte en snelle verloop van dit proefschrift.   
 
Sylvie 
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Sylvie Daminet werd op 21 juli 1968 geboren te Genk, België. Zij begon in 
1986 met de studie Diergeneeskunde aan de Universiteit Luik en behaalde het diploma 
van Doctor in de Diergeneeskunde in 1992 met grote onderscheiding.  
 
Onmiddellijk daarna voltooide ze een internship gevolgd door een residency in 
de Interne Geneeskunde van de Kleine Huisdieren aan de Universiteit van Montreal in 
Canada. In 1996 werd zij diplomate van het Amerikaanse en het Europese College van 
Interne Geneeskunde (ACVIM&ECVIM-ca).  In 1998 behaalde zij een Masters degree 
over de evaluatie van de schildklierfunctie bij de hond.  Ze doceerde daarna aan de 
Faculteiten van Montreal en Prince Edward Island in Canada en was Lecturer aan de 
Royal Veterinary College van London in Engeland.  Dr Daminet is nu reeds 2 jaren 
gastprofessor aan de Vakgroep Geneeskunde en Klinische Biologie van de Kleine 
Huisdieren en is er verantwoordelijk voor de Interne Geneeskunde van de Kleine 
Huisdieren.  Binnen haar algemene activiteiten als internist heeft ze een bijzondere 
interesse voor de endocrinologie en de urologie/nefrologie van de kleine huisdieren. 
 
Haar interesse in de schildklierproblematiek bij de hond ontstond vanuit de 
klinische ervaring met vele honden die onterecht behandeld werden voor hypothyroïdie.  
Haar onderzoek in samenwerking met Prof. Paradis over deze topic begon in 1996.  Uit 
deze eerste studies vloeiden verdere studies voort aan de Faculteit Diergeneeskunde van 
Gent onder promotorschap van Prof. De Rick. 
  
Sylvie Daminet is auteur of mede-auteur van 31 publicaties in nationale en 
internationale tijdschriften. Zij gaf vele postuniversitaire bijscholingen voor practici en 
was 8 keren uitgenodigde spreker op internationale congressen. Ze is secretaresse van 
de European Society of Veterinary Urology and Nefrology en is lid van het 
examencomité van de ECVIM-ca. 
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